Datasets:
Add CSA free sample (v1): nearest-term forward catalysts + asset master
Browse files- README.md +73 -0
- SAMPLE_LICENSE.md +15 -0
- asset_master_sample.csv +465 -0
- asset_master_sample.json +0 -0
- catalyst_calendar_sample.csv +151 -0
- catalyst_calendar_sample.json +1802 -0
- regulatory_events_sample.csv +14 -0
README.md
ADDED
|
@@ -0,0 +1,73 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
---
|
| 2 |
+
license: cc-by-nc-4.0
|
| 3 |
+
pretty_name: "CSA — Clinical-Stage Asset Intelligence (Free Sample)"
|
| 4 |
+
task_categories:
|
| 5 |
+
- tabular-classification
|
| 6 |
+
tags:
|
| 7 |
+
- biotech
|
| 8 |
+
- clinical-trials
|
| 9 |
+
- finance
|
| 10 |
+
- pharmaceuticals
|
| 11 |
+
- catalyst-calendar
|
| 12 |
+
- healthcare
|
| 13 |
+
size_categories:
|
| 14 |
+
- n<1K
|
| 15 |
+
configs:
|
| 16 |
+
- config_name: catalyst_calendar
|
| 17 |
+
data_files: catalyst_calendar_sample.csv
|
| 18 |
+
default: true
|
| 19 |
+
- config_name: asset_master
|
| 20 |
+
data_files: asset_master_sample.csv
|
| 21 |
+
---
|
| 22 |
+
|
| 23 |
+
# CSA — Clinical-Stage Asset Intelligence · Free Sample
|
| 24 |
+
|
| 25 |
+
**Clinical trials, FDA, and SEC — linked to the drug asset and the listed sponsor, with a
|
| 26 |
+
forward catalyst calendar.** This is a free 150-row sample of the nearest-term
|
| 27 |
+
catalysts; the full snapshot carries **2,103 forward catalysts** across
|
| 28 |
+
**139 listed sponsors** and **1,841 resolved assets**.
|
| 29 |
+
|
| 30 |
+
> **Data, not investment advice.** CSA is information, not a recommendation to buy, sell,
|
| 31 |
+
> or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates)
|
| 32 |
+
> routinely slip and are graded by confidence — verify anything material against the
|
| 33 |
+
> `source_url` on each row.
|
| 34 |
+
|
| 35 |
+
## What's inside
|
| 36 |
+
|
| 37 |
+
| File | Rows | What it is |
|
| 38 |
+
| :-- | :-- | :-- |
|
| 39 |
+
| `catalyst_calendar_sample.csv` | 150 | Nearest-term forward catalysts (2026-07-18 → 2027-09-01), 108 assets, 50 sponsors. |
|
| 40 |
+
| `asset_master_sample.csv` | 464 | The asset ↔ trial ↔ sponsor ↔ ticker rows behind them. |
|
| 41 |
+
| `*_sample.json` | — | The same tables as records-oriented JSON. |
|
| 42 |
+
|
| 43 |
+
### `catalyst_calendar_sample.csv`
|
| 44 |
+
`event_date` · `ticker` · `asset` · `event_type` (PDUFA / READOUT / …) · `event_window`
|
| 45 |
+
· `date_precision` · `confidence` · `source` (sec_8k / clinicaltrials) · `nct_id` · `source_url`.
|
| 46 |
+
|
| 47 |
+
### `asset_master_sample.csv`
|
| 48 |
+
`asset` · `nct_id` · `phase` · `status` · `primary_completion` · `conditions` · `arm_role`
|
| 49 |
+
· `sponsor_raw` · `company_name` · `ticker`.
|
| 50 |
+
|
| 51 |
+
## How it's built
|
| 52 |
+
|
| 53 |
+
- **Active-moiety resolution** keys each asset to its FDA-registered UNII set (GSRS), not
|
| 54 |
+
fuzzy names — audited to **zero cross-molecule merges**.
|
| 55 |
+
- **Sponsor → listed ticker** through acquisitions, to the primary US listing.
|
| 56 |
+
- **Dual-channel catalysts**: SEC 8-K disclosure text + active late-phase
|
| 57 |
+
ClinicalTrials.gov protocol readouts. Every row carries its source.
|
| 58 |
+
|
| 59 |
+
Sample scope: active, industry-sponsored, Phase 3 trials in cardiometabolic, oncology and
|
| 60 |
+
immunology. Asset names are normalized for readability; the sample is curated to
|
| 61 |
+
clinical-stage, single-sponsor assets.
|
| 62 |
+
|
| 63 |
+
## Sources & license
|
| 64 |
+
|
| 65 |
+
All primary sources are U.S. Government / public domain: **ClinicalTrials.gov**,
|
| 66 |
+
**openFDA**, **SEC EDGAR**, **GSRS/UNII**. This sample is released under **CC-BY-NC-4.0**
|
| 67 |
+
(free to use and share with attribution, not to re-sell). See `SAMPLE_LICENSE.md`.
|
| 68 |
+
|
| 69 |
+
## Get the full dataset
|
| 70 |
+
|
| 71 |
+
The complete, commercially-licensed snapshot (all 2,103 catalysts, CSV +
|
| 72 |
+
JSON, monthly editions + delta feed) → **https://csa-public.pages.dev**
|
| 73 |
+
· code: **https://github.com/CSA-pub/CSA-public** · contact: **https://csa-public.pages.dev/#contact**
|
SAMPLE_LICENSE.md
ADDED
|
@@ -0,0 +1,15 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# CSA Free Sample — License (CC-BY-NC-4.0)
|
| 2 |
+
|
| 3 |
+
This **free sample** of CSA (Clinical-Stage Asset Intelligence) is licensed under the
|
| 4 |
+
**Creative Commons Attribution-NonCommercial 4.0 International License**
|
| 5 |
+
(https://creativecommons.org/licenses/by-nc/4.0/).
|
| 6 |
+
|
| 7 |
+
You may use, share, and adapt it **with attribution** and **for non-commercial purposes**.
|
| 8 |
+
The underlying primary data is U.S. Government / public domain (ClinicalTrials.gov,
|
| 9 |
+
openFDA, SEC EDGAR, GSRS/UNII); the linkage, resolution, and catalyst compilation are
|
| 10 |
+
DataEngineered's own work.
|
| 11 |
+
|
| 12 |
+
For **commercial use, redistribution, or the full dataset** (all catalysts, monthly
|
| 13 |
+
editions, API), see the commercially-licensed snapshot at **https://csa-public.pages.dev**.
|
| 14 |
+
|
| 15 |
+
**Data, not investment advice.** Provided "as is", without warranty. © 2026 DataEngineered
|
asset_master_sample.csv
ADDED
|
@@ -0,0 +1,465 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
asset,nct_id,phase,status,primary_completion,conditions,arm_role,sponsor_raw,company_name,ticker
|
| 2 |
+
abrocitinib,NCT06807268,PHASE3,RECRUITING,2027-05-02,Eczema,experimental,Pfizer,PFIZER INC,PFE
|
| 3 |
+
abrocitinib,NCT06807281,PHASE3,RECRUITING,2032-02-22,Atopic Dermatitis,experimental,Pfizer,PFIZER INC,PFE
|
| 4 |
+
acasunlimab,NCT06635824,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,"PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC",experimental,Genmab,GENMAB A/S,GMAB
|
| 5 |
+
alectinib,NCT03178552,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-10-31,Non-Small Cell Lung Cancer,experimental,Hoffmann-La Roche,,
|
| 6 |
+
alectinib,NCT03768063,PHASE3,ACTIVE_NOT_RECRUITING,2028-07-05,Cancer,experimental,Hoffmann-La Roche,,
|
| 7 |
+
alectinib,NCT05170204,PHASE3,ACTIVE_NOT_RECRUITING,2030-06-16,Non-Small Cell Lung Cancer,experimental,Hoffmann-La Roche,,
|
| 8 |
+
alectinib,NCT05722886,PHASE2;PHASE3,RECRUITING,2029-10,Haematological Malignancy; Solid Tumour,experimental,Cancer Research UK,,
|
| 9 |
+
alectinib,NCT05770037,PHASE2;PHASE3,RECRUITING,2029-10,Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma; Solid Tumour,experimental,Cancer Research UK,,
|
| 10 |
+
alectinib,NCT06765109,PHASE3,RECRUITING,2029-12,Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive,active_comparator,Nuvalent Inc.,"Nuvalent, Inc.",NUVL
|
| 11 |
+
anifrolumab,NCT04877691,PHASE3,ACTIVE_NOT_RECRUITING,2025-08-22,Systemic Lupus Erythematosus,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 12 |
+
anifrolumab,NCT05138133,PHASE3,ACTIVE_NOT_RECRUITING,2027-02-26,Lupus Nephritis,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 13 |
+
anifrolumab,NCT05835310,PHASE3,RECRUITING,2028-10-05,Systemic Lupus Erythematosus,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 14 |
+
anifrolumab,NCT07430306,PHASE3,RECRUITING,2029-01-26,Systemic Lupus Erythematosus,other,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 15 |
+
anifrolumab,NCT07691970,PHASE3,NOT_YET_RECRUITING,2032-12-31,Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 16 |
+
axitinib,NCT05059522,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-31,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,experimental,Pfizer,PFIZER INC,PFE
|
| 17 |
+
axitinib,NCT06364631,PHASE3,RECRUITING,2032-05-05,Metastatic Kidney Cancer; Metastatic Kidney Carcinoma,other,"Gustave Roussy, Cancer Campus, Grand Paris",,
|
| 18 |
+
belzutifan,NCT04195750,PHASE3,ACTIVE_NOT_RECRUITING,2024-04-15,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 19 |
+
belzutifan,NCT04586231,PHASE3,ACTIVE_NOT_RECRUITING,2026-02-02,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 20 |
+
belzutifan,NCT04736706,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-29,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 21 |
+
belzutifan,NCT05239728,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-28,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 22 |
+
belzutifan,NCT05899049,PHASE3,ACTIVE_NOT_RECRUITING,2027-06-07,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 23 |
+
belzutifan,NCT07227402,PHASE3,RECRUITING,2032-02-27,Renal Cell Carcinoma,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 24 |
+
belzutifan,NCT07405164,PHASE3,RECRUITING,2034-01-14,Von Hippel-Lindau Disease; Malignant Neoplasms,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 25 |
+
belzutifan,NCT07489495,PHASE3,RECRUITING,2030-11-27,"Carcinoma, Renal Cell",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 26 |
+
binimetinib,NCT04657991,PHASE3,ACTIVE_NOT_RECRUITING,2026-01-12,Melanoma,experimental,Pfizer,PFIZER INC,PFE
|
| 27 |
+
binimetinib,NCT05615818,PHASE3,RECRUITING,2027-06,Biliary Tract Neoplasms,experimental,UNICANCER,,
|
| 28 |
+
cagrilintide,NCT05567796,PHASE3,ACTIVE_NOT_RECRUITING,2024-10-30,Obesity,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 29 |
+
cagrilintide,NCT05669755,PHASE3,ACTIVE_NOT_RECRUITING,2027-09-01,Cardiovascular Disease,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 30 |
+
cagrilintide,NCT06780449,PHASE3,ACTIVE_NOT_RECRUITING,2028-08-28,Obesity,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 31 |
+
cagrilintide,NCT07011667,PHASE3,ACTIVE_NOT_RECRUITING,2027-03-01,Obesity,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 32 |
+
cagrilintide,NCT07220642,PHASE3,ACTIVE_NOT_RECRUITING,2027-05-11,Obesity; Overweight,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 33 |
+
cagrilintide,NCT07220759,PHASE3,ACTIVE_NOT_RECRUITING,2027-05-12,Overweight; Obesity; Type 2 Diabetes,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 34 |
+
cagrilintide,NCT07253285,PHASE3,RECRUITING,2030-03-20,Overweight; Obesity,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 35 |
+
cagrilintide,NCT07282613,PHASE3,NOT_YET_RECRUITING,2029-09-07,"Diabetes Mellitus, Type 2",experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 36 |
+
cagrilintide,NCT07564414,PHASE3,RECRUITING,2028-02-23,Obesity; Type 2 Diabetes,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 37 |
+
camizestrant,NCT04711252,PHASE3,ACTIVE_NOT_RECRUITING,2026-08-24,ER-Positive HER2-Negative Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 38 |
+
camizestrant,NCT04964934,PHASE3,ACTIVE_NOT_RECRUITING,2025-06-30,ER-Positive HER2-Negative Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 39 |
+
camizestrant,NCT05774951,PHASE3,RECRUITING,2027-04-20,"Breast Cancer, Early Breast Cancer",experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 40 |
+
camizestrant,NCT05952557,PHASE3,RECRUITING,2030-03-04,"Breast Cancer, Early Breast Cancer",experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 41 |
+
camizestrant,NCT06380751,PHASE3,RECRUITING,2029-03-30,Advanced Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 42 |
+
camizestrant,NCT07647328,PHASE3,RECRUITING,2029-02-28,ER-Positive HER2-Negative Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 43 |
+
cenerimod,NCT05648500,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-31,"Lupus Erythematosus, Systemic",experimental,Viatris Innovation GmbH,Viatris Inc,VTRS
|
| 44 |
+
cenerimod,NCT05672576,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-31,"Lupus Erythematosus, Systemic",experimental,Viatris Innovation GmbH,Viatris Inc,VTRS
|
| 45 |
+
cenerimod,NCT06475742,PHASE3,ENROLLING_BY_INVITATION,2028-05,"Lupus Erythematosus, Systemic",experimental,Viatris Innovation GmbH,Viatris Inc,VTRS
|
| 46 |
+
cenerimod,NCT07201129,PHASE3,RECRUITING,2029-08,"Nephritis, Lupus; Lupus Erythematosus, Systemic",experimental,Viatris Innovation GmbH,Viatris Inc,VTRS
|
| 47 |
+
cretostimogene grenadenorepvec,NCT04452591,PHASE3,ACTIVE_NOT_RECRUITING,2030-06-16,Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer,experimental,"CG Oncology, Inc.","CG Oncology, Inc.",CGON
|
| 48 |
+
cretostimogene grenadenorepvec,NCT06111235,PHASE3,ACTIVE_NOT_RECRUITING,2026-11,Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma,experimental,"CG Oncology, Inc.","CG Oncology, Inc.",CGON
|
| 49 |
+
dapagliflozin,NCT05374291,PHASE3,ENROLLING_BY_INVITATION,2027-07,"Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death",experimental,University Medical Center Groningen,,
|
| 50 |
+
dapagliflozin,NCT05886088,PHASE3,NOT_YET_RECRUITING,2026-05,Type 2 Diabetes Mellitus,active_comparator,EMS,,
|
| 51 |
+
dapagliflozin,NCT07082114,PHASE3,RECRUITING,2027-02-16,Type 2 Diabetes,active_comparator,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",,
|
| 52 |
+
dapagliflozin,NCT07662044,PHASE3,RECRUITING,2028-07-14,Type 2 Diabetes Mellitus,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 53 |
+
dapagliflozin,NCT07662109,PHASE3,RECRUITING,2028-07-05,Type 2 Diabetes Mellitus,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 54 |
+
darolutamide,NCT03903835,PHASE3,RECRUITING,2026-12,Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC),experimental,Karolinska Institutet,,
|
| 55 |
+
darolutamide,NCT04136353,PHASE3,ACTIVE_NOT_RECRUITING,2028-01-31,Prostate Cancer,experimental,University of Sydney,,
|
| 56 |
+
darolutamide,NCT04464226,PHASE3,ACTIVE_NOT_RECRUITING,2028-06-26,Cancer,experimental,Bayer,,
|
| 57 |
+
darolutamide,NCT04916613,PHASE3,RECRUITING,2028-03,Prostate Cancer Metastatic,experimental,UNICANCER,,
|
| 58 |
+
darolutamide,NCT05116475,PHASE3,RECRUITING,2026-02,Prostate Cancer,experimental,Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie,,
|
| 59 |
+
darolutamide,NCT05794906,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,Biochemically Recurrent Prostate Cancer,experimental,Bayer,,
|
| 60 |
+
darolutamide,NCT06120491,PHASE3,ACTIVE_NOT_RECRUITING,2027-09-30,Metastatic Castration-Sensitive Prostate Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 61 |
+
darolutamide,NCT06276465,PHASE3,RECRUITING,2029-10-15,"Prostatic Cancer, Castration-Resistant",experimental,UNICANCER,,
|
| 62 |
+
darolutamide,NCT06282588,PHASE2;PHASE3,RECRUITING,2030-07-31,Prostate Cancer,experimental,Cancer Research Antwerp,,
|
| 63 |
+
darolutamide,NCT06625970,PHASE3,RECRUITING,2033-10,High Risk Prostate Carcinoma; Prostate Cancer,experimental,UNICANCER,,
|
| 64 |
+
darolutamide,NCT07611110,PHASE3,RECRUITING,2029-02-13,Metastatic Castration-resistant Prostate Cancer,active_comparator,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 65 |
+
darolutamide,NCT07711002,PHASE3,NOT_YET_RECRUITING,2031-06-17,Metastatic Hormone-Sensitive Prostate Cancer (mHSPC),experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 66 |
+
darovasertib,NCT05987332,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2027-01-15,Metastatic Uveal Melanoma,experimental,IDEAYA Biosciences,"IDEAYA Biosciences, Inc.",IDYA
|
| 67 |
+
darovasertib,NCT07015190,PHASE3,RECRUITING,2030-10,Uveal Melanoma,experimental,IDEAYA Biosciences,"IDEAYA Biosciences, Inc.",IDYA
|
| 68 |
+
datopotamab deruxtecan,NCT04656652,PHASE3,ACTIVE_NOT_RECRUITING,2024-05-10,Non-small Cell Lung Cancer,experimental,Daiichi Sankyo,,
|
| 69 |
+
datopotamab deruxtecan,NCT05104866,PHASE3,ACTIVE_NOT_RECRUITING,2024-07-24,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 70 |
+
datopotamab deruxtecan,NCT05215340,PHASE3,ACTIVE_NOT_RECRUITING,2030-03-04,Metastatic Non Small Cell Lung Cancer,experimental,Daiichi Sankyo,,
|
| 71 |
+
datopotamab deruxtecan,NCT05374512,PHASE3,ACTIVE_NOT_RECRUITING,2025-08-25,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 72 |
+
datopotamab deruxtecan,NCT05555732,PHASE3,ACTIVE_NOT_RECRUITING,2029-05-11,Metastatic Non Small Cell Lung Cancer,experimental,Daiichi Sankyo,,
|
| 73 |
+
datopotamab deruxtecan,NCT05629585,PHASE3,ACTIVE_NOT_RECRUITING,2027-09-20,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 74 |
+
datopotamab deruxtecan,NCT05687266,PHASE3,ACTIVE_NOT_RECRUITING,2027-11-01,NSCLC,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 75 |
+
datopotamab deruxtecan,NCT06103864,PHASE3,RECRUITING,2027-07-28,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 76 |
+
datopotamab deruxtecan,NCT06112379,PHASE3,ACTIVE_NOT_RECRUITING,2028-11-20,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 77 |
+
datopotamab deruxtecan,NCT06350097,PHASE3,RECRUITING,2028-03-21,Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 78 |
+
datopotamab deruxtecan,NCT06357533,PHASE3,RECRUITING,2029-12-28,Non-Small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 79 |
+
datopotamab deruxtecan,NCT06417814,PHASE3,RECRUITING,2026-09-30,Metastatic Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 80 |
+
datopotamab deruxtecan,NCT06564844,PHASE3,ACTIVE_NOT_RECRUITING,2027-06-30,Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 81 |
+
datopotamab deruxtecan,NCT07129993,PHASE2;PHASE3,RECRUITING,2029-06-01,Urothelial Cancer; Bladder Cancer,experimental,Daiichi Sankyo,,
|
| 82 |
+
datopotamab deruxtecan,NCT07205822,PHASE3,RECRUITING,2028-02-02,Breast Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 83 |
+
datopotamab deruxtecan,NCT07291037,PHASE3,RECRUITING,2029-01-29,Non-small Cell Lung Cancer (NSCLC),experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 84 |
+
daunorubicin,NCT03117751,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma,experimental,St. Jude Children's Research Hospital,,
|
| 85 |
+
daunorubicin,NCT03897127,PHASE3,ACTIVE_NOT_RECRUITING,2027-06,Acute Myeloid Leukemia,active_comparator,University of Ulm,,
|
| 86 |
+
daunorubicin,NCT05726110,PHASE3,RECRUITING,2024-12-10,Relapsed or Refractory Acute Myeloid Leukemia,experimental,Shanxi Bethune Hospital,,
|
| 87 |
+
daunorubicin,NCT07007312,PHASE3,RECRUITING,2031-11,Acute Myeloid Leukemia (AML),experimental,"Kura Oncology, Inc.","Kura Oncology, Inc.",KURA
|
| 88 |
+
daunorubicin,NCT07255872,PHASE2;PHASE3,NOT_YET_RECRUITING,2027-12,Acute Myeloid Leukemia,experimental,"Sichuan Baili Pharmaceutical Co., Ltd.",,
|
| 89 |
+
deucravacitinib,NCT04036435,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-25,Psoriasis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 90 |
+
deucravacitinib,NCT04772079,PHASE3,RECRUITING,2029-01-01,Plaque Psoriasis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 91 |
+
deucravacitinib,NCT04908189,PHASE3,ACTIVE_NOT_RECRUITING,2024-02-06,Psoriatic Arthritis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 92 |
+
deucravacitinib,NCT04908202,PHASE3,ACTIVE_NOT_RECRUITING,2024-09-05,Psoriatic Arthritis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 93 |
+
deucravacitinib,NCT05617677,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-19,Systemic Lupus Erythematosus,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 94 |
+
deucravacitinib,NCT05620407,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-19,Systemic Lupus Erythematosus,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 95 |
+
deucravacitinib,NCT06143878,PHASE3,ACTIVE_NOT_RECRUITING,2024-09-17,Plaque Psoriasis,active_comparator,"Janssen Research & Development, LLC",,
|
| 96 |
+
deucravacitinib,NCT06220604,PHASE3,ACTIVE_NOT_RECRUITING,2024-11-15,Plaque Psoriasis,active_comparator,"Janssen Research & Development, LLC",,
|
| 97 |
+
deucravacitinib,NCT06869551,PHASE3,RECRUITING,2030-03-06,Juvenile Psoriatic Arthritis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 98 |
+
deucravacitinib,NCT06979453,PHASE3,RECRUITING,2029-10-12,Plaque Psoriasis,active_comparator,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 99 |
+
deucravacitinib,NCT07116967,PHASE3,RECRUITING,2031-01-16,Plaque Psoriasis,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 100 |
+
deucravacitinib,NCT07326813,PHASE3,RECRUITING,2027-07-12,Plaque Psoriasis,active_comparator,"InventisBio Co., Ltd",,
|
| 101 |
+
deucrictibant,NCT05396105,PHASE2;PHASE3,ENROLLING_BY_INVITATION,2027-06,"Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 102 |
+
deucrictibant,NCT05396105,PHASE2;PHASE3,ENROLLING_BY_INVITATION,2027-06,"Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 103 |
+
deucrictibant,NCT05396105,PHASE2;PHASE3,ENROLLING_BY_INVITATION,2027-06,"Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 104 |
+
deucrictibant,NCT05396105,PHASE2;PHASE3,ENROLLING_BY_INVITATION,2027-06,"Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor",experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 105 |
+
deucrictibant,NCT06669754,PHASE3,ACTIVE_NOT_RECRUITING,2026-08,Hereditary Angioedema (HAE),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 106 |
+
deucrictibant,NCT06679881,PHASE3,RECRUITING,2028-12,Hereditary Angioedema (HAE),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 107 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 108 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 109 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 110 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 111 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 112 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 113 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 114 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 115 |
+
deucrictibant,NCT07266805,PHASE3,RECRUITING,2027-06,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),experimental,Pharvaris Netherlands B.V.,Pharvaris N.V.,PHVS
|
| 116 |
+
deuruxolitinib,NCT03898479,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2027-05,Alopecia Areata,experimental,"Sun Pharmaceutical Industries, Inc.",TEVA PHARMACEUTICAL INDUSTRIES LTD,TEVA
|
| 117 |
+
deuruxolitinib,NCT07133308,PHASE3,RECRUITING,2028-05,Alopecia Areata,experimental,"Sun Pharmaceutical Industries, Inc.",TEVA PHARMACEUTICAL INDUSTRIES LTD,TEVA
|
| 118 |
+
deuruxolitinib,NCT07617597,PHASE3,RECRUITING,2028-02,Alopecia Areata,experimental,Sun Pharma Japan Limited,,
|
| 119 |
+
disitamab vedotin,NCT05302284,PHASE3,RECRUITING,2026-12-31,Urothelial Carcinoma; HER2-expressing,experimental,"RemeGen Co., Ltd.",,
|
| 120 |
+
disitamab vedotin,NCT05911295,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-29,Urothelial Carcinoma,experimental,"Seagen, a wholly owned subsidiary of Pfizer",PFIZER INC,PFE
|
| 121 |
+
disitamab vedotin,NCT05980481,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2025-07-10,Gastric Cancer,experimental,"RemeGen Co., Ltd.",,
|
| 122 |
+
disitamab vedotin,NCT05980481,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2025-07-10,Gastric Cancer,experimental,"RemeGen Co., Ltd.",,
|
| 123 |
+
disitamab vedotin,NCT06221748,PHASE2;PHASE3,RECRUITING,2026-12,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,experimental,"RemeGen Co., Ltd.",,
|
| 124 |
+
disitamab vedotin,NCT07315750,PHASE3,RECRUITING,2029-06-30,Gastric Carcinoma,experimental,"RemeGen Co., Ltd.",,
|
| 125 |
+
donidalorsen,NCT05392114,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,Hereditary Angioedema,experimental,"Ionis Pharmaceuticals, Inc.",IONIS PHARMACEUTICALS INC,IONS
|
| 126 |
+
donidalorsen,NCT07298447,PHASE3,RECRUITING,2029-06,Hereditary Angioedema (HAE),experimental,"Ionis Pharmaceuticals, Inc.",IONIS PHARMACEUTICALS INC,IONS
|
| 127 |
+
efgartigimod,NCT04833894,PHASE2;PHASE3,RECRUITING,2027-03,Generalized Myasthenia Gravis,experimental,argenx,ARGENX SE,ARGX
|
| 128 |
+
efgartigimod,NCT06298552,PHASE3,ACTIVE_NOT_RECRUITING,2025-06-30,"Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis",experimental,argenx,ARGENX SE,ARGX
|
| 129 |
+
efgartigimod,NCT07217587,PHASE3,RECRUITING,2027-09-28,Myasthenia Gravis,active_comparator,"Janssen Research & Development, LLC",,
|
| 130 |
+
eftilagimod alfa,NCT06726265,PHASE3,ACTIVE_NOT_RECRUITING,2027-06,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),experimental,Immutep S.A.S.,IMMUTEP Ltd,IMMP
|
| 131 |
+
eftilagimod alpha,NCT05747794,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-10-31,Breast Carcinoma,experimental,Immutep S.A.S.,IMMUTEP Ltd,IMMP
|
| 132 |
+
elranatamab,NCT05020236,PHASE3,RECRUITING,2026-04-27,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 133 |
+
elranatamab,NCT05317416,PHASE3,ACTIVE_NOT_RECRUITING,2027-08-04,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 134 |
+
elranatamab,NCT05317416,PHASE3,ACTIVE_NOT_RECRUITING,2027-08-04,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 135 |
+
elranatamab,NCT05317416,PHASE3,ACTIVE_NOT_RECRUITING,2027-08-04,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 136 |
+
elranatamab,NCT05317416,PHASE3,ACTIVE_NOT_RECRUITING,2027-08-04,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 137 |
+
elranatamab,NCT05623020,PHASE3,RECRUITING,2030-10-18,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 138 |
+
elranatamab,NCT06152575,PHASE3,RECRUITING,2026-08-30,Multiple Myeloma,experimental,Pfizer,PFIZER INC,PFE
|
| 139 |
+
elranatamab,NCT06918002,PHASE3,RECRUITING,2036-05,"Multiple Myeloma, Newly Diagnosed",experimental,Intergroupe Francophone du Myelome,,
|
| 140 |
+
elranatamab,NCT07647432,PHASE2;PHASE3,NOT_YET_RECRUITING,2029-12-01,Plasmablastic Lymphoma; Hiv; Consolidation,experimental,University of Illinois at Chicago,,
|
| 141 |
+
encorafenib,NCT04607421,PHASE3,ACTIVE_NOT_RECRUITING,2025-03-01,Neoplasms,experimental,Pfizer,PFIZER INC,PFE
|
| 142 |
+
encorafenib,NCT04657991,PHASE3,ACTIVE_NOT_RECRUITING,2026-01-12,Melanoma,experimental,Pfizer,PFIZER INC,PFE
|
| 143 |
+
encorafenib,NCT05615818,PHASE3,RECRUITING,2027-06,Biliary Tract Neoplasms,experimental,UNICANCER,,
|
| 144 |
+
enlicitide decanoate,NCT06008756,PHASE3,ACTIVE_NOT_RECRUITING,2029-11-29,Arteriosclerosis; Hypercholesterolaemia,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 145 |
+
enlicitide decanoate,NCT06492291,PHASE3,ACTIVE_NOT_RECRUITING,2028-10-13,Hypercholesterolemia,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 146 |
+
enlicitide decanoate,NCT07058077,PHASE2;PHASE3,RECRUITING,2033-12-04,Heterozygous Familial Hypercholesterolemia (HeFH),experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 147 |
+
enlicitide decanoate,NCT07216482,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-02,Hyperlipidemia,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 148 |
+
epcoritamab,NCT04628494,PHASE3,ACTIVE_NOT_RECRUITING,2025-10-13,Diffuse Large B-cell Lymphoma,experimental,Genmab,GENMAB A/S,GMAB
|
| 149 |
+
epcoritamab,NCT05409066,PHASE3,ACTIVE_NOT_RECRUITING,2029-12,Follicular Lymphoma (FL),experimental,Genmab,GENMAB A/S,GMAB
|
| 150 |
+
epcoritamab,NCT05578976,PHASE3,ACTIVE_NOT_RECRUITING,2027-06,Diffuse Large B-Cell Lymphoma,experimental,Genmab,GENMAB A/S,GMAB
|
| 151 |
+
epcoritamab,NCT06191744,PHASE3,RECRUITING,2037-11,Follicular Lymphoma (FL),experimental,Genmab,GENMAB A/S,GMAB
|
| 152 |
+
epcoritamab,NCT06508658,PHASE3,ACTIVE_NOT_RECRUITING,2028-03,Diffuse Large B-Cell Lymphoma,experimental,Genmab,GENMAB A/S,GMAB
|
| 153 |
+
epcoritamab,NCT07226752,PHASE3,ACTIVE_NOT_RECRUITING,2025-10-13,Diffuse Large B-Cell Lymphoma,experimental,Genmab,GENMAB A/S,GMAB
|
| 154 |
+
erwinia asparaginase,NCT03020030,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-30,"Acute Lymphoblastic Leukemia, Pediatric",experimental,Dana-Farber Cancer Institute,DANA Inc,DAN
|
| 155 |
+
erwinia asparaginase,NCT03117751,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma,experimental,St. Jude Children's Research Hospital,,
|
| 156 |
+
fianlimab,NCT05352672,PHASE3,ACTIVE_NOT_RECRUITING,2026-03-12,Melanoma,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 157 |
+
fianlimab,NCT05608291,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-27,Melanoma,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 158 |
+
fianlimab,NCT05785767,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2027-09-28,Advanced Non-Small Cell Lung Cancer,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 159 |
+
fianlimab,NCT05800015,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2030-01-16,Non-small Cell Lung Cancer,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 160 |
+
fianlimab,NCT06246916,PHASE3,RECRUITING,2027-03-22,Melanoma,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 161 |
+
golcadomide,NCT06356129,PHASE3,ACTIVE_NOT_RECRUITING,2027-08-09,Large B-cell Lymphoma,experimental,Celgene,BRISTOL MYERS SQUIBB CO,BMY
|
| 162 |
+
golcadomide,NCT06911502,PHASE3,RECRUITING,2028-04-24,Follicular Lymphoma,experimental,Celgene,BRISTOL MYERS SQUIBB CO,BMY
|
| 163 |
+
ianalumab,NCT05624749,PHASE3,ACTIVE_NOT_RECRUITING,2027-04-12,Systemic Lupus Erythematosus,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 164 |
+
ianalumab,NCT05639114,PHASE3,ACTIVE_NOT_RECRUITING,2027-03-24,Systemic Lupus Erythematosus,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 165 |
+
ianalumab,NCT06133972,PHASE3,RECRUITING,2030-04-08,Systemic Lupus Erythematosus,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 166 |
+
ianalumab,NCT06711887,PHASE3,RECRUITING,2035-08-01,Lupus Nephritis,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 167 |
+
ibrutinib,NCT01804686,PHASE3,RECRUITING,2026-12-31,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemia; Chronic Graft Versus Host Disease,experimental,"Janssen Research & Development, LLC",,
|
| 168 |
+
ibrutinib,NCT02477696,PHASE3,ACTIVE_NOT_RECRUITING,2020-09-15,Chronic Lymphocytic Leukemia,active_comparator,Acerta Pharma BV,,
|
| 169 |
+
ibrutinib,NCT03462719,PHASE3,ACTIVE_NOT_RECRUITING,2021-02-26,"Leukemia, Lymphocytic, Chronic, B-Cell",experimental,"Janssen Research & Development, LLC",,
|
| 170 |
+
ibrutinib,NCT03462719,PHASE3,ACTIVE_NOT_RECRUITING,2021-02-26,"Leukemia, Lymphocytic, Chronic, B-Cell",experimental,"Janssen Research & Development, LLC",,
|
| 171 |
+
ibrutinib,NCT04212013,PHASE3,ACTIVE_NOT_RECRUITING,2027-03-18,Marginal Zone Lymphoma,experimental,Memorial Sloan Kettering Cancer Center,,
|
| 172 |
+
ibrutinib,NCT04608318,PHASE3,ACTIVE_NOT_RECRUITING,2027-09,Chronic Lymphoid Leukemia,experimental,German CLL Study Group,,
|
| 173 |
+
ibrutinib,NCT04662255,PHASE3,ACTIVE_NOT_RECRUITING,2027-01,"Lymphoma, Mantle-Cell",active_comparator,"Loxo Oncology, Inc.",,
|
| 174 |
+
ibrutinib,NCT05254743,PHASE3,RECRUITING,2027-10,"Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma",active_comparator,"Loxo Oncology, Inc.",,
|
| 175 |
+
ibrutinib,NCT06136559,PHASE3,RECRUITING,2032-09-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,active_comparator,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 176 |
+
ibrutinib,NCT07377578,PHASE3,RECRUITING,2031-05-30,Mantle Cell Lymphoma,active_comparator,Guangzhou Lupeng Pharmaceutical Company LTD.,,
|
| 177 |
+
ifinatamab deruxtecan,NCT06203210,PHASE3,RECRUITING,2027-04-30,Small Cell Lung Cancer,experimental,Daiichi Sankyo,,
|
| 178 |
+
ifinatamab deruxtecan,NCT06644781,PHASE3,RECRUITING,2028-06-01,Esophageal Squamous Cell Carcinoma,experimental,Daiichi Sankyo,,
|
| 179 |
+
ifinatamab deruxtecan,NCT06925737,PHASE3,RECRUITING,2028-06-26,Prostate Cancer; Prostatic Neoplasms,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 180 |
+
inclisiran,NCT03705234,PHASE3,ACTIVE_NOT_RECRUITING,2026-10,Atherosclerotic Cardiovascular Disease,experimental,University of Oxford,,
|
| 181 |
+
inclisiran,NCT04765657,PHASE3,ACTIVE_NOT_RECRUITING,2022-06-09,Hypercholesterolemia,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 182 |
+
inclisiran,NCT05030428,PHASE3,ACTIVE_NOT_RECRUITING,2027-10-13,Atherosclerotic Cardiovascular Disease,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 183 |
+
inclisiran,NCT05360446,PHASE3,ACTIVE_NOT_RECRUITING,2026-10-26,Coronary Artery Disease,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 184 |
+
inclisiran,NCT05682378,PHASE3,RECRUITING,2032-03-25,Heterozygous or Homozygous Familial Hypercholesterolemia,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 185 |
+
inclisiran,NCT06597006,PHASE3,RECRUITING,2028-03-23,Familial Hypercholesterolemia - Homozygous,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 186 |
+
inclisiran,NCT06597019,PHASE3,RECRUITING,2028-03-21,Familial Hypercholesterolemia - Heterozygous,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 187 |
+
inclisiran,NCT06813911,PHASE3,RECRUITING,2028-02-03,Atherosclerotic Cardiovascular Disease (ASCVD),active_comparator,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 188 |
+
inclisiran,NCT07102628,PHASE3,RECRUITING,2027-02-11,Acute Coronary Syndrome,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 189 |
+
iptacopan,NCT06517758,PHASE3,RECRUITING,2027-04-30,Generalized Myasthenia Gravis,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 190 |
+
ivonescimab,NCT05184712,PHASE3,ACTIVE_NOT_RECRUITING,2023-03-10,Non-Squamous Non-small Cell Lung Cancer,experimental,Akeso,,
|
| 191 |
+
ivonescimab,NCT05499390,PHASE3,ACTIVE_NOT_RECRUITING,2024-01-29,Advanced Non-small-cell Lung Cancer,experimental,Akeso,,
|
| 192 |
+
ivonescimab,NCT05899608,PHASE3,RECRUITING,2028-12-31,Non-Small Cell Lung Cancer,experimental,Summit Therapeutics,Summit Therapeutics Inc.,SMMT
|
| 193 |
+
ivonescimab,NCT06396065,PHASE3,ACTIVE_NOT_RECRUITING,2025-04-12,Non-Squamous Non-small Cell Lung Cancer,experimental,Summit Therapeutics,Summit Therapeutics Inc.,SMMT
|
| 194 |
+
ivonescimab,NCT06767514,PHASE3,RECRUITING,2028-04,Non-Small Cell Lung Cancer,experimental,Summit Therapeutics,Summit Therapeutics Inc.,SMMT
|
| 195 |
+
ivonescimab,NCT06767527,PHASE3,RECRUITING,2026-12,Triple-Negative Breast Cancer (TNBC),experimental,Akeso,,
|
| 196 |
+
ivonescimab,NCT06951503,PHASE3,RECRUITING,2027-01-13,Colorectal Adenocarcinoma,experimental,Akeso,,
|
| 197 |
+
ivonescimab,NCT07010263,PHASE3,RECRUITING,2028-12-31,Small Cell Lung Cancer,experimental,Akeso,,
|
| 198 |
+
ivonescimab,NCT07228832,PHASE3,RECRUITING,2028-05-31,Metastatic Colorectal Cancer (CRC),experimental,Summit Therapeutics,Summit Therapeutics Inc.,SMMT
|
| 199 |
+
laroprovstat,NCT06834932,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2027-02-22,Dyslipidaemia,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 200 |
+
laroprovstat,NCT07000123,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-11,Cardiovascular Disease,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 201 |
+
laroprovstat,NCT07000136,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-04,Heterozygous Familial Hypercholesterolaemia,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 202 |
+
laroprovstat,NCT07000357,PHASE3,RECRUITING,2029-10-26,Cardiovascular Disease,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 203 |
+
laroprovstat,NCT07619131,PHASE3,NOT_YET_RECRUITING,2027-07-30,Hypercholesterolaemia,active_comparator,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 204 |
+
lebrikizumab,NCT05559359,PHASE3,ACTIVE_NOT_RECRUITING,2026-01-14,Atopic Dermatitis; Eczema,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 205 |
+
lebrikizumab,NCT05735483,PHASE3,ENROLLING_BY_INVITATION,2027-12,Atopic Dermatitis; Eczema,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 206 |
+
lebrikizumab,NCT06280716,PHASE3,ACTIVE_NOT_RECRUITING,2025-09-25,Atopic Dermatitis,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 207 |
+
lebrikizumab,NCT06526182,PHASE3,ACTIVE_NOT_RECRUITING,2027-04-25,"Dermatitis, Atopic; Eczema",experimental,"Almirall, S.A.",,
|
| 208 |
+
lebrikizumab,NCT07542483,PHASE3,NOT_YET_RECRUITING,2028-08,Nummular Eczema,experimental,"Almirall, S.A.",,
|
| 209 |
+
lerotinib,NCT04415853,PHASE3,RECRUITING,2026-08,Esophageal Cancer,experimental,"Sunshine Lake Pharma Co., Ltd.",Sunshine Biopharma Inc.,SBFM
|
| 210 |
+
lisaftoclax,NCT06319456,PHASE3,RECRUITING,2027-08,CLL/SLL,experimental,Ascentage Pharma Group Inc.,ASCENTAGE PHARMA GROUP INTERNATIONAL,AAPG
|
| 211 |
+
lisaftoclax,NCT06389292,PHASE3,RECRUITING,2028-05-25,Acute Myeloid Leukemia,experimental,Ascentage Pharma Group Inc.,ASCENTAGE PHARMA GROUP INTERNATIONAL,AAPG
|
| 212 |
+
litifilimab,NCT04895241,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,"Lupus Erythematosus, Systemic",experimental,Biogen,BIOGEN INC.,BIIB
|
| 213 |
+
litifilimab,NCT04961567,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-27,"Lupus Erythematosus, Systemic",experimental,Biogen,BIOGEN INC.,BIIB
|
| 214 |
+
litifilimab,NCT05352919,PHASE3,ENROLLING_BY_INVITATION,2030-03-29,Systemic Lupus Erythematosus (SLE),experimental,Biogen,BIOGEN INC.,BIIB
|
| 215 |
+
litifilimab,NCT05531565,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-10-20,Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus,experimental,Biogen,BIOGEN INC.,BIIB
|
| 216 |
+
litifilimab,NCT06044337,PHASE3,ENROLLING_BY_INVITATION,2029-06-26,Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus,experimental,Biogen,BIOGEN INC.,BIIB
|
| 217 |
+
lorlatanib,NCT05059522,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-31,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,experimental,Pfizer,PFIZER INC,PFE
|
| 218 |
+
lutikizumab,NCT06468228,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,Hidradenitis Suppurativa,experimental,AbbVie,AbbVie Inc.,ABBV
|
| 219 |
+
maridebart cafraglutide,NCT06858839,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-21,Obesity,experimental,Amgen,AMGEN INC,AMGN
|
| 220 |
+
maridebart cafraglutide,NCT06858878,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-21,"Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight",experimental,Amgen,AMGEN INC,AMGN
|
| 221 |
+
maridebart cafraglutide,NCT06987695,PHASE3,ACTIVE_NOT_RECRUITING,2027-04-27,Obesity Disease,experimental,Amgen,AMGEN INC,AMGN
|
| 222 |
+
maridebart cafraglutide,NCT07037433,PHASE3,RECRUITING,2028-06-30,Atherosclerotic Cardiovascular Disease; Overweight; Obesity,experimental,Amgen,AMGEN INC,AMGN
|
| 223 |
+
maridebart cafraglutide,NCT07037459,PHASE3,RECRUITING,2028-06-30,Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity,experimental,Amgen,AMGEN INC,AMGN
|
| 224 |
+
maridebart cafraglutide,NCT07225686,PHASE3,RECRUITING,2027-09-29,Obesity; Obstructive Sleep Apnea,experimental,Amgen,AMGEN INC,AMGN
|
| 225 |
+
maridebart cafraglutide,NCT07226765,PHASE3,RECRUITING,2027-09-29,Obstructive Sleep Apnea,experimental,Amgen,AMGEN INC,AMGN
|
| 226 |
+
maridebart cafraglutide,NCT07575399,PHASE3,RECRUITING,2028-01-03,Obesity or Overweight,experimental,Amgen,AMGEN INC,AMGN
|
| 227 |
+
maridebart cafraglutide,NCT07684144,PHASE3,NOT_YET_RECRUITING,2027-12-26,"Obesity; Overweight; Diabetes Mellitus, Type 2",experimental,Amgen,AMGEN INC,AMGN
|
| 228 |
+
maridebart cafraglutide,NCT07684235,PHASE3,NOT_YET_RECRUITING,2027-12-26,Obesity; Overweight,experimental,Amgen,AMGEN INC,AMGN
|
| 229 |
+
mercaptopurine,NCT03020030,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-30,"Acute Lymphoblastic Leukemia, Pediatric",other,Dana-Farber Cancer Institute,DANA Inc,DAN
|
| 230 |
+
mercaptopurine,NCT03117751,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma,experimental,St. Jude Children's Research Hospital,,
|
| 231 |
+
mevrometostat,NCT06551324,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-13,Metastatic Castrate Resistant Prostate Cancer (mCRPC),experimental,Pfizer,PFIZER INC,PFE
|
| 232 |
+
mevrometostat,NCT06629779,PHASE3,RECRUITING,2026-12-02,Metastatic Castration-Resistant Prostate Cancer,experimental,Pfizer,PFIZER INC,PFE
|
| 233 |
+
mevrometostat,NCT07028853,PHASE3,RECRUITING,2028-09-12,Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,experimental,Pfizer,PFIZER INC,PFE
|
| 234 |
+
mezigdomide,NCT05519085,PHASE3,RECRUITING,2027-01-10,Relapsed or Refractory Multiple Myeloma,experimental,Celgene,BRISTOL MYERS SQUIBB CO,BMY
|
| 235 |
+
mezigdomide,NCT05552976,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-18,Relapsed or Refractory Multiple Myeloma,experimental,Bristol-Myers Squibb,BRISTOL MYERS SQUIBB CO,BMY
|
| 236 |
+
mibavademab,NCT06548100,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-14,Generalized Lipodystrophy,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 237 |
+
mibavademab,NCT07220772,PHASE3,RECRUITING,2027-06-18,Monogenic Obesity,experimental,Regeneron Pharmaceuticals,"REGENERON PHARMACEUTICALS, INC.",REGN
|
| 238 |
+
midazolam,NCT05208047,PHASE3,RECRUITING,2025-09-30,Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer,experimental,"Cogent Biosciences, Inc.","Cogent Biosciences, Inc.",COGT
|
| 239 |
+
midazolam,NCT05646862,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-13,Breast Cancer,experimental,Hoffmann-La Roche,,
|
| 240 |
+
migalastat,NCT04020055,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-31,Fabry Disease,experimental,Amicus Therapeutics,,
|
| 241 |
+
migalastat,NCT05280548,PHASE3,ACTIVE_NOT_RECRUITING,2026-05-22,Fabry Disease,active_comparator,Sanofi,Sanofi,SNY
|
| 242 |
+
migalastat,NCT06904261,PHASE3,RECRUITING,2027-12,Fabry Disease,experimental,Amicus Therapeutics,,
|
| 243 |
+
minoxidil,NCT05888922,PHASE3,RECRUITING,2026-10,Androgenetic Alopecia; Female Pattern Baldness,experimental,"Industrial Farmacéutica Cantabria, S.A.",,
|
| 244 |
+
minoxidil,NCT05888922,PHASE3,RECRUITING,2026-10,Androgenetic Alopecia; Female Pattern Baldness,active_comparator,"Industrial Farmacéutica Cantabria, S.A.",,
|
| 245 |
+
minoxidil,NCT06501924,PHASE3,NOT_YET_RECRUITING,2025-10-17,Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness,active_comparator,"Applied Biology, Inc.",,
|
| 246 |
+
minoxidil,NCT07080931,PHASE3,RECRUITING,2027-12,Androgenetic Alopecia,experimental,"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.",Sunshine Biopharma Inc.,SBFM
|
| 247 |
+
minoxidil,NCT07435012,PHASE3,RECRUITING,2027-12,Androgenic Alopecia,active_comparator,Triple Hair Inc,,
|
| 248 |
+
minoxidil,NCT07529977,PHASE3,NOT_YET_RECRUITING,2028-10-30,Androgenetic Alopecia; Androgenetic Alopecia (AGA),experimental,Eurofarma Laboratorios S.A.,,
|
| 249 |
+
monalizumab,NCT04590963,PHASE3,ACTIVE_NOT_RECRUITING,2022-05-11,Squamous Cell Carcinoma of the Head and Neck,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 250 |
+
monalizumab,NCT05221840,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Non-Small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 251 |
+
nelarabine,NCT03020030,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-30,"Acute Lymphoblastic Leukemia, Pediatric",other,Dana-Farber Cancer Institute,DANA Inc,DAN
|
| 252 |
+
nelarabine,NCT03117751,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma,experimental,St. Jude Children's Research Hospital,,
|
| 253 |
+
nemtabrutinib,NCT05624554,PHASE3,ACTIVE_NOT_RECRUITING,2027-05-19,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 254 |
+
nemtabrutinib,NCT05947851,PHASE3,RECRUITING,2032-06-01,"Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 255 |
+
nemtabrutinib,NCT06136559,PHASE3,RECRUITING,2032-09-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 256 |
+
niraparib,NCT02655016,PHASE3,ACTIVE_NOT_RECRUITING,2019-05-17,Ovarian Neoplasms,experimental,"Tesaro, Inc.",,
|
| 257 |
+
niraparib,NCT03602859,PHASE3,ACTIVE_NOT_RECRUITING,2024-10-31,"Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",experimental,"Tesaro, Inc.",,
|
| 258 |
+
niraparib,NCT03651206,PHASE2;PHASE3,RECRUITING,2027-06,Ovarian Carcinosarcoma; Endometrial Carcinosarcoma,experimental,ARCAGY/ GINECO GROUP,,
|
| 259 |
+
niraparib,NCT03748641,PHASE3,ACTIVE_NOT_RECRUITING,2021-10-08,Castration-Resistant Prostatic Cancer,experimental,"Janssen Research & Development, LLC",,
|
| 260 |
+
niraparib,NCT03768063,PHASE3,ACTIVE_NOT_RECRUITING,2028-07-05,Cancer,experimental,Hoffmann-La Roche,,
|
| 261 |
+
niraparib,NCT03981796,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-26,Neoplasms,active_comparator,"Tesaro, Inc.",,
|
| 262 |
+
niraparib,NCT04497844,PHASE3,ACTIVE_NOT_RECRUITING,2025-01-07,Metastatic Castration-sensitive Prostate Cancer,experimental,"Janssen Research & Development, LLC",,
|
| 263 |
+
niraparib,NCT04915755,PHASE3,ACTIVE_NOT_RECRUITING,2024-06-28,"Neoplasms, Breast",experimental,GlaxoSmithKline,,
|
| 264 |
+
niraparib,NCT05615818,PHASE3,RECRUITING,2027-06,Biliary Tract Neoplasms,experimental,UNICANCER,,
|
| 265 |
+
niraparib,NCT06388733,PHASE3,ACTIVE_NOT_RECRUITING,2027-12,"Glioblastoma; GBM; Brain Neoplasms, Adult, Malignant; Brain Tumor",experimental,Ivy Brain Tumor Center,,
|
| 266 |
+
niraparib,NCT06915025,PHASE3,RECRUITING,2032-10-31,Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma,experimental,Imunon,"Imunon, Inc.",IMNN
|
| 267 |
+
obicetrapib,NCT05202509,PHASE3,ACTIVE_NOT_RECRUITING,2026-11,Atherosclerotic Cardiovascular Disease,experimental,NewAmsterdam Pharma,NewAmsterdam Pharma Co N.V.,NAMS
|
| 268 |
+
obicetrapib,NCT07219602,PHASE3,RECRUITING,2028-03,Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS),experimental,NewAmsterdam Pharma,NewAmsterdam Pharma Co N.V.,NAMS
|
| 269 |
+
oleclumab,NCT05221840,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Non-Small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 270 |
+
olezarsen,NCT05681351,PHASE3,ACTIVE_NOT_RECRUITING,2027-03,Severe Hypertriglyceridemia,experimental,"Ionis Pharmaceuticals, Inc.",IONIS PHARMACEUTICALS INC,IONS
|
| 271 |
+
olverembatinib,NCT06051409,PHASE3,RECRUITING,2027-12-31,"Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",experimental,Ascentage Pharma Group Inc.,ASCENTAGE PHARMA GROUP INTERNATIONAL,AAPG
|
| 272 |
+
olverembatinib,NCT06423911,PHASE3,RECRUITING,2025-12,"Chronic Myeloid Leukemia; CML; CML, Chronic Phase",other,Ascentage Pharma Group Inc.,ASCENTAGE PHARMA GROUP INTERNATIONAL,AAPG
|
| 273 |
+
olverembatinib,NCT06640361,PHASE3,RECRUITING,2027-03-31,GIST,experimental,Ascentage Pharma Group Inc.,ASCENTAGE PHARMA GROUP INTERNATIONAL,AAPG
|
| 274 |
+
olvimulogene nanivacirepvec,NCT05281471,PHASE3,RECRUITING,2026-12,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma,experimental,Genelux Corporation,GENELUX Corp,GNLX
|
| 275 |
+
orforglipron,NCT05869903,PHASE3,ACTIVE_NOT_RECRUITING,2025-07-25,Obesity; Overweight; Overweight or Obesity,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 276 |
+
orforglipron,NCT06649045,PHASE3,ACTIVE_NOT_RECRUITING,2026-11,OSA; Overweight or Obesity,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 277 |
+
orforglipron,NCT06672549,PHASE3,RECRUITING,2027-02,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 278 |
+
orforglipron,NCT06672939,PHASE3,RECRUITING,2027-12,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 279 |
+
orforglipron,NCT06948422,PHASE3,ACTIVE_NOT_RECRUITING,2027-09,Hypertension,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 280 |
+
orforglipron,NCT06948435,PHASE3,ACTIVE_NOT_RECRUITING,2027-09,Hypertension; Overweight or Obesity,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 281 |
+
orforglipron,NCT06952530,PHASE3,ACTIVE_NOT_RECRUITING,2027-09,Hypertension,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 282 |
+
orforglipron,NCT06972459,PHASE3,ACTIVE_NOT_RECRUITING,2027-08,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 283 |
+
orforglipron,NCT06972472,PHASE3,ACTIVE_NOT_RECRUITING,2027-08,Obesity; Overweight; Type 2 Diabetes,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 284 |
+
orforglipron,NCT06993792,PHASE3,ACTIVE_NOT_RECRUITING,2027-08,Obesity; Overweight; Type 2 Diabetes,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 285 |
+
orforglipron,NCT07153471,PHASE3,RECRUITING,2028-04,Osteoarthritis,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 286 |
+
orforglipron,NCT07202884,PHASE3,RECRUITING,2028-03,"Urinary Incontinence,Stress",experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 287 |
+
orforglipron,NCT07223593,PHASE3,RECRUITING,2028-06,Peripheral Arterial Disease,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 288 |
+
orforglipron,NCT07241390,PHASE3,RECRUITING,2031-08,Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 289 |
+
orforglipron,NCT07613307,PHASE3,NOT_YET_RECRUITING,2027-05,"Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide",experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 290 |
+
orforglipron,NCT07668336,PHASE3,NOT_YET_RECRUITING,2030-03,"Diabetes Mellitus, Type 2",experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 291 |
+
paltusotine,NCT07087054,PHASE3,RECRUITING,2027-08,Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor,experimental,Crinetics Pharmaceuticals Inc.,"Crinetics Pharmaceuticals, Inc.",CRNX
|
| 292 |
+
patidegib,NCT06050122,PHASE3,ACTIVE_NOT_RECRUITING,2026-08,Gorlin Syndrome,experimental,"Sol-Gel Technologies, Ltd.",Sol-Gel Technologies Ltd.,SLGL
|
| 293 |
+
pazopanib,NCT03592472,PHASE3,RECRUITING,2026-12-30,Renal Cell Carcinoma,experimental,"Xynomic Pharmaceuticals, Inc.",,
|
| 294 |
+
pazopanib,NCT06263231,PHASE3,ACTIVE_NOT_RECRUITING,2027-12,"Sarcoma,Soft Tissue",active_comparator,"Intensity Therapeutics, Inc.","INTENSITY THERAPEUTICS, INC.",INTS
|
| 295 |
+
pegaspargase,NCT03020030,PHASE3,ACTIVE_NOT_RECRUITING,2026-11-30,"Acute Lymphoblastic Leukemia, Pediatric",experimental,Dana-Farber Cancer Institute,DANA Inc,DAN
|
| 296 |
+
pegaspargase,NCT03117751,PHASE2;PHASE3,ACTIVE_NOT_RECRUITING,2026-09-30,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma,experimental,St. Jude Children's Research Hospital,,
|
| 297 |
+
pegaspargase,NCT05700448,PHASE3,NOT_YET_RECRUITING,2029-12,Extranodal NK/T-cell Lymphoma,experimental,CStone Pharmaceuticals,,
|
| 298 |
+
pelabresib,NCT06401356,PHASE3,RECRUITING,2027-06-02,Hematologic Malignancy; Solid Tumor; Advanced Malignancies,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 299 |
+
pitolisant,NCT06366464,PHASE3,RECRUITING,2026-07,Prader-Willi Syndrome,experimental,"Harmony Biosciences Management, Inc.","Harmony Biosciences Holdings, Inc.",HRMY
|
| 300 |
+
pitolisant,NCT07219485,PHASE3,ENROLLING_BY_INVITATION,2030-08,Prader-Willi Syndrome,experimental,"Harmony Biosciences Management, Inc.","Harmony Biosciences Holdings, Inc.",HRMY
|
| 301 |
+
povorcitinib,NCT06113445,PHASE3,ACTIVE_NOT_RECRUITING,2026-02-24,NonSegmental Vitiligo,experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 302 |
+
povorcitinib,NCT06113471,PHASE3,ACTIVE_NOT_RECRUITING,2026-03-17,NonSegmental Vitiligo,experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 303 |
+
povorcitinib,NCT06212999,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-26,Hidradenitis Suppurativa (HS),experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 304 |
+
povorcitinib,NCT06855498,PHASE3,RECRUITING,2028-02-28,Hidradenitis Suppurativa (HS),experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 305 |
+
ralinepag,NCT03683186,PHASE3,ENROLLING_BY_INVITATION,2026-12,"PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease",experimental,United Therapeutics,UNITED THERAPEUTICS Corp,UTHR
|
| 306 |
+
ravulizumab,NCT05644561,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-15,Generalized Myasthenia Gravis; gMG,experimental,"Alexion Pharmaceuticals, Inc.",ASTRAZENECA PLC,AZN
|
| 307 |
+
ravulizumab,NCT07024563,PHASE3,RECRUITING,2028-07-12,IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephritis; Henoch-schonlein Purpura Nephritis; IgA Vasculitis,experimental,"Alexion Pharmaceuticals, Inc.",ASTRAZENECA PLC,AZN
|
| 308 |
+
ravulizumab,NCT07596784,PHASE3,NOT_YET_RECRUITING,2027-08-27,Generalized Myasthenia Gravis; gMG,experimental,"Alexion Pharmaceuticals, Inc.",ASTRAZENECA PLC,AZN
|
| 309 |
+
recombinant human tissue kallikrein,NCT05065216,PHASE2;PHASE3,RECRUITING,2026-12,Acute Stroke; Ischemic Stroke; Stroke,experimental,DiaMedica Therapeutics Inc,DiaMedica Therapeutics Inc.,DMAC
|
| 310 |
+
rescue medications,NCT06132958,PHASE3,ACTIVE_NOT_RECRUITING,2028-01-10,Endometrial Cancer,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 311 |
+
rescue medications,NCT06356311,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-04,Gastroesophageal Cancer,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 312 |
+
rescue medications,NCT07216703,PHASE3,RECRUITING,2031-10-29,Cervical Cancer,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 313 |
+
rescue medications,NCT07318558,PHASE3,RECRUITING,2033-02-25,Ovarian Neoplasms; Ovarian Cancer,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 314 |
+
resmetirom,NCT03900429,PHASE3,ACTIVE_NOT_RECRUITING,2028-01,NASH - Nonalcoholic Steatohepatitis,active_comparator,"Madrigal Pharmaceuticals, Inc.","MADRIGAL PHARMACEUTICALS, INC.",MDGL
|
| 315 |
+
resmetirom,NCT04951219,PHASE3,ACTIVE_NOT_RECRUITING,2027-03,Non-Alcoholic Fatty Liver Disease,experimental,"Madrigal Pharmaceuticals, Inc.","MADRIGAL PHARMACEUTICALS, INC.",MDGL
|
| 316 |
+
resmetirom,NCT05500222,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,"NASH; Cirrhosis, Liver",active_comparator,"Madrigal Pharmaceuticals, Inc.","MADRIGAL PHARMACEUTICALS, INC.",MDGL
|
| 317 |
+
retatrutide,NCT05882045,PHASE3,ACTIVE_NOT_RECRUITING,2026-04-16,Obesity; Cardiovascular Diseases,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 318 |
+
retatrutide,NCT05929079,PHASE3,ACTIVE_NOT_RECRUITING,2026-05,Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 319 |
+
retatrutide,NCT06260722,PHASE3,ACTIVE_NOT_RECRUITING,2026-08,"Diabetes Mellitus, Type 2",experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 320 |
+
retatrutide,NCT06297603,PHASE3,ACTIVE_NOT_RECRUITING,2026-10,Type 2 Diabetes,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 321 |
+
retatrutide,NCT06383390,PHASE3,ACTIVE_NOT_RECRUITING,2029-02,Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD),experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 322 |
+
retatrutide,NCT06662383,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,Obesity,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 323 |
+
retatrutide,NCT06859268,PHASE3,ACTIVE_NOT_RECRUITING,2028-04,Obesity,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 324 |
+
retatrutide,NCT07035093,PHASE3,RECRUITING,2027-09,Obesity; Overweight; Chronic Low Back Pain (CLBP),experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 325 |
+
retatrutide,NCT07165028,PHASE3,RECRUITING,2030-08,Metabolic Dysfunction-Associated Steatotic Liver Disease,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 326 |
+
retatrutide,NCT07232719,PHASE3,ACTIVE_NOT_RECRUITING,2027-07,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 327 |
+
retatrutide,NCT07357415,PHASE3,ACTIVE_NOT_RECRUITING,2028-10,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 328 |
+
rezvilutamide,NCT07241416,PHASE3,RECRUITING,2027-03,Metastatic Hormone-sensitive Prostate Cancer (mHSPC),experimental,"Jiangsu HengRui Medicine Co., Ltd.",,
|
| 329 |
+
rezvilutamide,NCT07611110,PHASE3,RECRUITING,2029-02-13,Metastatic Castration-resistant Prostate Cancer,active_comparator,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 330 |
+
rilvegostomig,NCT06109779,PHASE3,ACTIVE_NOT_RECRUITING,2029-01-02,Biliary Tract Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 331 |
+
rilvegostomig,NCT06357533,PHASE3,RECRUITING,2029-12-28,Non-Small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 332 |
+
rilvegostomig,NCT06467357,PHASE3,RECRUITING,2028-06-12,Biliary Tract Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 333 |
+
rilvegostomig,NCT06564844,PHASE3,ACTIVE_NOT_RECRUITING,2027-06-30,Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 334 |
+
rilvegostomig,NCT06627647,PHASE3,RECRUITING,2030-11-18,Non-squamous Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 335 |
+
rilvegostomig,NCT06692738,PHASE3,RECRUITING,2030-07-01,Non-small Cell Lung Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 336 |
+
rilvegostomig,NCT06764875,PHASE3,RECRUITING,2029-04-27,HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 337 |
+
rilvegostomig,NCT06868277,PHASE3,RECRUITING,2030-01-17,"Carcinoma, Non-Small Cell Lung",experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 338 |
+
rilvegostomig,NCT06921785,PHASE3,RECRUITING,2029-03-16,Hepatocellular Carcinoma,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 339 |
+
rilvegostomig,NCT06989112,PHASE3,RECRUITING,2029-01-19,Endometrial Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 340 |
+
rilvegostomig,NCT07221253,PHASE3,RECRUITING,2029-07-31,Biliary Tract Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 341 |
+
rilvegostomig,NCT07431281,PHASE3,RECRUITING,2029-08-16,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 342 |
+
rina,NCT06619236,PHASE3,ACTIVE_NOT_RECRUITING,2027-02,Platinum-resistant Ovarian Cancer,experimental,Genmab,GENMAB A/S,GMAB
|
| 343 |
+
rina,NCT07166094,PHASE3,RECRUITING,2029-08,Endometrial Cancer; Recurrent or Progressive Endometrial Cancer,experimental,Genmab,GENMAB A/S,GMAB
|
| 344 |
+
rina,NCT07225270,PHASE3,RECRUITING,2028-10,Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC,experimental,Genmab,GENMAB A/S,GMAB
|
| 345 |
+
rina,NCT07564141,PHASE3,NOT_YET_RECRUITING,2029-12,Platinum-Sensitive Ovarian Cancer; Ovarian Cancer,experimental,Genmab,GENMAB A/S,GMAB
|
| 346 |
+
rina,NCT07604766,PHASE3,NOT_YET_RECRUITING,2027-09,Platinum-resistant Ovarian Cancer,experimental,Genmab,GENMAB A/S,GMAB
|
| 347 |
+
ritlecitinib,NCT06072183,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 348 |
+
ritlecitinib,NCT06072183,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 349 |
+
ritlecitinib,NCT06072183,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 350 |
+
ritlecitinib,NCT06072183,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-30,Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 351 |
+
ritlecitinib,NCT06163326,PHASE3,ACTIVE_NOT_RECRUITING,2027-03-31,Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 352 |
+
ritlecitinib,NCT06163326,PHASE3,ACTIVE_NOT_RECRUITING,2027-03-31,Vitiligo,experimental,Pfizer,PFIZER INC,PFE
|
| 353 |
+
ritlecitinib,NCT06873945,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-21,Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 354 |
+
ritlecitinib,NCT06873945,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-21,Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 355 |
+
ritlecitinib higher,NCT07029711,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-02,Severe Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 356 |
+
ritlecitinib higher,NCT07029828,PHASE3,RECRUITING,2030-06-26,Severe Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 357 |
+
ritlecitinib lower,NCT07029711,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-02,Severe Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 358 |
+
ritlecitinib lower,NCT07029828,PHASE3,RECRUITING,2030-06-26,Severe Alopecia Areata,experimental,Pfizer,PFIZER INC,PFE
|
| 359 |
+
rosuvastatin calcium,NCT03016819,PHASE3,RECRUITING,2027-12,Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma,active_comparator,"Advenchen Laboratories, LLC",,
|
| 360 |
+
rosuvastatin calcium,NCT04602754,PHASE3,RECRUITING,2026-05,Dyslipidemia Associated With Type II Diabetes Mellitus,active_comparator,EMS,,
|
| 361 |
+
rosuvastatin calcium,NCT07216482,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-02,Hyperlipidemia,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 362 |
+
rosuvastatin calcium,NCT07474649,PHASE3,NOT_YET_RECRUITING,2028-06-01,Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia,experimental,Daiichi Sankyo,,
|
| 363 |
+
sacituzumab govitecan hziy,NCT04639986,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,Metastatic Breast Cancer,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 364 |
+
sacituzumab govitecan hziy,NCT05089734,PHASE3,ACTIVE_NOT_RECRUITING,2023-11-29,Non-Small Cell Lung Cancer,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 365 |
+
sacituzumab govitecan hziy,NCT05382286,PHASE3,ACTIVE_NOT_RECRUITING,2027-02,Triple Negative Breast Cancer; PD-L1 Positive,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 366 |
+
sacituzumab govitecan hziy,NCT05382299,PHASE3,ACTIVE_NOT_RECRUITING,2028-07,Triple Negative Breast Cancer; PD-L1 Negative,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 367 |
+
sacituzumab govitecan hziy,NCT05633654,PHASE3,RECRUITING,2027-06,Triple Negative Breast Cancer,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 368 |
+
sacituzumab govitecan hziy,NCT05840211,PHASE3,ACTIVE_NOT_RECRUITING,2028-04,Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 369 |
+
sacituzumab govitecan hziy,NCT06486441,PHASE3,ACTIVE_NOT_RECRUITING,2029-06,Endometrial Cancer,experimental,Gilead Sciences,"GILEAD SCIENCES, INC.",GILD
|
| 370 |
+
setmelanotide,NCT05093634,PHASE3,ACTIVE_NOT_RECRUITING,2025-12-22,Obesity; Genetic Obesity,experimental,"Rhythm Pharmaceuticals, Inc.","RHYTHM PHARMACEUTICALS, INC.",RYTM
|
| 371 |
+
setmelanotide,NCT05774756,PHASE3,ACTIVE_NOT_RECRUITING,2025-03-18,Hypothalamic Obesity,experimental,"Rhythm Pharmaceuticals, Inc.","RHYTHM PHARMACEUTICALS, INC.",RYTM
|
| 372 |
+
setmelanotide,NCT06760546,PHASE3,RECRUITING,2027-03-13,Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pituitary Stalk Interruption Syndrome,experimental,"Rhythm Pharmaceuticals, Inc.","RHYTHM PHARMACEUTICALS, INC.",RYTM
|
| 373 |
+
sonelokimab,NCT06641076,PHASE3,ACTIVE_NOT_RECRUITING,2027-02-04,"Arthritis, Psoriatic",experimental,MoonLake Immunotherapeutics AG,MoonLake Immunotherapeutics,MLTX
|
| 374 |
+
sonelokimab,NCT06641089,PHASE3,RECRUITING,2027-01-15,"Arthritis, Psoriatic",experimental,MoonLake Immunotherapeutics AG,MoonLake Immunotherapeutics,MLTX
|
| 375 |
+
sonelokimab,NCT06768671,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-28,Hidradenitis Suppurativa,experimental,MoonLake Immunotherapeutics AG,MoonLake Immunotherapeutics,MLTX
|
| 376 |
+
sonelokimab,NCT07007637,PHASE3,ENROLLING_BY_INVITATION,2028-06-13,Hidradenitis Suppurativa,experimental,MoonLake Immunotherapeutics AG,MoonLake Immunotherapeutics,MLTX
|
| 377 |
+
sonelokimab,NCT07223138,PHASE3,ENROLLING_BY_INVITATION,2028-02-04,"Arthritis, Psoriatic",experimental,MoonLake Immunotherapeutics AG,MoonLake Immunotherapeutics,MLTX
|
| 378 |
+
sotagliflozin,NCT06217302,PHASE3,RECRUITING,2028-12,"Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure",active_comparator,Alessandro Doria,,
|
| 379 |
+
sotagliflozin,NCT06481891,PHASE3,RECRUITING,2026-07,"Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy",experimental,Lexicon Pharmaceuticals,"LEXICON PHARMACEUTICALS, INC.",LXRX
|
| 380 |
+
sotorasib,NCT04303780,PHASE3,ACTIVE_NOT_RECRUITING,2022-08-02,"KRAS p, G12c Mutated /Advanced Metastatic NSCLC",experimental,Amgen,AMGEN INC,AMGN
|
| 381 |
+
sotorasib,NCT05920356,PHASE3,RECRUITING,2027-06-30,Non-Small Cell Lung Cancer (NSCLC),experimental,Amgen,AMGEN INC,AMGN
|
| 382 |
+
sotorasib,NCT06252649,PHASE3,RECRUITING,2028-09-25,Metastatic Colorectal Cancer,experimental,Amgen,AMGEN INC,AMGN
|
| 383 |
+
sotorasib,NCT06497556,PHASE3,ACTIVE_NOT_RECRUITING,2026-05-19,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,active_comparator,Hoffmann-La Roche,,
|
| 384 |
+
supportive care measures,NCT06170788,PHASE3,RECRUITING,2028-01-25,Non-small Cell Lung Cancer (NSCLC),experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 385 |
+
supportive care measures,NCT06356311,PHASE3,ACTIVE_NOT_RECRUITING,2027-01-04,Gastroesophageal Cancer,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 386 |
+
tafasitamab,NCT04680052,PHASE3,ACTIVE_NOT_RECRUITING,2024-02-23,Follicular Lymphoma; Marginal Zone Lymphoma,experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 387 |
+
tafasitamab,NCT04824092,PHASE3,ACTIVE_NOT_RECRUITING,2026-09-01,Diffuse Large B-cell Lymphoma,experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 388 |
+
tafasitamab,NCT05429268,PHASE3,ACTIVE_NOT_RECRUITING,2026-03-30,Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma,experimental,Incyte Corporation,INCYTE CORP,INCY
|
| 389 |
+
tafasitamab,NCT06521255,PHASE3,RECRUITING,2028-09,DLBCL,experimental,"Beijing InnoCare Pharma Tech Co., Ltd.",,
|
| 390 |
+
talazoparib,NCT05059522,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-31,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,experimental,Pfizer,PFIZER INC,PFE
|
| 391 |
+
tapinarof,NCT05172726,PHASE3,ACTIVE_NOT_RECRUITING,2026-10,Plaque Psoriasis,experimental,Organon and Co,Organon & Co.,OGN
|
| 392 |
+
tapinarof,NCT05981118,PHASE2;PHASE3,ENROLLING_BY_INVITATION,2026-07,ICD10 Code L40.9 for Psoriasis,active_comparator,Wake Forest University Health Sciences,,
|
| 393 |
+
tapinarof,NCT07265479,PHASE3,RECRUITING,2028-01,Atopic Dermatitis,experimental,Organon and Co,Organon & Co.,OGN
|
| 394 |
+
tarlatamab,NCT05740566,PHASE3,ACTIVE_NOT_RECRUITING,2025-01-29,Small Cell Lung Cancer (SCLC),experimental,Amgen,AMGEN INC,AMGN
|
| 395 |
+
tarlatamab,NCT06117774,PHASE3,ACTIVE_NOT_RECRUITING,2030-04-20,Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer,experimental,Amgen,AMGEN INC,AMGN
|
| 396 |
+
tarlatamab,NCT06211036,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-05,Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer,experimental,Amgen,AMGEN INC,AMGN
|
| 397 |
+
tarlatamab,NCT07005128,PHASE3,RECRUITING,2029-01-04,Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer,experimental,Amgen,AMGEN INC,AMGN
|
| 398 |
+
tarlatamab,NCT07637513,PHASE3,NOT_YET_RECRUITING,2037-11,Limited Stage Small-Cell Lung Cancer,experimental,"PrECOG, LLC.",,
|
| 399 |
+
telisotuzumab adizutecan,NCT06614192,PHASE3,ACTIVE_NOT_RECRUITING,2027-08,Metastatic Colorectal Cancer,experimental,AbbVie,AbbVie Inc.,ABBV
|
| 400 |
+
telisotuzumab adizutecan,NCT07005102,PHASE2;PHASE3,RECRUITING,2031-12,Non-Squamous Non-Small Cell Lung Cancer,experimental,AbbVie,AbbVie Inc.,ABBV
|
| 401 |
+
telisotuzumab adizutecan,NCT07155187,PHASE2;PHASE3,RECRUITING,2030-09,Non-Small Cell Lung Cancer,experimental,AbbVie,AbbVie Inc.,ABBV
|
| 402 |
+
telisotuzumab adizutecan,NCT07525206,PHASE3,RECRUITING,2029-05,Colorectal Cancer,experimental,AbbVie,AbbVie Inc.,ABBV
|
| 403 |
+
telitacicept,NCT06456580,PHASE3,RECRUITING,2027-05,Generalized Myasthenia Gravis,experimental,Vor Biopharma,Vor Biopharma Inc.,VOR
|
| 404 |
+
telitacicept,NCT07249632,PHASE3,RECRUITING,2026-12-31,"Myasthenia Gravis, Ocular",experimental,"RemeGen Co., Ltd.",,
|
| 405 |
+
tezepelumab,NCT06023589,PHASE3,RECRUITING,2028-05-31,Asthma,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 406 |
+
tezepelumab,NCT06740045,PHASE3,NOT_YET_RECRUITING,2025-03,Asthma; Chronic Rhinosinusitis With Nasal Polyps,experimental,"Dr. Andrew Thamboo, MD",,
|
| 407 |
+
tezepelumab,NCT07013123,PHASE3,NOT_YET_RECRUITING,2029-08-18,Severe Asthma; Allergy to House Dust Mites,experimental,"University Hospital, Montpellier",,
|
| 408 |
+
tezepelumab,NCT07302516,PHASE3,NOT_YET_RECRUITING,2028-12,Asthma,experimental,"Qilu Pharmaceutical Co., Ltd.",,
|
| 409 |
+
tezepelumab,NCT07363642,PHASE3,RECRUITING,2027-08-07,Severe Asthma,experimental,AstraZeneca,ASTRAZENECA PLC,AZN
|
| 410 |
+
tirzepatide,NCT05556512,PHASE3,ACTIVE_NOT_RECRUITING,2027-10,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 411 |
+
tirzepatide,NCT06075667,PHASE3,ACTIVE_NOT_RECRUITING,2026-06-02,Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 412 |
+
tirzepatide,NCT06439277,PHASE3,RECRUITING,2027-10,Obesity; Weight Gain,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 413 |
+
tirzepatide,NCT06662383,PHASE3,ACTIVE_NOT_RECRUITING,2026-12,Obesity,active_comparator,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 414 |
+
tirzepatide,NCT06914895,PHASE3,ACTIVE_NOT_RECRUITING,2026-11,Type 1 Diabetes; Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 415 |
+
tirzepatide,NCT06937086,PHASE3,RECRUITING,2028-04,Ulcerative Colitis; Obesity or Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 416 |
+
tirzepatide,NCT06937099,PHASE3,RECRUITING,2028-05,Crohn's Disease; Obesity or Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 417 |
+
tirzepatide,NCT06962280,PHASE3,ACTIVE_NOT_RECRUITING,2026-11,Type 1 Diabetes; Obesity; Overweight,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 418 |
+
tirzepatide,NCT07165028,PHASE3,RECRUITING,2030-08,Metabolic Dysfunction-Associated Steatotic Liver Disease,experimental,Eli Lilly and Company,ELI LILLY & Co,LLY
|
| 419 |
+
tirzepatide,NCT07481747,PHASE3,RECRUITING,2027-02-14,Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities,experimental,Hudson Biotech,,
|
| 420 |
+
tisagenlecleucel,NCT04094311,PHASE3,RECRUITING,2027-03-31,B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma,experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 421 |
+
tisagenlecleucel,NCT05888493,PHASE3,ACTIVE_NOT_RECRUITING,2028-07-25,Follicular Lymphoma (FL),experimental,Novartis Pharmaceuticals,NOVARTIS AG,NVS
|
| 422 |
+
tocilizumab,NCT04408638,PHASE3,ACTIVE_NOT_RECRUITING,2028-03-31,Diffuse Large B-cell Lymphoma,experimental,Hoffmann-La Roche,,
|
| 423 |
+
tocilizumab,NCT04888221,PHASE3,ACTIVE_NOT_RECRUITING,2025-01-29,Giant Cell Arteritis; Neurovascular Disorder,experimental,Assistance Publique - Hôpitaux de Paris,,
|
| 424 |
+
tocilizumab,NCT05171647,PHASE3,ACTIVE_NOT_RECRUITING,2025-02-17,Non-Hodgkin Lymphoma,experimental,Hoffmann-La Roche,,
|
| 425 |
+
tocilizumab,NCT06084936,PHASE3,RECRUITING,2027-08-31,Lymphoma,experimental,Hoffmann-La Roche,,
|
| 426 |
+
tocilizumab,NCT07570173,PHASE2;PHASE3,RECRUITING,2033-10-18,B-cell Acute Lymphoblastic Leukemia,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 427 |
+
tofacitinib,NCT04624230,PHASE3,ACTIVE_NOT_RECRUITING,2027-04-14,Ulcerative Colitis,experimental,Pfizer,PFIZER INC,PFE
|
| 428 |
+
tofacitinib,NCT06020144,PHASE3,ACTIVE_NOT_RECRUITING,2026-01-15,Rheumatoid Arthritis,active_comparator,"Hangzhou Highlightll Pharmaceutical Co., Ltd",,
|
| 429 |
+
tradipitant,NCT07446439,PHASE3,RECRUITING,2026-12-01,Nausea and Vomiting; Obesity,experimental,Vanda Pharmaceuticals,Vanda Pharmaceuticals Inc.,VNDA
|
| 430 |
+
tulisokibart,NCT06052059,PHASE3,ACTIVE_NOT_RECRUITING,2026-08-01,Ulcerative Colitis,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 431 |
+
tulisokibart,NCT06052059,PHASE3,ACTIVE_NOT_RECRUITING,2026-08-01,Ulcerative Colitis,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 432 |
+
tulisokibart,NCT06430801,PHASE3,RECRUITING,2028-10-30,Crohn's Disease,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 433 |
+
tulisokibart,NCT06430801,PHASE3,RECRUITING,2028-10-30,Crohn's Disease,experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 434 |
+
tulisokibart,NCT06651281,PHASE3,RECRUITING,2037-12-17,"Crohn Disease; Colitis, Ulcerative",experimental,Merck Sharp & Dohme LLC,"Merck & Co., Inc.",MRK
|
| 435 |
+
utomilumab,NCT05059522,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-31,Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors,experimental,Pfizer,PFIZER INC,PFE
|
| 436 |
+
vepdegestrant,NCT05654623,PHASE3,ACTIVE_NOT_RECRUITING,2025-01-31,Advanced Breast Cancer,experimental,Pfizer,PFIZER INC,PFE
|
| 437 |
+
vepdegestrant,NCT05909397,PHASE3,ACTIVE_NOT_RECRUITING,2026-12-30,Breast Cancer,experimental,Pfizer,PFIZER INC,PFE
|
| 438 |
+
zanidatamab,NCT05152147,PHASE3,ACTIVE_NOT_RECRUITING,2026-07-31,Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma,experimental,Jazz Pharmaceuticals,Jazz Pharmaceuticals plc,JAZZ
|
| 439 |
+
zanidatamab,NCT05615818,PHASE3,RECRUITING,2027-06,Biliary Tract Neoplasms,experimental,UNICANCER,,
|
| 440 |
+
zanidatamab,NCT06282575,PHASE3,RECRUITING,2028-12-01,Biliary Tract Cancer,experimental,Jazz Pharmaceuticals,Jazz Pharmaceuticals plc,JAZZ
|
| 441 |
+
zanidatamab,NCT06435429,PHASE3,RECRUITING,2028-04-28,Metastatic HER2-positive Breast Cancer,experimental,Jazz Pharmaceuticals,Jazz Pharmaceuticals plc,JAZZ
|
| 442 |
+
zanubrutinib,NCT03336333,PHASE3,ACTIVE_NOT_RECRUITING,2021-05-07,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,experimental,BeiGene,,
|
| 443 |
+
zanubrutinib,NCT04002297,PHASE3,ACTIVE_NOT_RECRUITING,2027-03,Mantle Cell Lymphoma; Non-Hodgkin Lymphoma,experimental,BeOne Medicines,BeOne Medicines Ltd.,ONC
|
| 444 |
+
zanubrutinib,NCT04170283,PHASE3,ACTIVE_NOT_RECRUITING,2027-11,B-cell Malignancies,experimental,BeiGene,,
|
| 445 |
+
zanubrutinib,NCT04662255,PHASE3,ACTIVE_NOT_RECRUITING,2027-01,"Lymphoma, Mantle-Cell",active_comparator,"Loxo Oncology, Inc.",,
|
| 446 |
+
zanubrutinib,NCT05100862,PHASE3,ACTIVE_NOT_RECRUITING,2028-07,Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma,experimental,BeOne Medicines,BeOne Medicines Ltd.,ONC
|
| 447 |
+
zanubrutinib,NCT06073821,PHASE3,ACTIVE_NOT_RECRUITING,2032-02,CLL,experimental,BeOne Medicines,BeOne Medicines Ltd.,ONC
|
| 448 |
+
zanubrutinib,NCT06742996,PHASE3,RECRUITING,2028-08-31,Mantle Cell Lymphoma; B Cell Lymphoma,experimental,BeOne Medicines,BeOne Medicines Ltd.,ONC
|
| 449 |
+
zanubrutinib,NCT07277231,PHASE3,RECRUITING,2031-02,Chronic Lymphocytic Leukemia,experimental,BeOne Medicines,BeOne Medicines Ltd.,ONC
|
| 450 |
+
zanubrutinib,NCT07377578,PHASE3,RECRUITING,2031-05-30,Mantle Cell Lymphoma,active_comparator,Guangzhou Lupeng Pharmaceutical Company LTD.,,
|
| 451 |
+
zasocitinib,NCT06323356,PHASE3,ACTIVE_NOT_RECRUITING,2025-10-15,Generalized Pustular Psoriasis; Erythrodermic Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 452 |
+
zasocitinib,NCT06550076,PHASE3,ACTIVE_NOT_RECRUITING,2029-08-05,Plaque Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 453 |
+
zasocitinib,NCT06671483,PHASE3,RECRUITING,2027-05-18,Psoriatic Arthritis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 454 |
+
zasocitinib,NCT06671496,PHASE3,RECRUITING,2027-05-18,Psoriatic Arthritis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 455 |
+
zasocitinib,NCT07250802,PHASE3,RECRUITING,2033-01-24,Plaque Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 456 |
+
zasocitinib,NCT07250802,PHASE3,RECRUITING,2033-01-24,Plaque Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 457 |
+
zasocitinib,NCT07250802,PHASE3,RECRUITING,2033-01-24,Plaque Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 458 |
+
zasocitinib,NCT07250802,PHASE3,RECRUITING,2033-01-24,Plaque Psoriasis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 459 |
+
zasocitinib,NCT07286058,PHASE3,RECRUITING,2029-12-18,Psoriatic Arthritis,experimental,Takeda,TAKEDA PHARMACEUTICAL CO LTD,TAK
|
| 460 |
+
ziltivekimab,NCT05636176,PHASE3,ACTIVE_NOT_RECRUITING,2027-07-02,Heart Failure,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 461 |
+
ziltivekimab,NCT06200207,PHASE3,RECRUITING,2026-10-01,Heart Failure; Systemic Inflammation,active_comparator,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 462 |
+
ziltivekimab,NCT07276282,PHASE3,RECRUITING,2028-09-01,Coronary Artery Disease; Acute Myocardial Infarction (AMI); Coronary Atherosclerosis of Native Coronary Artery,experimental,ECRI bv,,
|
| 463 |
+
ziltivekimab,NCT07301034,PHASE3,RECRUITING,2028-11-14,Myocardial Infarction,experimental,Novo Nordisk A/S,NOVO NORDISK A S,NVO
|
| 464 |
+
zodasiran,NCT07037771,PHASE3,RECRUITING,2027-08-20,Homozygous Familial Hypercholesterolemia,experimental,Arrowhead Pharmaceuticals,"ARROWHEAD PHARMACEUTICALS, INC.",ARWR
|
| 465 |
+
zodasiran,NCT07473843,PHASE3,NOT_YET_RECRUITING,2028-07,Homozygous Familial Hypercholesterolemia,experimental,Arrowhead Pharmaceuticals,"ARROWHEAD PHARMACEUTICALS, INC.",ARWR
|
asset_master_sample.json
ADDED
|
The diff for this file is too large to render.
See raw diff
|
|
|
catalyst_calendar_sample.csv
ADDED
|
@@ -0,0 +1,151 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
event_date,ticker,asset,event_type,event_window,date_precision,confidence,source,nct_id,source_url
|
| 2 |
+
2026-07-18,BMY,mezigdomide,READOUT,"Jul 18, 2026",day,medium,clinicaltrials,NCT05552976,https://clinicaltrials.gov/study/NCT05552976
|
| 3 |
+
2026-07-25,BMY,deucravacitinib,READOUT,"Jul 25, 2026",day,medium,clinicaltrials,NCT04036435,https://clinicaltrials.gov/study/NCT04036435
|
| 4 |
+
2026-07-27,REGN,fianlimab,READOUT,"Jul 27, 2026",day,medium,clinicaltrials,NCT05608291,https://clinicaltrials.gov/study/NCT05608291
|
| 5 |
+
2026-07-31,HRMY,pitolisant,READOUT,Jul 2026,month,medium,clinicaltrials,NCT06366464,https://clinicaltrials.gov/study/NCT06366464
|
| 6 |
+
2026-07-31,LXRX,sotagliflozin,READOUT,Jul 2026,month,medium,clinicaltrials,NCT06481891,https://clinicaltrials.gov/study/NCT06481891
|
| 7 |
+
2026-07-31,JAZZ,zanidatamab,READOUT,"Jul 31, 2026",day,medium,clinicaltrials,NCT05152147,https://clinicaltrials.gov/study/NCT05152147
|
| 8 |
+
2026-08-01,MRK,tulisokibart,READOUT,"Aug 1, 2026",day,medium,clinicaltrials,NCT06052059,https://clinicaltrials.gov/study/NCT06052059
|
| 9 |
+
2026-08-24,AZN,camizestrant,READOUT,"Aug 24, 2026",day,medium,clinicaltrials,NCT04711252,https://clinicaltrials.gov/study/NCT04711252
|
| 10 |
+
2026-08-30,PFE,elranatamab,READOUT,"Aug 30, 2026",day,medium,clinicaltrials,NCT06152575,https://clinicaltrials.gov/study/NCT06152575
|
| 11 |
+
2026-08-31,PHVS,deucrictibant,READOUT,Aug 2026,month,medium,clinicaltrials,NCT06669754,https://clinicaltrials.gov/study/NCT06669754
|
| 12 |
+
2026-08-31,SBFM,lerotinib,READOUT,Aug 2026,month,medium,clinicaltrials,NCT04415853,https://clinicaltrials.gov/study/NCT04415853
|
| 13 |
+
2026-08-31,SLGL,patidegib,READOUT,Aug 2026,month,medium,clinicaltrials,NCT06050122,https://clinicaltrials.gov/study/NCT06050122
|
| 14 |
+
2026-08-31,LLY,retatrutide,READOUT,Aug 2026,month,medium,clinicaltrials,NCT06260722,https://clinicaltrials.gov/study/NCT06260722
|
| 15 |
+
2026-09-01,INCY,tafasitamab,READOUT,"Sep 1, 2026",day,medium,clinicaltrials,NCT04824092,https://clinicaltrials.gov/study/NCT04824092
|
| 16 |
+
2026-09-27,BIIB,litifilimab,READOUT,"Sep 27, 2026",day,medium,clinicaltrials,NCT04961567,https://clinicaltrials.gov/study/NCT04961567
|
| 17 |
+
2026-09-28,MLTX,sonelokimab,READOUT,"Sep 28, 2026",day,medium,clinicaltrials,NCT06768671,https://clinicaltrials.gov/study/NCT06768671
|
| 18 |
+
2026-09-30,AZN,datopotamab deruxtecan,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT06417814,https://clinicaltrials.gov/study/NCT06417814
|
| 19 |
+
2026-09-30,KURA,daunorubicin,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT03117751,https://clinicaltrials.gov/study/NCT03117751
|
| 20 |
+
2026-09-30,DAN,erwinia asparaginase,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT03117751,https://clinicaltrials.gov/study/NCT03117751
|
| 21 |
+
2026-09-30,BIIB,litifilimab,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT04895241,https://clinicaltrials.gov/study/NCT04895241
|
| 22 |
+
2026-09-30,DAN,mercaptopurine,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT03117751,https://clinicaltrials.gov/study/NCT03117751
|
| 23 |
+
2026-09-30,AZN,monalizumab,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT05221840,https://clinicaltrials.gov/study/NCT05221840
|
| 24 |
+
2026-09-30,DAN,nelarabine,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT03117751,https://clinicaltrials.gov/study/NCT03117751
|
| 25 |
+
2026-09-30,AZN,oleclumab,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT05221840,https://clinicaltrials.gov/study/NCT05221840
|
| 26 |
+
2026-09-30,DAN,pegaspargase,READOUT,"Sep 30, 2026",day,medium,clinicaltrials,NCT03117751,https://clinicaltrials.gov/study/NCT03117751
|
| 27 |
+
2026-10-19,BMY,deucravacitinib,READOUT,"Oct 19, 2026",day,medium,clinicaltrials,NCT05617677,https://clinicaltrials.gov/study/NCT05617677
|
| 28 |
+
2026-10-20,BIIB,litifilimab,READOUT,"Oct 20, 2026",day,medium,clinicaltrials,NCT05531565,https://clinicaltrials.gov/study/NCT05531565
|
| 29 |
+
2026-10-26,NVS,inclisiran,READOUT,"Oct 26, 2026",day,medium,clinicaltrials,NCT05360446,https://clinicaltrials.gov/study/NCT05360446
|
| 30 |
+
2026-10-28,MRK,belzutifan,READOUT,"Oct 28, 2026",day,medium,clinicaltrials,NCT05239728,https://clinicaltrials.gov/study/NCT05239728
|
| 31 |
+
2026-10-29,MRK,belzutifan,READOUT,"Oct 29, 2026",day,medium,clinicaltrials,NCT04736706,https://clinicaltrials.gov/study/NCT04736706
|
| 32 |
+
2026-10-31,NUVL,alectinib,READOUT,"Oct 31, 2026",day,medium,clinicaltrials,NCT03178552,https://clinicaltrials.gov/study/NCT03178552
|
| 33 |
+
2026-10-31,VTRS,cenerimod,READOUT,"Oct 31, 2026",day,medium,clinicaltrials,NCT05648500,https://clinicaltrials.gov/study/NCT05648500
|
| 34 |
+
2026-10-31,IMMP,eftilagimod alpha,READOUT,"Oct 31, 2026",day,medium,clinicaltrials,NCT05747794,https://clinicaltrials.gov/study/NCT05747794
|
| 35 |
+
2026-10-31,NVS,inclisiran,READOUT,Oct 2026,month,medium,clinicaltrials,NCT03705234,https://clinicaltrials.gov/study/NCT03705234
|
| 36 |
+
2026-10-31,SBFM,minoxidil,READOUT,Oct 2026,month,medium,clinicaltrials,NCT05888922,https://clinicaltrials.gov/study/NCT05888922
|
| 37 |
+
2026-10-31,LLY,retatrutide,READOUT,Oct 2026,month,medium,clinicaltrials,NCT06297603,https://clinicaltrials.gov/study/NCT06297603
|
| 38 |
+
2026-10-31,OGN,tapinarof,READOUT,Oct 2026,month,medium,clinicaltrials,NCT05172726,https://clinicaltrials.gov/study/NCT05172726
|
| 39 |
+
2026-11-13,COGT,midazolam,READOUT,"Nov 13, 2026",day,medium,clinicaltrials,NCT05646862,https://clinicaltrials.gov/study/NCT05646862
|
| 40 |
+
2026-11-30,CGON,cretostimogene grenadenorepvec,READOUT,Nov 2026,month,medium,clinicaltrials,NCT06111235,https://clinicaltrials.gov/study/NCT06111235
|
| 41 |
+
2026-11-30,DAN,erwinia asparaginase,READOUT,"Nov 30, 2026",day,medium,clinicaltrials,NCT03020030,https://clinicaltrials.gov/study/NCT03020030
|
| 42 |
+
2026-11-30,NAMS,obicetrapib,READOUT,Nov 2026,month,medium,clinicaltrials,NCT05202509,https://clinicaltrials.gov/study/NCT05202509
|
| 43 |
+
2026-11-30,LLY,orforglipron,READOUT,Nov 2026,month,medium,clinicaltrials,NCT06649045,https://clinicaltrials.gov/study/NCT06649045
|
| 44 |
+
2026-11-30,DAN,pegaspargase,READOUT,"Nov 30, 2026",day,medium,clinicaltrials,NCT03020030,https://clinicaltrials.gov/study/NCT03020030
|
| 45 |
+
2026-11-30,LLY,tirzepatide,READOUT,Nov 2026,month,medium,clinicaltrials,NCT06914895,https://clinicaltrials.gov/study/NCT06914895
|
| 46 |
+
2026-12-01,VNDA,tradipitant,READOUT,"Dec 1, 2026",day,medium,clinicaltrials,NCT07446439,https://clinicaltrials.gov/study/NCT07446439
|
| 47 |
+
2026-12-02,MRK,enlicitide decanoate,READOUT,"Dec 2, 2026",day,medium,clinicaltrials,NCT07216482,https://clinicaltrials.gov/study/NCT07216482
|
| 48 |
+
2026-12-02,PFE,mevrometostat,READOUT,"Dec 2, 2026",day,medium,clinicaltrials,NCT06629779,https://clinicaltrials.gov/study/NCT06629779
|
| 49 |
+
2026-12-02,PFE,ritlecitinib higher,READOUT,"Dec 2, 2026",day,medium,clinicaltrials,NCT07029711,https://clinicaltrials.gov/study/NCT07029711
|
| 50 |
+
2026-12-02,PFE,ritlecitinib lower,READOUT,"Dec 2, 2026",day,medium,clinicaltrials,NCT07029711,https://clinicaltrials.gov/study/NCT07029711
|
| 51 |
+
2026-12-02,MRK,rosuvastatin calcium,READOUT,"Dec 2, 2026",day,medium,clinicaltrials,NCT07216482,https://clinicaltrials.gov/study/NCT07216482
|
| 52 |
+
2026-12-21,PFE,ritlecitinib,READOUT,"Dec 21, 2026",day,medium,clinicaltrials,NCT06873945,https://clinicaltrials.gov/study/NCT06873945
|
| 53 |
+
2026-12-26,INCY,povorcitinib,READOUT,"Dec 26, 2026",day,medium,clinicaltrials,NCT06212999,https://clinicaltrials.gov/study/NCT06212999
|
| 54 |
+
2026-12-30,INTS,pazopanib,READOUT,"Dec 30, 2026",day,medium,clinicaltrials,NCT03592472,https://clinicaltrials.gov/study/NCT03592472
|
| 55 |
+
2026-12-30,PFE,vepdegestrant,READOUT,"Dec 30, 2026",day,medium,clinicaltrials,NCT05909397,https://clinicaltrials.gov/study/NCT05909397
|
| 56 |
+
2026-12-31,PFE,axitinib,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT05059522,https://clinicaltrials.gov/study/NCT05059522
|
| 57 |
+
2026-12-31,AZN,darolutamide,READOUT,Dec 2026,month,medium,clinicaltrials,NCT03903835,https://clinicaltrials.gov/study/NCT03903835
|
| 58 |
+
2026-12-31,PFE,disitamab vedotin,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT05302284,https://clinicaltrials.gov/study/NCT05302284
|
| 59 |
+
2026-12-31,IONS,donidalorsen,READOUT,Dec 2026,month,medium,clinicaltrials,NCT05392114,https://clinicaltrials.gov/study/NCT05392114
|
| 60 |
+
2026-12-31,MRK,ibrutinib,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT01804686,https://clinicaltrials.gov/study/NCT01804686
|
| 61 |
+
2026-12-31,SMMT,ivonescimab,READOUT,Dec 2026,month,medium,clinicaltrials,NCT06767527,https://clinicaltrials.gov/study/NCT06767527
|
| 62 |
+
2026-12-31,PFE,lorlatanib,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT05059522,https://clinicaltrials.gov/study/NCT05059522
|
| 63 |
+
2026-12-31,ABBV,lutikizumab,READOUT,Dec 2026,month,medium,clinicaltrials,NCT06468228,https://clinicaltrials.gov/study/NCT06468228
|
| 64 |
+
2026-12-31,SNY,migalastat,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT04020055,https://clinicaltrials.gov/study/NCT04020055
|
| 65 |
+
2026-12-31,GNLX,olvimulogene nanivacirepvec,READOUT,Dec 2026,month,medium,clinicaltrials,NCT05281471,https://clinicaltrials.gov/study/NCT05281471
|
| 66 |
+
2026-12-31,UTHR,ralinepag,READOUT,Dec 2026,month,medium,clinicaltrials,NCT03683186,https://clinicaltrials.gov/study/NCT03683186
|
| 67 |
+
2026-12-31,DMAC,recombinant human tissue kallikrein,READOUT,Dec 2026,month,medium,clinicaltrials,NCT05065216,https://clinicaltrials.gov/study/NCT05065216
|
| 68 |
+
2026-12-31,LLY,retatrutide,READOUT,Dec 2026,month,medium,clinicaltrials,NCT06662383,https://clinicaltrials.gov/study/NCT06662383
|
| 69 |
+
2026-12-31,GILD,sacituzumab govitecan hziy,READOUT,Dec 2026,month,medium,clinicaltrials,NCT04639986,https://clinicaltrials.gov/study/NCT04639986
|
| 70 |
+
2026-12-31,PFE,talazoparib,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT05059522,https://clinicaltrials.gov/study/NCT05059522
|
| 71 |
+
2026-12-31,VOR,telitacicept,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT07249632,https://clinicaltrials.gov/study/NCT07249632
|
| 72 |
+
2026-12-31,PFE,utomilumab,READOUT,"Dec 31, 2026",day,medium,clinicaltrials,NCT05059522,https://clinicaltrials.gov/study/NCT05059522
|
| 73 |
+
2027-01-04,AZN,laroprovstat,READOUT,"Jan 4, 2027",day,medium,clinicaltrials,NCT07000136,https://clinicaltrials.gov/study/NCT07000136
|
| 74 |
+
2027-01-04,MRK,rescue medications,READOUT,"Jan 4, 2027",day,medium,clinicaltrials,NCT06356311,https://clinicaltrials.gov/study/NCT06356311
|
| 75 |
+
2027-01-04,MRK,supportive care measures,READOUT,"Jan 4, 2027",day,medium,clinicaltrials,NCT06356311,https://clinicaltrials.gov/study/NCT06356311
|
| 76 |
+
2027-01-10,BMY,mezigdomide,READOUT,"Jan 10, 2027",day,medium,clinicaltrials,NCT05519085,https://clinicaltrials.gov/study/NCT05519085
|
| 77 |
+
2027-01-11,AZN,laroprovstat,READOUT,"Jan 11, 2027",day,medium,clinicaltrials,NCT07000123,https://clinicaltrials.gov/study/NCT07000123
|
| 78 |
+
2027-01-13,SMMT,ivonescimab,READOUT,"Jan 13, 2027",day,medium,clinicaltrials,NCT06951503,https://clinicaltrials.gov/study/NCT06951503
|
| 79 |
+
2027-01-15,IDYA,darovasertib,READOUT,"Jan 15, 2027",day,medium,clinicaltrials,NCT05987332,https://clinicaltrials.gov/study/NCT05987332
|
| 80 |
+
2027-01-15,MLTX,sonelokimab,READOUT,"Jan 15, 2027",day,medium,clinicaltrials,NCT06641089,https://clinicaltrials.gov/study/NCT06641089
|
| 81 |
+
2027-01-21,AMGN,maridebart cafraglutide,READOUT,"Jan 21, 2027",day,medium,clinicaltrials,NCT06858839,https://clinicaltrials.gov/study/NCT06858839
|
| 82 |
+
2027-01-29,PFE,disitamab vedotin,READOUT,"Jan 29, 2027",day,medium,clinicaltrials,NCT05911295,https://clinicaltrials.gov/study/NCT05911295
|
| 83 |
+
2027-02-04,MLTX,sonelokimab,READOUT,"Feb 4, 2027",day,medium,clinicaltrials,NCT06641076,https://clinicaltrials.gov/study/NCT06641076
|
| 84 |
+
2027-02-11,NVS,inclisiran,READOUT,"Feb 11, 2027",day,medium,clinicaltrials,NCT07102628,https://clinicaltrials.gov/study/NCT07102628
|
| 85 |
+
2027-02-14,LLY,tirzepatide,READOUT,"Feb 14, 2027",day,medium,clinicaltrials,NCT07481747,https://clinicaltrials.gov/study/NCT07481747
|
| 86 |
+
2027-02-22,AZN,laroprovstat,READOUT,"Feb 22, 2027",day,medium,clinicaltrials,NCT06834932,https://clinicaltrials.gov/study/NCT06834932
|
| 87 |
+
2027-02-26,AZN,anifrolumab,READOUT,"Feb 26, 2027",day,medium,clinicaltrials,NCT05138133,https://clinicaltrials.gov/study/NCT05138133
|
| 88 |
+
2027-02-28,LLY,orforglipron,READOUT,Feb 2027,month,medium,clinicaltrials,NCT06672549,https://clinicaltrials.gov/study/NCT06672549
|
| 89 |
+
2027-02-28,GMAB,rina,READOUT,Feb 2027,month,medium,clinicaltrials,NCT06619236,https://clinicaltrials.gov/study/NCT06619236
|
| 90 |
+
2027-02-28,GILD,sacituzumab govitecan hziy,READOUT,Feb 2027,month,medium,clinicaltrials,NCT05382286,https://clinicaltrials.gov/study/NCT05382286
|
| 91 |
+
2027-03-01,NVO,cagrilintide,READOUT,"Mar 1, 2027",day,medium,clinicaltrials,NCT07011667,https://clinicaltrials.gov/study/NCT07011667
|
| 92 |
+
2027-03-13,RYTM,setmelanotide,READOUT,"Mar 13, 2027",day,medium,clinicaltrials,NCT06760546,https://clinicaltrials.gov/study/NCT06760546
|
| 93 |
+
2027-03-18,MRK,ibrutinib,READOUT,"Mar 18, 2027",day,medium,clinicaltrials,NCT04212013,https://clinicaltrials.gov/study/NCT04212013
|
| 94 |
+
2027-03-22,REGN,fianlimab,READOUT,"Mar 22, 2027",day,medium,clinicaltrials,NCT06246916,https://clinicaltrials.gov/study/NCT06246916
|
| 95 |
+
2027-03-24,NVS,ianalumab,READOUT,"Mar 24, 2027",day,medium,clinicaltrials,NCT05639114,https://clinicaltrials.gov/study/NCT05639114
|
| 96 |
+
2027-03-31,ARGX,efgartigimod,READOUT,Mar 2027,month,medium,clinicaltrials,NCT04833894,https://clinicaltrials.gov/study/NCT04833894
|
| 97 |
+
2027-03-31,IONS,olezarsen,READOUT,Mar 2027,month,medium,clinicaltrials,NCT05681351,https://clinicaltrials.gov/study/NCT05681351
|
| 98 |
+
2027-03-31,AAPG,olverembatinib,READOUT,"Mar 31, 2027",day,medium,clinicaltrials,NCT06640361,https://clinicaltrials.gov/study/NCT06640361
|
| 99 |
+
2027-03-31,MDGL,resmetirom,READOUT,Mar 2027,month,medium,clinicaltrials,NCT04951219,https://clinicaltrials.gov/study/NCT04951219
|
| 100 |
+
2027-03-31,AZN,rezvilutamide,READOUT,Mar 2027,month,medium,clinicaltrials,NCT07241416,https://clinicaltrials.gov/study/NCT07241416
|
| 101 |
+
2027-03-31,PFE,ritlecitinib,READOUT,"Mar 31, 2027",day,medium,clinicaltrials,NCT06163326,https://clinicaltrials.gov/study/NCT06163326
|
| 102 |
+
2027-03-31,NVS,tisagenlecleucel,READOUT,"Mar 31, 2027",day,medium,clinicaltrials,NCT04094311,https://clinicaltrials.gov/study/NCT04094311
|
| 103 |
+
2027-03-31,ONC,zanubrutinib,READOUT,Mar 2027,month,medium,clinicaltrials,NCT04002297,https://clinicaltrials.gov/study/NCT04002297
|
| 104 |
+
2027-04-12,NVS,ianalumab,READOUT,"Apr 12, 2027",day,medium,clinicaltrials,NCT05624749,https://clinicaltrials.gov/study/NCT05624749
|
| 105 |
+
2027-04-14,PFE,tofacitinib,READOUT,"Apr 14, 2027",day,medium,clinicaltrials,NCT04624230,https://clinicaltrials.gov/study/NCT04624230
|
| 106 |
+
2027-04-20,AZN,camizestrant,READOUT,"Apr 20, 2027",day,medium,clinicaltrials,NCT05774951,https://clinicaltrials.gov/study/NCT05774951
|
| 107 |
+
2027-04-25,LLY,lebrikizumab,READOUT,"Apr 25, 2027",day,medium,clinicaltrials,NCT06526182,https://clinicaltrials.gov/study/NCT06526182
|
| 108 |
+
2027-04-27,AMGN,maridebart cafraglutide,READOUT,"Apr 27, 2027",day,medium,clinicaltrials,NCT06987695,https://clinicaltrials.gov/study/NCT06987695
|
| 109 |
+
2027-04-30,MRK,ifinatamab deruxtecan,READOUT,"Apr 30, 2027",day,medium,clinicaltrials,NCT06203210,https://clinicaltrials.gov/study/NCT06203210
|
| 110 |
+
2027-04-30,NVS,iptacopan,READOUT,"Apr 30, 2027",day,medium,clinicaltrials,NCT06517758,https://clinicaltrials.gov/study/NCT06517758
|
| 111 |
+
2027-05-02,PFE,abrocitinib,READOUT,"May 2, 2027",day,medium,clinicaltrials,NCT06807268,https://clinicaltrials.gov/study/NCT06807268
|
| 112 |
+
2027-05-11,NVO,cagrilintide,READOUT,"May 11, 2027",day,medium,clinicaltrials,NCT07220642,https://clinicaltrials.gov/study/NCT07220642
|
| 113 |
+
2027-05-12,NVO,cagrilintide,READOUT,"May 12, 2027",day,medium,clinicaltrials,NCT07220759,https://clinicaltrials.gov/study/NCT07220759
|
| 114 |
+
2027-05-18,TAK,zasocitinib,READOUT,"May 18, 2027",day,medium,clinicaltrials,NCT06671483,https://clinicaltrials.gov/study/NCT06671483
|
| 115 |
+
2027-05-19,MRK,nemtabrutinib,READOUT,"May 19, 2027",day,medium,clinicaltrials,NCT05624554,https://clinicaltrials.gov/study/NCT05624554
|
| 116 |
+
2027-05-31,TEVA,deuruxolitinib,READOUT,May 2027,month,medium,clinicaltrials,NCT03898479,https://clinicaltrials.gov/study/NCT03898479
|
| 117 |
+
2027-05-31,LLY,orforglipron,READOUT,May 2027,month,medium,clinicaltrials,NCT07613307,https://clinicaltrials.gov/study/NCT07613307
|
| 118 |
+
2027-05-31,VOR,telitacicept,READOUT,May 2027,month,medium,clinicaltrials,NCT06456580,https://clinicaltrials.gov/study/NCT06456580
|
| 119 |
+
2027-06-02,NVS,pelabresib,READOUT,"Jun 2, 2027",day,medium,clinicaltrials,NCT06401356,https://clinicaltrials.gov/study/NCT06401356
|
| 120 |
+
2027-06-07,MRK,belzutifan,READOUT,"Jun 7, 2027",day,medium,clinicaltrials,NCT05899049,https://clinicaltrials.gov/study/NCT05899049
|
| 121 |
+
2027-06-18,REGN,mibavademab,READOUT,"Jun 18, 2027",day,medium,clinicaltrials,NCT07220772,https://clinicaltrials.gov/study/NCT07220772
|
| 122 |
+
2027-06-30,PFE,binimetinib,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05615818,https://clinicaltrials.gov/study/NCT05615818
|
| 123 |
+
2027-06-30,AZN,datopotamab deruxtecan,READOUT,"Jun 30, 2027",day,medium,clinicaltrials,NCT06564844,https://clinicaltrials.gov/study/NCT06564844
|
| 124 |
+
2027-06-30,PHVS,deucrictibant,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05396105,https://clinicaltrials.gov/study/NCT05396105
|
| 125 |
+
2027-06-30,IMMP,eftilagimod alfa,READOUT,Jun 2027,month,medium,clinicaltrials,NCT06726265,https://clinicaltrials.gov/study/NCT06726265
|
| 126 |
+
2027-06-30,PFE,encorafenib,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05615818,https://clinicaltrials.gov/study/NCT05615818
|
| 127 |
+
2027-06-30,GMAB,epcoritamab,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05578976,https://clinicaltrials.gov/study/NCT05578976
|
| 128 |
+
2027-06-30,IMNN,niraparib,READOUT,Jun 2027,month,medium,clinicaltrials,NCT03651206,https://clinicaltrials.gov/study/NCT03651206
|
| 129 |
+
2027-06-30,AZN,rilvegostomig,READOUT,"Jun 30, 2027",day,medium,clinicaltrials,NCT06564844,https://clinicaltrials.gov/study/NCT06564844
|
| 130 |
+
2027-06-30,GILD,sacituzumab govitecan hziy,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05633654,https://clinicaltrials.gov/study/NCT05633654
|
| 131 |
+
2027-06-30,AMGN,sotorasib,READOUT,"Jun 30, 2027",day,medium,clinicaltrials,NCT05920356,https://clinicaltrials.gov/study/NCT05920356
|
| 132 |
+
2027-06-30,JAZZ,zanidatamab,READOUT,Jun 2027,month,medium,clinicaltrials,NCT05615818,https://clinicaltrials.gov/study/NCT05615818
|
| 133 |
+
2027-07-02,NVO,ziltivekimab,READOUT,"Jul 2, 2027",day,medium,clinicaltrials,NCT05636176,https://clinicaltrials.gov/study/NCT05636176
|
| 134 |
+
2027-07-05,AMGN,tarlatamab,READOUT,"Jul 5, 2027",day,medium,clinicaltrials,NCT06211036,https://clinicaltrials.gov/study/NCT06211036
|
| 135 |
+
2027-07-28,AZN,datopotamab deruxtecan,READOUT,"Jul 28, 2027",day,medium,clinicaltrials,NCT06103864,https://clinicaltrials.gov/study/NCT06103864
|
| 136 |
+
2027-07-30,GMAB,acasunlimab,READOUT,"Jul 30, 2027",day,medium,clinicaltrials,NCT06635824,https://clinicaltrials.gov/study/NCT06635824
|
| 137 |
+
2027-07-30,AZN,darolutamide,READOUT,"Jul 30, 2027",day,medium,clinicaltrials,NCT05794906,https://clinicaltrials.gov/study/NCT05794906
|
| 138 |
+
2027-07-30,PFE,ritlecitinib,READOUT,"Jul 30, 2027",day,medium,clinicaltrials,NCT06072183,https://clinicaltrials.gov/study/NCT06072183
|
| 139 |
+
2027-07-31,AZN,dapagliflozin,READOUT,Jul 2027,month,medium,clinicaltrials,NCT05374291,https://clinicaltrials.gov/study/NCT05374291
|
| 140 |
+
2027-07-31,LLY,retatrutide,READOUT,Jul 2027,month,medium,clinicaltrials,NCT07232719,https://clinicaltrials.gov/study/NCT07232719
|
| 141 |
+
2027-08-04,PFE,elranatamab,READOUT,"Aug 4, 2027",day,medium,clinicaltrials,NCT05317416,https://clinicaltrials.gov/study/NCT05317416
|
| 142 |
+
2027-08-07,AZN,tezepelumab,READOUT,"Aug 7, 2027",day,medium,clinicaltrials,NCT07363642,https://clinicaltrials.gov/study/NCT07363642
|
| 143 |
+
2027-08-09,BMY,golcadomide,READOUT,"Aug 9, 2027",day,medium,clinicaltrials,NCT06356129,https://clinicaltrials.gov/study/NCT06356129
|
| 144 |
+
2027-08-20,ARWR,zodasiran,READOUT,"Aug 20, 2027",day,medium,clinicaltrials,NCT07037771,https://clinicaltrials.gov/study/NCT07037771
|
| 145 |
+
2027-08-27,AZN,ravulizumab,READOUT,"Aug 27, 2027",day,medium,clinicaltrials,NCT07596784,https://clinicaltrials.gov/study/NCT07596784
|
| 146 |
+
2027-08-31,AAPG,lisaftoclax,READOUT,Aug 2027,month,medium,clinicaltrials,NCT06319456,https://clinicaltrials.gov/study/NCT06319456
|
| 147 |
+
2027-08-31,LLY,orforglipron,READOUT,Aug 2027,month,medium,clinicaltrials,NCT06972459,https://clinicaltrials.gov/study/NCT06972459
|
| 148 |
+
2027-08-31,CRNX,paltusotine,READOUT,Aug 2027,month,medium,clinicaltrials,NCT07087054,https://clinicaltrials.gov/study/NCT07087054
|
| 149 |
+
2027-08-31,ABBV,telisotuzumab adizutecan,READOUT,Aug 2027,month,medium,clinicaltrials,NCT06614192,https://clinicaltrials.gov/study/NCT06614192
|
| 150 |
+
2027-08-31,MRK,tocilizumab,READOUT,"Aug 31, 2027",day,medium,clinicaltrials,NCT06084936,https://clinicaltrials.gov/study/NCT06084936
|
| 151 |
+
2027-09-01,NVO,cagrilintide,READOUT,"Sep 1, 2027",day,medium,clinicaltrials,NCT05669755,https://clinicaltrials.gov/study/NCT05669755
|
catalyst_calendar_sample.json
ADDED
|
@@ -0,0 +1,1802 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
[
|
| 2 |
+
{
|
| 3 |
+
"event_date": "2026-07-18",
|
| 4 |
+
"ticker": "BMY",
|
| 5 |
+
"asset": "mezigdomide",
|
| 6 |
+
"event_type": "READOUT",
|
| 7 |
+
"event_window": "Jul 18, 2026",
|
| 8 |
+
"date_precision": "day",
|
| 9 |
+
"confidence": "medium",
|
| 10 |
+
"source": "clinicaltrials",
|
| 11 |
+
"nct_id": "NCT05552976",
|
| 12 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05552976"
|
| 13 |
+
},
|
| 14 |
+
{
|
| 15 |
+
"event_date": "2026-07-25",
|
| 16 |
+
"ticker": "BMY",
|
| 17 |
+
"asset": "deucravacitinib",
|
| 18 |
+
"event_type": "READOUT",
|
| 19 |
+
"event_window": "Jul 25, 2026",
|
| 20 |
+
"date_precision": "day",
|
| 21 |
+
"confidence": "medium",
|
| 22 |
+
"source": "clinicaltrials",
|
| 23 |
+
"nct_id": "NCT04036435",
|
| 24 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04036435"
|
| 25 |
+
},
|
| 26 |
+
{
|
| 27 |
+
"event_date": "2026-07-27",
|
| 28 |
+
"ticker": "REGN",
|
| 29 |
+
"asset": "fianlimab",
|
| 30 |
+
"event_type": "READOUT",
|
| 31 |
+
"event_window": "Jul 27, 2026",
|
| 32 |
+
"date_precision": "day",
|
| 33 |
+
"confidence": "medium",
|
| 34 |
+
"source": "clinicaltrials",
|
| 35 |
+
"nct_id": "NCT05608291",
|
| 36 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05608291"
|
| 37 |
+
},
|
| 38 |
+
{
|
| 39 |
+
"event_date": "2026-07-31",
|
| 40 |
+
"ticker": "HRMY",
|
| 41 |
+
"asset": "pitolisant",
|
| 42 |
+
"event_type": "READOUT",
|
| 43 |
+
"event_window": "Jul 2026",
|
| 44 |
+
"date_precision": "month",
|
| 45 |
+
"confidence": "medium",
|
| 46 |
+
"source": "clinicaltrials",
|
| 47 |
+
"nct_id": "NCT06366464",
|
| 48 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06366464"
|
| 49 |
+
},
|
| 50 |
+
{
|
| 51 |
+
"event_date": "2026-07-31",
|
| 52 |
+
"ticker": "LXRX",
|
| 53 |
+
"asset": "sotagliflozin",
|
| 54 |
+
"event_type": "READOUT",
|
| 55 |
+
"event_window": "Jul 2026",
|
| 56 |
+
"date_precision": "month",
|
| 57 |
+
"confidence": "medium",
|
| 58 |
+
"source": "clinicaltrials",
|
| 59 |
+
"nct_id": "NCT06481891",
|
| 60 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06481891"
|
| 61 |
+
},
|
| 62 |
+
{
|
| 63 |
+
"event_date": "2026-07-31",
|
| 64 |
+
"ticker": "JAZZ",
|
| 65 |
+
"asset": "zanidatamab",
|
| 66 |
+
"event_type": "READOUT",
|
| 67 |
+
"event_window": "Jul 31, 2026",
|
| 68 |
+
"date_precision": "day",
|
| 69 |
+
"confidence": "medium",
|
| 70 |
+
"source": "clinicaltrials",
|
| 71 |
+
"nct_id": "NCT05152147",
|
| 72 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05152147"
|
| 73 |
+
},
|
| 74 |
+
{
|
| 75 |
+
"event_date": "2026-08-01",
|
| 76 |
+
"ticker": "MRK",
|
| 77 |
+
"asset": "tulisokibart",
|
| 78 |
+
"event_type": "READOUT",
|
| 79 |
+
"event_window": "Aug 1, 2026",
|
| 80 |
+
"date_precision": "day",
|
| 81 |
+
"confidence": "medium",
|
| 82 |
+
"source": "clinicaltrials",
|
| 83 |
+
"nct_id": "NCT06052059",
|
| 84 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06052059"
|
| 85 |
+
},
|
| 86 |
+
{
|
| 87 |
+
"event_date": "2026-08-24",
|
| 88 |
+
"ticker": "AZN",
|
| 89 |
+
"asset": "camizestrant",
|
| 90 |
+
"event_type": "READOUT",
|
| 91 |
+
"event_window": "Aug 24, 2026",
|
| 92 |
+
"date_precision": "day",
|
| 93 |
+
"confidence": "medium",
|
| 94 |
+
"source": "clinicaltrials",
|
| 95 |
+
"nct_id": "NCT04711252",
|
| 96 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04711252"
|
| 97 |
+
},
|
| 98 |
+
{
|
| 99 |
+
"event_date": "2026-08-30",
|
| 100 |
+
"ticker": "PFE",
|
| 101 |
+
"asset": "elranatamab",
|
| 102 |
+
"event_type": "READOUT",
|
| 103 |
+
"event_window": "Aug 30, 2026",
|
| 104 |
+
"date_precision": "day",
|
| 105 |
+
"confidence": "medium",
|
| 106 |
+
"source": "clinicaltrials",
|
| 107 |
+
"nct_id": "NCT06152575",
|
| 108 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06152575"
|
| 109 |
+
},
|
| 110 |
+
{
|
| 111 |
+
"event_date": "2026-08-31",
|
| 112 |
+
"ticker": "PHVS",
|
| 113 |
+
"asset": "deucrictibant",
|
| 114 |
+
"event_type": "READOUT",
|
| 115 |
+
"event_window": "Aug 2026",
|
| 116 |
+
"date_precision": "month",
|
| 117 |
+
"confidence": "medium",
|
| 118 |
+
"source": "clinicaltrials",
|
| 119 |
+
"nct_id": "NCT06669754",
|
| 120 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06669754"
|
| 121 |
+
},
|
| 122 |
+
{
|
| 123 |
+
"event_date": "2026-08-31",
|
| 124 |
+
"ticker": "SBFM",
|
| 125 |
+
"asset": "lerotinib",
|
| 126 |
+
"event_type": "READOUT",
|
| 127 |
+
"event_window": "Aug 2026",
|
| 128 |
+
"date_precision": "month",
|
| 129 |
+
"confidence": "medium",
|
| 130 |
+
"source": "clinicaltrials",
|
| 131 |
+
"nct_id": "NCT04415853",
|
| 132 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04415853"
|
| 133 |
+
},
|
| 134 |
+
{
|
| 135 |
+
"event_date": "2026-08-31",
|
| 136 |
+
"ticker": "SLGL",
|
| 137 |
+
"asset": "patidegib",
|
| 138 |
+
"event_type": "READOUT",
|
| 139 |
+
"event_window": "Aug 2026",
|
| 140 |
+
"date_precision": "month",
|
| 141 |
+
"confidence": "medium",
|
| 142 |
+
"source": "clinicaltrials",
|
| 143 |
+
"nct_id": "NCT06050122",
|
| 144 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06050122"
|
| 145 |
+
},
|
| 146 |
+
{
|
| 147 |
+
"event_date": "2026-08-31",
|
| 148 |
+
"ticker": "LLY",
|
| 149 |
+
"asset": "retatrutide",
|
| 150 |
+
"event_type": "READOUT",
|
| 151 |
+
"event_window": "Aug 2026",
|
| 152 |
+
"date_precision": "month",
|
| 153 |
+
"confidence": "medium",
|
| 154 |
+
"source": "clinicaltrials",
|
| 155 |
+
"nct_id": "NCT06260722",
|
| 156 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06260722"
|
| 157 |
+
},
|
| 158 |
+
{
|
| 159 |
+
"event_date": "2026-09-01",
|
| 160 |
+
"ticker": "INCY",
|
| 161 |
+
"asset": "tafasitamab",
|
| 162 |
+
"event_type": "READOUT",
|
| 163 |
+
"event_window": "Sep 1, 2026",
|
| 164 |
+
"date_precision": "day",
|
| 165 |
+
"confidence": "medium",
|
| 166 |
+
"source": "clinicaltrials",
|
| 167 |
+
"nct_id": "NCT04824092",
|
| 168 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04824092"
|
| 169 |
+
},
|
| 170 |
+
{
|
| 171 |
+
"event_date": "2026-09-27",
|
| 172 |
+
"ticker": "BIIB",
|
| 173 |
+
"asset": "litifilimab",
|
| 174 |
+
"event_type": "READOUT",
|
| 175 |
+
"event_window": "Sep 27, 2026",
|
| 176 |
+
"date_precision": "day",
|
| 177 |
+
"confidence": "medium",
|
| 178 |
+
"source": "clinicaltrials",
|
| 179 |
+
"nct_id": "NCT04961567",
|
| 180 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04961567"
|
| 181 |
+
},
|
| 182 |
+
{
|
| 183 |
+
"event_date": "2026-09-28",
|
| 184 |
+
"ticker": "MLTX",
|
| 185 |
+
"asset": "sonelokimab",
|
| 186 |
+
"event_type": "READOUT",
|
| 187 |
+
"event_window": "Sep 28, 2026",
|
| 188 |
+
"date_precision": "day",
|
| 189 |
+
"confidence": "medium",
|
| 190 |
+
"source": "clinicaltrials",
|
| 191 |
+
"nct_id": "NCT06768671",
|
| 192 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06768671"
|
| 193 |
+
},
|
| 194 |
+
{
|
| 195 |
+
"event_date": "2026-09-30",
|
| 196 |
+
"ticker": "AZN",
|
| 197 |
+
"asset": "datopotamab deruxtecan",
|
| 198 |
+
"event_type": "READOUT",
|
| 199 |
+
"event_window": "Sep 30, 2026",
|
| 200 |
+
"date_precision": "day",
|
| 201 |
+
"confidence": "medium",
|
| 202 |
+
"source": "clinicaltrials",
|
| 203 |
+
"nct_id": "NCT06417814",
|
| 204 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06417814"
|
| 205 |
+
},
|
| 206 |
+
{
|
| 207 |
+
"event_date": "2026-09-30",
|
| 208 |
+
"ticker": "KURA",
|
| 209 |
+
"asset": "daunorubicin",
|
| 210 |
+
"event_type": "READOUT",
|
| 211 |
+
"event_window": "Sep 30, 2026",
|
| 212 |
+
"date_precision": "day",
|
| 213 |
+
"confidence": "medium",
|
| 214 |
+
"source": "clinicaltrials",
|
| 215 |
+
"nct_id": "NCT03117751",
|
| 216 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| 217 |
+
},
|
| 218 |
+
{
|
| 219 |
+
"event_date": "2026-09-30",
|
| 220 |
+
"ticker": "DAN",
|
| 221 |
+
"asset": "erwinia asparaginase",
|
| 222 |
+
"event_type": "READOUT",
|
| 223 |
+
"event_window": "Sep 30, 2026",
|
| 224 |
+
"date_precision": "day",
|
| 225 |
+
"confidence": "medium",
|
| 226 |
+
"source": "clinicaltrials",
|
| 227 |
+
"nct_id": "NCT03117751",
|
| 228 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| 229 |
+
},
|
| 230 |
+
{
|
| 231 |
+
"event_date": "2026-09-30",
|
| 232 |
+
"ticker": "BIIB",
|
| 233 |
+
"asset": "litifilimab",
|
| 234 |
+
"event_type": "READOUT",
|
| 235 |
+
"event_window": "Sep 30, 2026",
|
| 236 |
+
"date_precision": "day",
|
| 237 |
+
"confidence": "medium",
|
| 238 |
+
"source": "clinicaltrials",
|
| 239 |
+
"nct_id": "NCT04895241",
|
| 240 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04895241"
|
| 241 |
+
},
|
| 242 |
+
{
|
| 243 |
+
"event_date": "2026-09-30",
|
| 244 |
+
"ticker": "DAN",
|
| 245 |
+
"asset": "mercaptopurine",
|
| 246 |
+
"event_type": "READOUT",
|
| 247 |
+
"event_window": "Sep 30, 2026",
|
| 248 |
+
"date_precision": "day",
|
| 249 |
+
"confidence": "medium",
|
| 250 |
+
"source": "clinicaltrials",
|
| 251 |
+
"nct_id": "NCT03117751",
|
| 252 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| 253 |
+
},
|
| 254 |
+
{
|
| 255 |
+
"event_date": "2026-09-30",
|
| 256 |
+
"ticker": "AZN",
|
| 257 |
+
"asset": "monalizumab",
|
| 258 |
+
"event_type": "READOUT",
|
| 259 |
+
"event_window": "Sep 30, 2026",
|
| 260 |
+
"date_precision": "day",
|
| 261 |
+
"confidence": "medium",
|
| 262 |
+
"source": "clinicaltrials",
|
| 263 |
+
"nct_id": "NCT05221840",
|
| 264 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05221840"
|
| 265 |
+
},
|
| 266 |
+
{
|
| 267 |
+
"event_date": "2026-09-30",
|
| 268 |
+
"ticker": "DAN",
|
| 269 |
+
"asset": "nelarabine",
|
| 270 |
+
"event_type": "READOUT",
|
| 271 |
+
"event_window": "Sep 30, 2026",
|
| 272 |
+
"date_precision": "day",
|
| 273 |
+
"confidence": "medium",
|
| 274 |
+
"source": "clinicaltrials",
|
| 275 |
+
"nct_id": "NCT03117751",
|
| 276 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| 277 |
+
},
|
| 278 |
+
{
|
| 279 |
+
"event_date": "2026-09-30",
|
| 280 |
+
"ticker": "AZN",
|
| 281 |
+
"asset": "oleclumab",
|
| 282 |
+
"event_type": "READOUT",
|
| 283 |
+
"event_window": "Sep 30, 2026",
|
| 284 |
+
"date_precision": "day",
|
| 285 |
+
"confidence": "medium",
|
| 286 |
+
"source": "clinicaltrials",
|
| 287 |
+
"nct_id": "NCT05221840",
|
| 288 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05221840"
|
| 289 |
+
},
|
| 290 |
+
{
|
| 291 |
+
"event_date": "2026-09-30",
|
| 292 |
+
"ticker": "DAN",
|
| 293 |
+
"asset": "pegaspargase",
|
| 294 |
+
"event_type": "READOUT",
|
| 295 |
+
"event_window": "Sep 30, 2026",
|
| 296 |
+
"date_precision": "day",
|
| 297 |
+
"confidence": "medium",
|
| 298 |
+
"source": "clinicaltrials",
|
| 299 |
+
"nct_id": "NCT03117751",
|
| 300 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03117751"
|
| 301 |
+
},
|
| 302 |
+
{
|
| 303 |
+
"event_date": "2026-10-19",
|
| 304 |
+
"ticker": "BMY",
|
| 305 |
+
"asset": "deucravacitinib",
|
| 306 |
+
"event_type": "READOUT",
|
| 307 |
+
"event_window": "Oct 19, 2026",
|
| 308 |
+
"date_precision": "day",
|
| 309 |
+
"confidence": "medium",
|
| 310 |
+
"source": "clinicaltrials",
|
| 311 |
+
"nct_id": "NCT05617677",
|
| 312 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05617677"
|
| 313 |
+
},
|
| 314 |
+
{
|
| 315 |
+
"event_date": "2026-10-20",
|
| 316 |
+
"ticker": "BIIB",
|
| 317 |
+
"asset": "litifilimab",
|
| 318 |
+
"event_type": "READOUT",
|
| 319 |
+
"event_window": "Oct 20, 2026",
|
| 320 |
+
"date_precision": "day",
|
| 321 |
+
"confidence": "medium",
|
| 322 |
+
"source": "clinicaltrials",
|
| 323 |
+
"nct_id": "NCT05531565",
|
| 324 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05531565"
|
| 325 |
+
},
|
| 326 |
+
{
|
| 327 |
+
"event_date": "2026-10-26",
|
| 328 |
+
"ticker": "NVS",
|
| 329 |
+
"asset": "inclisiran",
|
| 330 |
+
"event_type": "READOUT",
|
| 331 |
+
"event_window": "Oct 26, 2026",
|
| 332 |
+
"date_precision": "day",
|
| 333 |
+
"confidence": "medium",
|
| 334 |
+
"source": "clinicaltrials",
|
| 335 |
+
"nct_id": "NCT05360446",
|
| 336 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05360446"
|
| 337 |
+
},
|
| 338 |
+
{
|
| 339 |
+
"event_date": "2026-10-28",
|
| 340 |
+
"ticker": "MRK",
|
| 341 |
+
"asset": "belzutifan",
|
| 342 |
+
"event_type": "READOUT",
|
| 343 |
+
"event_window": "Oct 28, 2026",
|
| 344 |
+
"date_precision": "day",
|
| 345 |
+
"confidence": "medium",
|
| 346 |
+
"source": "clinicaltrials",
|
| 347 |
+
"nct_id": "NCT05239728",
|
| 348 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05239728"
|
| 349 |
+
},
|
| 350 |
+
{
|
| 351 |
+
"event_date": "2026-10-29",
|
| 352 |
+
"ticker": "MRK",
|
| 353 |
+
"asset": "belzutifan",
|
| 354 |
+
"event_type": "READOUT",
|
| 355 |
+
"event_window": "Oct 29, 2026",
|
| 356 |
+
"date_precision": "day",
|
| 357 |
+
"confidence": "medium",
|
| 358 |
+
"source": "clinicaltrials",
|
| 359 |
+
"nct_id": "NCT04736706",
|
| 360 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04736706"
|
| 361 |
+
},
|
| 362 |
+
{
|
| 363 |
+
"event_date": "2026-10-31",
|
| 364 |
+
"ticker": "NUVL",
|
| 365 |
+
"asset": "alectinib",
|
| 366 |
+
"event_type": "READOUT",
|
| 367 |
+
"event_window": "Oct 31, 2026",
|
| 368 |
+
"date_precision": "day",
|
| 369 |
+
"confidence": "medium",
|
| 370 |
+
"source": "clinicaltrials",
|
| 371 |
+
"nct_id": "NCT03178552",
|
| 372 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03178552"
|
| 373 |
+
},
|
| 374 |
+
{
|
| 375 |
+
"event_date": "2026-10-31",
|
| 376 |
+
"ticker": "VTRS",
|
| 377 |
+
"asset": "cenerimod",
|
| 378 |
+
"event_type": "READOUT",
|
| 379 |
+
"event_window": "Oct 31, 2026",
|
| 380 |
+
"date_precision": "day",
|
| 381 |
+
"confidence": "medium",
|
| 382 |
+
"source": "clinicaltrials",
|
| 383 |
+
"nct_id": "NCT05648500",
|
| 384 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05648500"
|
| 385 |
+
},
|
| 386 |
+
{
|
| 387 |
+
"event_date": "2026-10-31",
|
| 388 |
+
"ticker": "IMMP",
|
| 389 |
+
"asset": "eftilagimod alpha",
|
| 390 |
+
"event_type": "READOUT",
|
| 391 |
+
"event_window": "Oct 31, 2026",
|
| 392 |
+
"date_precision": "day",
|
| 393 |
+
"confidence": "medium",
|
| 394 |
+
"source": "clinicaltrials",
|
| 395 |
+
"nct_id": "NCT05747794",
|
| 396 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05747794"
|
| 397 |
+
},
|
| 398 |
+
{
|
| 399 |
+
"event_date": "2026-10-31",
|
| 400 |
+
"ticker": "NVS",
|
| 401 |
+
"asset": "inclisiran",
|
| 402 |
+
"event_type": "READOUT",
|
| 403 |
+
"event_window": "Oct 2026",
|
| 404 |
+
"date_precision": "month",
|
| 405 |
+
"confidence": "medium",
|
| 406 |
+
"source": "clinicaltrials",
|
| 407 |
+
"nct_id": "NCT03705234",
|
| 408 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03705234"
|
| 409 |
+
},
|
| 410 |
+
{
|
| 411 |
+
"event_date": "2026-10-31",
|
| 412 |
+
"ticker": "SBFM",
|
| 413 |
+
"asset": "minoxidil",
|
| 414 |
+
"event_type": "READOUT",
|
| 415 |
+
"event_window": "Oct 2026",
|
| 416 |
+
"date_precision": "month",
|
| 417 |
+
"confidence": "medium",
|
| 418 |
+
"source": "clinicaltrials",
|
| 419 |
+
"nct_id": "NCT05888922",
|
| 420 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05888922"
|
| 421 |
+
},
|
| 422 |
+
{
|
| 423 |
+
"event_date": "2026-10-31",
|
| 424 |
+
"ticker": "LLY",
|
| 425 |
+
"asset": "retatrutide",
|
| 426 |
+
"event_type": "READOUT",
|
| 427 |
+
"event_window": "Oct 2026",
|
| 428 |
+
"date_precision": "month",
|
| 429 |
+
"confidence": "medium",
|
| 430 |
+
"source": "clinicaltrials",
|
| 431 |
+
"nct_id": "NCT06297603",
|
| 432 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06297603"
|
| 433 |
+
},
|
| 434 |
+
{
|
| 435 |
+
"event_date": "2026-10-31",
|
| 436 |
+
"ticker": "OGN",
|
| 437 |
+
"asset": "tapinarof",
|
| 438 |
+
"event_type": "READOUT",
|
| 439 |
+
"event_window": "Oct 2026",
|
| 440 |
+
"date_precision": "month",
|
| 441 |
+
"confidence": "medium",
|
| 442 |
+
"source": "clinicaltrials",
|
| 443 |
+
"nct_id": "NCT05172726",
|
| 444 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05172726"
|
| 445 |
+
},
|
| 446 |
+
{
|
| 447 |
+
"event_date": "2026-11-13",
|
| 448 |
+
"ticker": "COGT",
|
| 449 |
+
"asset": "midazolam",
|
| 450 |
+
"event_type": "READOUT",
|
| 451 |
+
"event_window": "Nov 13, 2026",
|
| 452 |
+
"date_precision": "day",
|
| 453 |
+
"confidence": "medium",
|
| 454 |
+
"source": "clinicaltrials",
|
| 455 |
+
"nct_id": "NCT05646862",
|
| 456 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05646862"
|
| 457 |
+
},
|
| 458 |
+
{
|
| 459 |
+
"event_date": "2026-11-30",
|
| 460 |
+
"ticker": "CGON",
|
| 461 |
+
"asset": "cretostimogene grenadenorepvec",
|
| 462 |
+
"event_type": "READOUT",
|
| 463 |
+
"event_window": "Nov 2026",
|
| 464 |
+
"date_precision": "month",
|
| 465 |
+
"confidence": "medium",
|
| 466 |
+
"source": "clinicaltrials",
|
| 467 |
+
"nct_id": "NCT06111235",
|
| 468 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06111235"
|
| 469 |
+
},
|
| 470 |
+
{
|
| 471 |
+
"event_date": "2026-11-30",
|
| 472 |
+
"ticker": "DAN",
|
| 473 |
+
"asset": "erwinia asparaginase",
|
| 474 |
+
"event_type": "READOUT",
|
| 475 |
+
"event_window": "Nov 30, 2026",
|
| 476 |
+
"date_precision": "day",
|
| 477 |
+
"confidence": "medium",
|
| 478 |
+
"source": "clinicaltrials",
|
| 479 |
+
"nct_id": "NCT03020030",
|
| 480 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03020030"
|
| 481 |
+
},
|
| 482 |
+
{
|
| 483 |
+
"event_date": "2026-11-30",
|
| 484 |
+
"ticker": "NAMS",
|
| 485 |
+
"asset": "obicetrapib",
|
| 486 |
+
"event_type": "READOUT",
|
| 487 |
+
"event_window": "Nov 2026",
|
| 488 |
+
"date_precision": "month",
|
| 489 |
+
"confidence": "medium",
|
| 490 |
+
"source": "clinicaltrials",
|
| 491 |
+
"nct_id": "NCT05202509",
|
| 492 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05202509"
|
| 493 |
+
},
|
| 494 |
+
{
|
| 495 |
+
"event_date": "2026-11-30",
|
| 496 |
+
"ticker": "LLY",
|
| 497 |
+
"asset": "orforglipron",
|
| 498 |
+
"event_type": "READOUT",
|
| 499 |
+
"event_window": "Nov 2026",
|
| 500 |
+
"date_precision": "month",
|
| 501 |
+
"confidence": "medium",
|
| 502 |
+
"source": "clinicaltrials",
|
| 503 |
+
"nct_id": "NCT06649045",
|
| 504 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06649045"
|
| 505 |
+
},
|
| 506 |
+
{
|
| 507 |
+
"event_date": "2026-11-30",
|
| 508 |
+
"ticker": "DAN",
|
| 509 |
+
"asset": "pegaspargase",
|
| 510 |
+
"event_type": "READOUT",
|
| 511 |
+
"event_window": "Nov 30, 2026",
|
| 512 |
+
"date_precision": "day",
|
| 513 |
+
"confidence": "medium",
|
| 514 |
+
"source": "clinicaltrials",
|
| 515 |
+
"nct_id": "NCT03020030",
|
| 516 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03020030"
|
| 517 |
+
},
|
| 518 |
+
{
|
| 519 |
+
"event_date": "2026-11-30",
|
| 520 |
+
"ticker": "LLY",
|
| 521 |
+
"asset": "tirzepatide",
|
| 522 |
+
"event_type": "READOUT",
|
| 523 |
+
"event_window": "Nov 2026",
|
| 524 |
+
"date_precision": "month",
|
| 525 |
+
"confidence": "medium",
|
| 526 |
+
"source": "clinicaltrials",
|
| 527 |
+
"nct_id": "NCT06914895",
|
| 528 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06914895"
|
| 529 |
+
},
|
| 530 |
+
{
|
| 531 |
+
"event_date": "2026-12-01",
|
| 532 |
+
"ticker": "VNDA",
|
| 533 |
+
"asset": "tradipitant",
|
| 534 |
+
"event_type": "READOUT",
|
| 535 |
+
"event_window": "Dec 1, 2026",
|
| 536 |
+
"date_precision": "day",
|
| 537 |
+
"confidence": "medium",
|
| 538 |
+
"source": "clinicaltrials",
|
| 539 |
+
"nct_id": "NCT07446439",
|
| 540 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07446439"
|
| 541 |
+
},
|
| 542 |
+
{
|
| 543 |
+
"event_date": "2026-12-02",
|
| 544 |
+
"ticker": "MRK",
|
| 545 |
+
"asset": "enlicitide decanoate",
|
| 546 |
+
"event_type": "READOUT",
|
| 547 |
+
"event_window": "Dec 2, 2026",
|
| 548 |
+
"date_precision": "day",
|
| 549 |
+
"confidence": "medium",
|
| 550 |
+
"source": "clinicaltrials",
|
| 551 |
+
"nct_id": "NCT07216482",
|
| 552 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07216482"
|
| 553 |
+
},
|
| 554 |
+
{
|
| 555 |
+
"event_date": "2026-12-02",
|
| 556 |
+
"ticker": "PFE",
|
| 557 |
+
"asset": "mevrometostat",
|
| 558 |
+
"event_type": "READOUT",
|
| 559 |
+
"event_window": "Dec 2, 2026",
|
| 560 |
+
"date_precision": "day",
|
| 561 |
+
"confidence": "medium",
|
| 562 |
+
"source": "clinicaltrials",
|
| 563 |
+
"nct_id": "NCT06629779",
|
| 564 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06629779"
|
| 565 |
+
},
|
| 566 |
+
{
|
| 567 |
+
"event_date": "2026-12-02",
|
| 568 |
+
"ticker": "PFE",
|
| 569 |
+
"asset": "ritlecitinib higher",
|
| 570 |
+
"event_type": "READOUT",
|
| 571 |
+
"event_window": "Dec 2, 2026",
|
| 572 |
+
"date_precision": "day",
|
| 573 |
+
"confidence": "medium",
|
| 574 |
+
"source": "clinicaltrials",
|
| 575 |
+
"nct_id": "NCT07029711",
|
| 576 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07029711"
|
| 577 |
+
},
|
| 578 |
+
{
|
| 579 |
+
"event_date": "2026-12-02",
|
| 580 |
+
"ticker": "PFE",
|
| 581 |
+
"asset": "ritlecitinib lower",
|
| 582 |
+
"event_type": "READOUT",
|
| 583 |
+
"event_window": "Dec 2, 2026",
|
| 584 |
+
"date_precision": "day",
|
| 585 |
+
"confidence": "medium",
|
| 586 |
+
"source": "clinicaltrials",
|
| 587 |
+
"nct_id": "NCT07029711",
|
| 588 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07029711"
|
| 589 |
+
},
|
| 590 |
+
{
|
| 591 |
+
"event_date": "2026-12-02",
|
| 592 |
+
"ticker": "MRK",
|
| 593 |
+
"asset": "rosuvastatin calcium",
|
| 594 |
+
"event_type": "READOUT",
|
| 595 |
+
"event_window": "Dec 2, 2026",
|
| 596 |
+
"date_precision": "day",
|
| 597 |
+
"confidence": "medium",
|
| 598 |
+
"source": "clinicaltrials",
|
| 599 |
+
"nct_id": "NCT07216482",
|
| 600 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07216482"
|
| 601 |
+
},
|
| 602 |
+
{
|
| 603 |
+
"event_date": "2026-12-21",
|
| 604 |
+
"ticker": "PFE",
|
| 605 |
+
"asset": "ritlecitinib",
|
| 606 |
+
"event_type": "READOUT",
|
| 607 |
+
"event_window": "Dec 21, 2026",
|
| 608 |
+
"date_precision": "day",
|
| 609 |
+
"confidence": "medium",
|
| 610 |
+
"source": "clinicaltrials",
|
| 611 |
+
"nct_id": "NCT06873945",
|
| 612 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06873945"
|
| 613 |
+
},
|
| 614 |
+
{
|
| 615 |
+
"event_date": "2026-12-26",
|
| 616 |
+
"ticker": "INCY",
|
| 617 |
+
"asset": "povorcitinib",
|
| 618 |
+
"event_type": "READOUT",
|
| 619 |
+
"event_window": "Dec 26, 2026",
|
| 620 |
+
"date_precision": "day",
|
| 621 |
+
"confidence": "medium",
|
| 622 |
+
"source": "clinicaltrials",
|
| 623 |
+
"nct_id": "NCT06212999",
|
| 624 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06212999"
|
| 625 |
+
},
|
| 626 |
+
{
|
| 627 |
+
"event_date": "2026-12-30",
|
| 628 |
+
"ticker": "INTS",
|
| 629 |
+
"asset": "pazopanib",
|
| 630 |
+
"event_type": "READOUT",
|
| 631 |
+
"event_window": "Dec 30, 2026",
|
| 632 |
+
"date_precision": "day",
|
| 633 |
+
"confidence": "medium",
|
| 634 |
+
"source": "clinicaltrials",
|
| 635 |
+
"nct_id": "NCT03592472",
|
| 636 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03592472"
|
| 637 |
+
},
|
| 638 |
+
{
|
| 639 |
+
"event_date": "2026-12-30",
|
| 640 |
+
"ticker": "PFE",
|
| 641 |
+
"asset": "vepdegestrant",
|
| 642 |
+
"event_type": "READOUT",
|
| 643 |
+
"event_window": "Dec 30, 2026",
|
| 644 |
+
"date_precision": "day",
|
| 645 |
+
"confidence": "medium",
|
| 646 |
+
"source": "clinicaltrials",
|
| 647 |
+
"nct_id": "NCT05909397",
|
| 648 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05909397"
|
| 649 |
+
},
|
| 650 |
+
{
|
| 651 |
+
"event_date": "2026-12-31",
|
| 652 |
+
"ticker": "PFE",
|
| 653 |
+
"asset": "axitinib",
|
| 654 |
+
"event_type": "READOUT",
|
| 655 |
+
"event_window": "Dec 31, 2026",
|
| 656 |
+
"date_precision": "day",
|
| 657 |
+
"confidence": "medium",
|
| 658 |
+
"source": "clinicaltrials",
|
| 659 |
+
"nct_id": "NCT05059522",
|
| 660 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| 661 |
+
},
|
| 662 |
+
{
|
| 663 |
+
"event_date": "2026-12-31",
|
| 664 |
+
"ticker": "AZN",
|
| 665 |
+
"asset": "darolutamide",
|
| 666 |
+
"event_type": "READOUT",
|
| 667 |
+
"event_window": "Dec 2026",
|
| 668 |
+
"date_precision": "month",
|
| 669 |
+
"confidence": "medium",
|
| 670 |
+
"source": "clinicaltrials",
|
| 671 |
+
"nct_id": "NCT03903835",
|
| 672 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03903835"
|
| 673 |
+
},
|
| 674 |
+
{
|
| 675 |
+
"event_date": "2026-12-31",
|
| 676 |
+
"ticker": "PFE",
|
| 677 |
+
"asset": "disitamab vedotin",
|
| 678 |
+
"event_type": "READOUT",
|
| 679 |
+
"event_window": "Dec 31, 2026",
|
| 680 |
+
"date_precision": "day",
|
| 681 |
+
"confidence": "medium",
|
| 682 |
+
"source": "clinicaltrials",
|
| 683 |
+
"nct_id": "NCT05302284",
|
| 684 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05302284"
|
| 685 |
+
},
|
| 686 |
+
{
|
| 687 |
+
"event_date": "2026-12-31",
|
| 688 |
+
"ticker": "IONS",
|
| 689 |
+
"asset": "donidalorsen",
|
| 690 |
+
"event_type": "READOUT",
|
| 691 |
+
"event_window": "Dec 2026",
|
| 692 |
+
"date_precision": "month",
|
| 693 |
+
"confidence": "medium",
|
| 694 |
+
"source": "clinicaltrials",
|
| 695 |
+
"nct_id": "NCT05392114",
|
| 696 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05392114"
|
| 697 |
+
},
|
| 698 |
+
{
|
| 699 |
+
"event_date": "2026-12-31",
|
| 700 |
+
"ticker": "MRK",
|
| 701 |
+
"asset": "ibrutinib",
|
| 702 |
+
"event_type": "READOUT",
|
| 703 |
+
"event_window": "Dec 31, 2026",
|
| 704 |
+
"date_precision": "day",
|
| 705 |
+
"confidence": "medium",
|
| 706 |
+
"source": "clinicaltrials",
|
| 707 |
+
"nct_id": "NCT01804686",
|
| 708 |
+
"source_url": "https://clinicaltrials.gov/study/NCT01804686"
|
| 709 |
+
},
|
| 710 |
+
{
|
| 711 |
+
"event_date": "2026-12-31",
|
| 712 |
+
"ticker": "SMMT",
|
| 713 |
+
"asset": "ivonescimab",
|
| 714 |
+
"event_type": "READOUT",
|
| 715 |
+
"event_window": "Dec 2026",
|
| 716 |
+
"date_precision": "month",
|
| 717 |
+
"confidence": "medium",
|
| 718 |
+
"source": "clinicaltrials",
|
| 719 |
+
"nct_id": "NCT06767527",
|
| 720 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06767527"
|
| 721 |
+
},
|
| 722 |
+
{
|
| 723 |
+
"event_date": "2026-12-31",
|
| 724 |
+
"ticker": "PFE",
|
| 725 |
+
"asset": "lorlatanib",
|
| 726 |
+
"event_type": "READOUT",
|
| 727 |
+
"event_window": "Dec 31, 2026",
|
| 728 |
+
"date_precision": "day",
|
| 729 |
+
"confidence": "medium",
|
| 730 |
+
"source": "clinicaltrials",
|
| 731 |
+
"nct_id": "NCT05059522",
|
| 732 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| 733 |
+
},
|
| 734 |
+
{
|
| 735 |
+
"event_date": "2026-12-31",
|
| 736 |
+
"ticker": "ABBV",
|
| 737 |
+
"asset": "lutikizumab",
|
| 738 |
+
"event_type": "READOUT",
|
| 739 |
+
"event_window": "Dec 2026",
|
| 740 |
+
"date_precision": "month",
|
| 741 |
+
"confidence": "medium",
|
| 742 |
+
"source": "clinicaltrials",
|
| 743 |
+
"nct_id": "NCT06468228",
|
| 744 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06468228"
|
| 745 |
+
},
|
| 746 |
+
{
|
| 747 |
+
"event_date": "2026-12-31",
|
| 748 |
+
"ticker": "SNY",
|
| 749 |
+
"asset": "migalastat",
|
| 750 |
+
"event_type": "READOUT",
|
| 751 |
+
"event_window": "Dec 31, 2026",
|
| 752 |
+
"date_precision": "day",
|
| 753 |
+
"confidence": "medium",
|
| 754 |
+
"source": "clinicaltrials",
|
| 755 |
+
"nct_id": "NCT04020055",
|
| 756 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04020055"
|
| 757 |
+
},
|
| 758 |
+
{
|
| 759 |
+
"event_date": "2026-12-31",
|
| 760 |
+
"ticker": "GNLX",
|
| 761 |
+
"asset": "olvimulogene nanivacirepvec",
|
| 762 |
+
"event_type": "READOUT",
|
| 763 |
+
"event_window": "Dec 2026",
|
| 764 |
+
"date_precision": "month",
|
| 765 |
+
"confidence": "medium",
|
| 766 |
+
"source": "clinicaltrials",
|
| 767 |
+
"nct_id": "NCT05281471",
|
| 768 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05281471"
|
| 769 |
+
},
|
| 770 |
+
{
|
| 771 |
+
"event_date": "2026-12-31",
|
| 772 |
+
"ticker": "UTHR",
|
| 773 |
+
"asset": "ralinepag",
|
| 774 |
+
"event_type": "READOUT",
|
| 775 |
+
"event_window": "Dec 2026",
|
| 776 |
+
"date_precision": "month",
|
| 777 |
+
"confidence": "medium",
|
| 778 |
+
"source": "clinicaltrials",
|
| 779 |
+
"nct_id": "NCT03683186",
|
| 780 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03683186"
|
| 781 |
+
},
|
| 782 |
+
{
|
| 783 |
+
"event_date": "2026-12-31",
|
| 784 |
+
"ticker": "DMAC",
|
| 785 |
+
"asset": "recombinant human tissue kallikrein",
|
| 786 |
+
"event_type": "READOUT",
|
| 787 |
+
"event_window": "Dec 2026",
|
| 788 |
+
"date_precision": "month",
|
| 789 |
+
"confidence": "medium",
|
| 790 |
+
"source": "clinicaltrials",
|
| 791 |
+
"nct_id": "NCT05065216",
|
| 792 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05065216"
|
| 793 |
+
},
|
| 794 |
+
{
|
| 795 |
+
"event_date": "2026-12-31",
|
| 796 |
+
"ticker": "LLY",
|
| 797 |
+
"asset": "retatrutide",
|
| 798 |
+
"event_type": "READOUT",
|
| 799 |
+
"event_window": "Dec 2026",
|
| 800 |
+
"date_precision": "month",
|
| 801 |
+
"confidence": "medium",
|
| 802 |
+
"source": "clinicaltrials",
|
| 803 |
+
"nct_id": "NCT06662383",
|
| 804 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06662383"
|
| 805 |
+
},
|
| 806 |
+
{
|
| 807 |
+
"event_date": "2026-12-31",
|
| 808 |
+
"ticker": "GILD",
|
| 809 |
+
"asset": "sacituzumab govitecan hziy",
|
| 810 |
+
"event_type": "READOUT",
|
| 811 |
+
"event_window": "Dec 2026",
|
| 812 |
+
"date_precision": "month",
|
| 813 |
+
"confidence": "medium",
|
| 814 |
+
"source": "clinicaltrials",
|
| 815 |
+
"nct_id": "NCT04639986",
|
| 816 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04639986"
|
| 817 |
+
},
|
| 818 |
+
{
|
| 819 |
+
"event_date": "2026-12-31",
|
| 820 |
+
"ticker": "PFE",
|
| 821 |
+
"asset": "talazoparib",
|
| 822 |
+
"event_type": "READOUT",
|
| 823 |
+
"event_window": "Dec 31, 2026",
|
| 824 |
+
"date_precision": "day",
|
| 825 |
+
"confidence": "medium",
|
| 826 |
+
"source": "clinicaltrials",
|
| 827 |
+
"nct_id": "NCT05059522",
|
| 828 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| 829 |
+
},
|
| 830 |
+
{
|
| 831 |
+
"event_date": "2026-12-31",
|
| 832 |
+
"ticker": "VOR",
|
| 833 |
+
"asset": "telitacicept",
|
| 834 |
+
"event_type": "READOUT",
|
| 835 |
+
"event_window": "Dec 31, 2026",
|
| 836 |
+
"date_precision": "day",
|
| 837 |
+
"confidence": "medium",
|
| 838 |
+
"source": "clinicaltrials",
|
| 839 |
+
"nct_id": "NCT07249632",
|
| 840 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07249632"
|
| 841 |
+
},
|
| 842 |
+
{
|
| 843 |
+
"event_date": "2026-12-31",
|
| 844 |
+
"ticker": "PFE",
|
| 845 |
+
"asset": "utomilumab",
|
| 846 |
+
"event_type": "READOUT",
|
| 847 |
+
"event_window": "Dec 31, 2026",
|
| 848 |
+
"date_precision": "day",
|
| 849 |
+
"confidence": "medium",
|
| 850 |
+
"source": "clinicaltrials",
|
| 851 |
+
"nct_id": "NCT05059522",
|
| 852 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05059522"
|
| 853 |
+
},
|
| 854 |
+
{
|
| 855 |
+
"event_date": "2027-01-04",
|
| 856 |
+
"ticker": "AZN",
|
| 857 |
+
"asset": "laroprovstat",
|
| 858 |
+
"event_type": "READOUT",
|
| 859 |
+
"event_window": "Jan 4, 2027",
|
| 860 |
+
"date_precision": "day",
|
| 861 |
+
"confidence": "medium",
|
| 862 |
+
"source": "clinicaltrials",
|
| 863 |
+
"nct_id": "NCT07000136",
|
| 864 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07000136"
|
| 865 |
+
},
|
| 866 |
+
{
|
| 867 |
+
"event_date": "2027-01-04",
|
| 868 |
+
"ticker": "MRK",
|
| 869 |
+
"asset": "rescue medications",
|
| 870 |
+
"event_type": "READOUT",
|
| 871 |
+
"event_window": "Jan 4, 2027",
|
| 872 |
+
"date_precision": "day",
|
| 873 |
+
"confidence": "medium",
|
| 874 |
+
"source": "clinicaltrials",
|
| 875 |
+
"nct_id": "NCT06356311",
|
| 876 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06356311"
|
| 877 |
+
},
|
| 878 |
+
{
|
| 879 |
+
"event_date": "2027-01-04",
|
| 880 |
+
"ticker": "MRK",
|
| 881 |
+
"asset": "supportive care measures",
|
| 882 |
+
"event_type": "READOUT",
|
| 883 |
+
"event_window": "Jan 4, 2027",
|
| 884 |
+
"date_precision": "day",
|
| 885 |
+
"confidence": "medium",
|
| 886 |
+
"source": "clinicaltrials",
|
| 887 |
+
"nct_id": "NCT06356311",
|
| 888 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06356311"
|
| 889 |
+
},
|
| 890 |
+
{
|
| 891 |
+
"event_date": "2027-01-10",
|
| 892 |
+
"ticker": "BMY",
|
| 893 |
+
"asset": "mezigdomide",
|
| 894 |
+
"event_type": "READOUT",
|
| 895 |
+
"event_window": "Jan 10, 2027",
|
| 896 |
+
"date_precision": "day",
|
| 897 |
+
"confidence": "medium",
|
| 898 |
+
"source": "clinicaltrials",
|
| 899 |
+
"nct_id": "NCT05519085",
|
| 900 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05519085"
|
| 901 |
+
},
|
| 902 |
+
{
|
| 903 |
+
"event_date": "2027-01-11",
|
| 904 |
+
"ticker": "AZN",
|
| 905 |
+
"asset": "laroprovstat",
|
| 906 |
+
"event_type": "READOUT",
|
| 907 |
+
"event_window": "Jan 11, 2027",
|
| 908 |
+
"date_precision": "day",
|
| 909 |
+
"confidence": "medium",
|
| 910 |
+
"source": "clinicaltrials",
|
| 911 |
+
"nct_id": "NCT07000123",
|
| 912 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07000123"
|
| 913 |
+
},
|
| 914 |
+
{
|
| 915 |
+
"event_date": "2027-01-13",
|
| 916 |
+
"ticker": "SMMT",
|
| 917 |
+
"asset": "ivonescimab",
|
| 918 |
+
"event_type": "READOUT",
|
| 919 |
+
"event_window": "Jan 13, 2027",
|
| 920 |
+
"date_precision": "day",
|
| 921 |
+
"confidence": "medium",
|
| 922 |
+
"source": "clinicaltrials",
|
| 923 |
+
"nct_id": "NCT06951503",
|
| 924 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06951503"
|
| 925 |
+
},
|
| 926 |
+
{
|
| 927 |
+
"event_date": "2027-01-15",
|
| 928 |
+
"ticker": "IDYA",
|
| 929 |
+
"asset": "darovasertib",
|
| 930 |
+
"event_type": "READOUT",
|
| 931 |
+
"event_window": "Jan 15, 2027",
|
| 932 |
+
"date_precision": "day",
|
| 933 |
+
"confidence": "medium",
|
| 934 |
+
"source": "clinicaltrials",
|
| 935 |
+
"nct_id": "NCT05987332",
|
| 936 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05987332"
|
| 937 |
+
},
|
| 938 |
+
{
|
| 939 |
+
"event_date": "2027-01-15",
|
| 940 |
+
"ticker": "MLTX",
|
| 941 |
+
"asset": "sonelokimab",
|
| 942 |
+
"event_type": "READOUT",
|
| 943 |
+
"event_window": "Jan 15, 2027",
|
| 944 |
+
"date_precision": "day",
|
| 945 |
+
"confidence": "medium",
|
| 946 |
+
"source": "clinicaltrials",
|
| 947 |
+
"nct_id": "NCT06641089",
|
| 948 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06641089"
|
| 949 |
+
},
|
| 950 |
+
{
|
| 951 |
+
"event_date": "2027-01-21",
|
| 952 |
+
"ticker": "AMGN",
|
| 953 |
+
"asset": "maridebart cafraglutide",
|
| 954 |
+
"event_type": "READOUT",
|
| 955 |
+
"event_window": "Jan 21, 2027",
|
| 956 |
+
"date_precision": "day",
|
| 957 |
+
"confidence": "medium",
|
| 958 |
+
"source": "clinicaltrials",
|
| 959 |
+
"nct_id": "NCT06858839",
|
| 960 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06858839"
|
| 961 |
+
},
|
| 962 |
+
{
|
| 963 |
+
"event_date": "2027-01-29",
|
| 964 |
+
"ticker": "PFE",
|
| 965 |
+
"asset": "disitamab vedotin",
|
| 966 |
+
"event_type": "READOUT",
|
| 967 |
+
"event_window": "Jan 29, 2027",
|
| 968 |
+
"date_precision": "day",
|
| 969 |
+
"confidence": "medium",
|
| 970 |
+
"source": "clinicaltrials",
|
| 971 |
+
"nct_id": "NCT05911295",
|
| 972 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05911295"
|
| 973 |
+
},
|
| 974 |
+
{
|
| 975 |
+
"event_date": "2027-02-04",
|
| 976 |
+
"ticker": "MLTX",
|
| 977 |
+
"asset": "sonelokimab",
|
| 978 |
+
"event_type": "READOUT",
|
| 979 |
+
"event_window": "Feb 4, 2027",
|
| 980 |
+
"date_precision": "day",
|
| 981 |
+
"confidence": "medium",
|
| 982 |
+
"source": "clinicaltrials",
|
| 983 |
+
"nct_id": "NCT06641076",
|
| 984 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06641076"
|
| 985 |
+
},
|
| 986 |
+
{
|
| 987 |
+
"event_date": "2027-02-11",
|
| 988 |
+
"ticker": "NVS",
|
| 989 |
+
"asset": "inclisiran",
|
| 990 |
+
"event_type": "READOUT",
|
| 991 |
+
"event_window": "Feb 11, 2027",
|
| 992 |
+
"date_precision": "day",
|
| 993 |
+
"confidence": "medium",
|
| 994 |
+
"source": "clinicaltrials",
|
| 995 |
+
"nct_id": "NCT07102628",
|
| 996 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07102628"
|
| 997 |
+
},
|
| 998 |
+
{
|
| 999 |
+
"event_date": "2027-02-14",
|
| 1000 |
+
"ticker": "LLY",
|
| 1001 |
+
"asset": "tirzepatide",
|
| 1002 |
+
"event_type": "READOUT",
|
| 1003 |
+
"event_window": "Feb 14, 2027",
|
| 1004 |
+
"date_precision": "day",
|
| 1005 |
+
"confidence": "medium",
|
| 1006 |
+
"source": "clinicaltrials",
|
| 1007 |
+
"nct_id": "NCT07481747",
|
| 1008 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07481747"
|
| 1009 |
+
},
|
| 1010 |
+
{
|
| 1011 |
+
"event_date": "2027-02-22",
|
| 1012 |
+
"ticker": "AZN",
|
| 1013 |
+
"asset": "laroprovstat",
|
| 1014 |
+
"event_type": "READOUT",
|
| 1015 |
+
"event_window": "Feb 22, 2027",
|
| 1016 |
+
"date_precision": "day",
|
| 1017 |
+
"confidence": "medium",
|
| 1018 |
+
"source": "clinicaltrials",
|
| 1019 |
+
"nct_id": "NCT06834932",
|
| 1020 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06834932"
|
| 1021 |
+
},
|
| 1022 |
+
{
|
| 1023 |
+
"event_date": "2027-02-26",
|
| 1024 |
+
"ticker": "AZN",
|
| 1025 |
+
"asset": "anifrolumab",
|
| 1026 |
+
"event_type": "READOUT",
|
| 1027 |
+
"event_window": "Feb 26, 2027",
|
| 1028 |
+
"date_precision": "day",
|
| 1029 |
+
"confidence": "medium",
|
| 1030 |
+
"source": "clinicaltrials",
|
| 1031 |
+
"nct_id": "NCT05138133",
|
| 1032 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05138133"
|
| 1033 |
+
},
|
| 1034 |
+
{
|
| 1035 |
+
"event_date": "2027-02-28",
|
| 1036 |
+
"ticker": "LLY",
|
| 1037 |
+
"asset": "orforglipron",
|
| 1038 |
+
"event_type": "READOUT",
|
| 1039 |
+
"event_window": "Feb 2027",
|
| 1040 |
+
"date_precision": "month",
|
| 1041 |
+
"confidence": "medium",
|
| 1042 |
+
"source": "clinicaltrials",
|
| 1043 |
+
"nct_id": "NCT06672549",
|
| 1044 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06672549"
|
| 1045 |
+
},
|
| 1046 |
+
{
|
| 1047 |
+
"event_date": "2027-02-28",
|
| 1048 |
+
"ticker": "GMAB",
|
| 1049 |
+
"asset": "rina",
|
| 1050 |
+
"event_type": "READOUT",
|
| 1051 |
+
"event_window": "Feb 2027",
|
| 1052 |
+
"date_precision": "month",
|
| 1053 |
+
"confidence": "medium",
|
| 1054 |
+
"source": "clinicaltrials",
|
| 1055 |
+
"nct_id": "NCT06619236",
|
| 1056 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06619236"
|
| 1057 |
+
},
|
| 1058 |
+
{
|
| 1059 |
+
"event_date": "2027-02-28",
|
| 1060 |
+
"ticker": "GILD",
|
| 1061 |
+
"asset": "sacituzumab govitecan hziy",
|
| 1062 |
+
"event_type": "READOUT",
|
| 1063 |
+
"event_window": "Feb 2027",
|
| 1064 |
+
"date_precision": "month",
|
| 1065 |
+
"confidence": "medium",
|
| 1066 |
+
"source": "clinicaltrials",
|
| 1067 |
+
"nct_id": "NCT05382286",
|
| 1068 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05382286"
|
| 1069 |
+
},
|
| 1070 |
+
{
|
| 1071 |
+
"event_date": "2027-03-01",
|
| 1072 |
+
"ticker": "NVO",
|
| 1073 |
+
"asset": "cagrilintide",
|
| 1074 |
+
"event_type": "READOUT",
|
| 1075 |
+
"event_window": "Mar 1, 2027",
|
| 1076 |
+
"date_precision": "day",
|
| 1077 |
+
"confidence": "medium",
|
| 1078 |
+
"source": "clinicaltrials",
|
| 1079 |
+
"nct_id": "NCT07011667",
|
| 1080 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07011667"
|
| 1081 |
+
},
|
| 1082 |
+
{
|
| 1083 |
+
"event_date": "2027-03-13",
|
| 1084 |
+
"ticker": "RYTM",
|
| 1085 |
+
"asset": "setmelanotide",
|
| 1086 |
+
"event_type": "READOUT",
|
| 1087 |
+
"event_window": "Mar 13, 2027",
|
| 1088 |
+
"date_precision": "day",
|
| 1089 |
+
"confidence": "medium",
|
| 1090 |
+
"source": "clinicaltrials",
|
| 1091 |
+
"nct_id": "NCT06760546",
|
| 1092 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06760546"
|
| 1093 |
+
},
|
| 1094 |
+
{
|
| 1095 |
+
"event_date": "2027-03-18",
|
| 1096 |
+
"ticker": "MRK",
|
| 1097 |
+
"asset": "ibrutinib",
|
| 1098 |
+
"event_type": "READOUT",
|
| 1099 |
+
"event_window": "Mar 18, 2027",
|
| 1100 |
+
"date_precision": "day",
|
| 1101 |
+
"confidence": "medium",
|
| 1102 |
+
"source": "clinicaltrials",
|
| 1103 |
+
"nct_id": "NCT04212013",
|
| 1104 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04212013"
|
| 1105 |
+
},
|
| 1106 |
+
{
|
| 1107 |
+
"event_date": "2027-03-22",
|
| 1108 |
+
"ticker": "REGN",
|
| 1109 |
+
"asset": "fianlimab",
|
| 1110 |
+
"event_type": "READOUT",
|
| 1111 |
+
"event_window": "Mar 22, 2027",
|
| 1112 |
+
"date_precision": "day",
|
| 1113 |
+
"confidence": "medium",
|
| 1114 |
+
"source": "clinicaltrials",
|
| 1115 |
+
"nct_id": "NCT06246916",
|
| 1116 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06246916"
|
| 1117 |
+
},
|
| 1118 |
+
{
|
| 1119 |
+
"event_date": "2027-03-24",
|
| 1120 |
+
"ticker": "NVS",
|
| 1121 |
+
"asset": "ianalumab",
|
| 1122 |
+
"event_type": "READOUT",
|
| 1123 |
+
"event_window": "Mar 24, 2027",
|
| 1124 |
+
"date_precision": "day",
|
| 1125 |
+
"confidence": "medium",
|
| 1126 |
+
"source": "clinicaltrials",
|
| 1127 |
+
"nct_id": "NCT05639114",
|
| 1128 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05639114"
|
| 1129 |
+
},
|
| 1130 |
+
{
|
| 1131 |
+
"event_date": "2027-03-31",
|
| 1132 |
+
"ticker": "ARGX",
|
| 1133 |
+
"asset": "efgartigimod",
|
| 1134 |
+
"event_type": "READOUT",
|
| 1135 |
+
"event_window": "Mar 2027",
|
| 1136 |
+
"date_precision": "month",
|
| 1137 |
+
"confidence": "medium",
|
| 1138 |
+
"source": "clinicaltrials",
|
| 1139 |
+
"nct_id": "NCT04833894",
|
| 1140 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04833894"
|
| 1141 |
+
},
|
| 1142 |
+
{
|
| 1143 |
+
"event_date": "2027-03-31",
|
| 1144 |
+
"ticker": "IONS",
|
| 1145 |
+
"asset": "olezarsen",
|
| 1146 |
+
"event_type": "READOUT",
|
| 1147 |
+
"event_window": "Mar 2027",
|
| 1148 |
+
"date_precision": "month",
|
| 1149 |
+
"confidence": "medium",
|
| 1150 |
+
"source": "clinicaltrials",
|
| 1151 |
+
"nct_id": "NCT05681351",
|
| 1152 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05681351"
|
| 1153 |
+
},
|
| 1154 |
+
{
|
| 1155 |
+
"event_date": "2027-03-31",
|
| 1156 |
+
"ticker": "AAPG",
|
| 1157 |
+
"asset": "olverembatinib",
|
| 1158 |
+
"event_type": "READOUT",
|
| 1159 |
+
"event_window": "Mar 31, 2027",
|
| 1160 |
+
"date_precision": "day",
|
| 1161 |
+
"confidence": "medium",
|
| 1162 |
+
"source": "clinicaltrials",
|
| 1163 |
+
"nct_id": "NCT06640361",
|
| 1164 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06640361"
|
| 1165 |
+
},
|
| 1166 |
+
{
|
| 1167 |
+
"event_date": "2027-03-31",
|
| 1168 |
+
"ticker": "MDGL",
|
| 1169 |
+
"asset": "resmetirom",
|
| 1170 |
+
"event_type": "READOUT",
|
| 1171 |
+
"event_window": "Mar 2027",
|
| 1172 |
+
"date_precision": "month",
|
| 1173 |
+
"confidence": "medium",
|
| 1174 |
+
"source": "clinicaltrials",
|
| 1175 |
+
"nct_id": "NCT04951219",
|
| 1176 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04951219"
|
| 1177 |
+
},
|
| 1178 |
+
{
|
| 1179 |
+
"event_date": "2027-03-31",
|
| 1180 |
+
"ticker": "AZN",
|
| 1181 |
+
"asset": "rezvilutamide",
|
| 1182 |
+
"event_type": "READOUT",
|
| 1183 |
+
"event_window": "Mar 2027",
|
| 1184 |
+
"date_precision": "month",
|
| 1185 |
+
"confidence": "medium",
|
| 1186 |
+
"source": "clinicaltrials",
|
| 1187 |
+
"nct_id": "NCT07241416",
|
| 1188 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07241416"
|
| 1189 |
+
},
|
| 1190 |
+
{
|
| 1191 |
+
"event_date": "2027-03-31",
|
| 1192 |
+
"ticker": "PFE",
|
| 1193 |
+
"asset": "ritlecitinib",
|
| 1194 |
+
"event_type": "READOUT",
|
| 1195 |
+
"event_window": "Mar 31, 2027",
|
| 1196 |
+
"date_precision": "day",
|
| 1197 |
+
"confidence": "medium",
|
| 1198 |
+
"source": "clinicaltrials",
|
| 1199 |
+
"nct_id": "NCT06163326",
|
| 1200 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06163326"
|
| 1201 |
+
},
|
| 1202 |
+
{
|
| 1203 |
+
"event_date": "2027-03-31",
|
| 1204 |
+
"ticker": "NVS",
|
| 1205 |
+
"asset": "tisagenlecleucel",
|
| 1206 |
+
"event_type": "READOUT",
|
| 1207 |
+
"event_window": "Mar 31, 2027",
|
| 1208 |
+
"date_precision": "day",
|
| 1209 |
+
"confidence": "medium",
|
| 1210 |
+
"source": "clinicaltrials",
|
| 1211 |
+
"nct_id": "NCT04094311",
|
| 1212 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04094311"
|
| 1213 |
+
},
|
| 1214 |
+
{
|
| 1215 |
+
"event_date": "2027-03-31",
|
| 1216 |
+
"ticker": "ONC",
|
| 1217 |
+
"asset": "zanubrutinib",
|
| 1218 |
+
"event_type": "READOUT",
|
| 1219 |
+
"event_window": "Mar 2027",
|
| 1220 |
+
"date_precision": "month",
|
| 1221 |
+
"confidence": "medium",
|
| 1222 |
+
"source": "clinicaltrials",
|
| 1223 |
+
"nct_id": "NCT04002297",
|
| 1224 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04002297"
|
| 1225 |
+
},
|
| 1226 |
+
{
|
| 1227 |
+
"event_date": "2027-04-12",
|
| 1228 |
+
"ticker": "NVS",
|
| 1229 |
+
"asset": "ianalumab",
|
| 1230 |
+
"event_type": "READOUT",
|
| 1231 |
+
"event_window": "Apr 12, 2027",
|
| 1232 |
+
"date_precision": "day",
|
| 1233 |
+
"confidence": "medium",
|
| 1234 |
+
"source": "clinicaltrials",
|
| 1235 |
+
"nct_id": "NCT05624749",
|
| 1236 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05624749"
|
| 1237 |
+
},
|
| 1238 |
+
{
|
| 1239 |
+
"event_date": "2027-04-14",
|
| 1240 |
+
"ticker": "PFE",
|
| 1241 |
+
"asset": "tofacitinib",
|
| 1242 |
+
"event_type": "READOUT",
|
| 1243 |
+
"event_window": "Apr 14, 2027",
|
| 1244 |
+
"date_precision": "day",
|
| 1245 |
+
"confidence": "medium",
|
| 1246 |
+
"source": "clinicaltrials",
|
| 1247 |
+
"nct_id": "NCT04624230",
|
| 1248 |
+
"source_url": "https://clinicaltrials.gov/study/NCT04624230"
|
| 1249 |
+
},
|
| 1250 |
+
{
|
| 1251 |
+
"event_date": "2027-04-20",
|
| 1252 |
+
"ticker": "AZN",
|
| 1253 |
+
"asset": "camizestrant",
|
| 1254 |
+
"event_type": "READOUT",
|
| 1255 |
+
"event_window": "Apr 20, 2027",
|
| 1256 |
+
"date_precision": "day",
|
| 1257 |
+
"confidence": "medium",
|
| 1258 |
+
"source": "clinicaltrials",
|
| 1259 |
+
"nct_id": "NCT05774951",
|
| 1260 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05774951"
|
| 1261 |
+
},
|
| 1262 |
+
{
|
| 1263 |
+
"event_date": "2027-04-25",
|
| 1264 |
+
"ticker": "LLY",
|
| 1265 |
+
"asset": "lebrikizumab",
|
| 1266 |
+
"event_type": "READOUT",
|
| 1267 |
+
"event_window": "Apr 25, 2027",
|
| 1268 |
+
"date_precision": "day",
|
| 1269 |
+
"confidence": "medium",
|
| 1270 |
+
"source": "clinicaltrials",
|
| 1271 |
+
"nct_id": "NCT06526182",
|
| 1272 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06526182"
|
| 1273 |
+
},
|
| 1274 |
+
{
|
| 1275 |
+
"event_date": "2027-04-27",
|
| 1276 |
+
"ticker": "AMGN",
|
| 1277 |
+
"asset": "maridebart cafraglutide",
|
| 1278 |
+
"event_type": "READOUT",
|
| 1279 |
+
"event_window": "Apr 27, 2027",
|
| 1280 |
+
"date_precision": "day",
|
| 1281 |
+
"confidence": "medium",
|
| 1282 |
+
"source": "clinicaltrials",
|
| 1283 |
+
"nct_id": "NCT06987695",
|
| 1284 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06987695"
|
| 1285 |
+
},
|
| 1286 |
+
{
|
| 1287 |
+
"event_date": "2027-04-30",
|
| 1288 |
+
"ticker": "MRK",
|
| 1289 |
+
"asset": "ifinatamab deruxtecan",
|
| 1290 |
+
"event_type": "READOUT",
|
| 1291 |
+
"event_window": "Apr 30, 2027",
|
| 1292 |
+
"date_precision": "day",
|
| 1293 |
+
"confidence": "medium",
|
| 1294 |
+
"source": "clinicaltrials",
|
| 1295 |
+
"nct_id": "NCT06203210",
|
| 1296 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06203210"
|
| 1297 |
+
},
|
| 1298 |
+
{
|
| 1299 |
+
"event_date": "2027-04-30",
|
| 1300 |
+
"ticker": "NVS",
|
| 1301 |
+
"asset": "iptacopan",
|
| 1302 |
+
"event_type": "READOUT",
|
| 1303 |
+
"event_window": "Apr 30, 2027",
|
| 1304 |
+
"date_precision": "day",
|
| 1305 |
+
"confidence": "medium",
|
| 1306 |
+
"source": "clinicaltrials",
|
| 1307 |
+
"nct_id": "NCT06517758",
|
| 1308 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06517758"
|
| 1309 |
+
},
|
| 1310 |
+
{
|
| 1311 |
+
"event_date": "2027-05-02",
|
| 1312 |
+
"ticker": "PFE",
|
| 1313 |
+
"asset": "abrocitinib",
|
| 1314 |
+
"event_type": "READOUT",
|
| 1315 |
+
"event_window": "May 2, 2027",
|
| 1316 |
+
"date_precision": "day",
|
| 1317 |
+
"confidence": "medium",
|
| 1318 |
+
"source": "clinicaltrials",
|
| 1319 |
+
"nct_id": "NCT06807268",
|
| 1320 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06807268"
|
| 1321 |
+
},
|
| 1322 |
+
{
|
| 1323 |
+
"event_date": "2027-05-11",
|
| 1324 |
+
"ticker": "NVO",
|
| 1325 |
+
"asset": "cagrilintide",
|
| 1326 |
+
"event_type": "READOUT",
|
| 1327 |
+
"event_window": "May 11, 2027",
|
| 1328 |
+
"date_precision": "day",
|
| 1329 |
+
"confidence": "medium",
|
| 1330 |
+
"source": "clinicaltrials",
|
| 1331 |
+
"nct_id": "NCT07220642",
|
| 1332 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07220642"
|
| 1333 |
+
},
|
| 1334 |
+
{
|
| 1335 |
+
"event_date": "2027-05-12",
|
| 1336 |
+
"ticker": "NVO",
|
| 1337 |
+
"asset": "cagrilintide",
|
| 1338 |
+
"event_type": "READOUT",
|
| 1339 |
+
"event_window": "May 12, 2027",
|
| 1340 |
+
"date_precision": "day",
|
| 1341 |
+
"confidence": "medium",
|
| 1342 |
+
"source": "clinicaltrials",
|
| 1343 |
+
"nct_id": "NCT07220759",
|
| 1344 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07220759"
|
| 1345 |
+
},
|
| 1346 |
+
{
|
| 1347 |
+
"event_date": "2027-05-18",
|
| 1348 |
+
"ticker": "TAK",
|
| 1349 |
+
"asset": "zasocitinib",
|
| 1350 |
+
"event_type": "READOUT",
|
| 1351 |
+
"event_window": "May 18, 2027",
|
| 1352 |
+
"date_precision": "day",
|
| 1353 |
+
"confidence": "medium",
|
| 1354 |
+
"source": "clinicaltrials",
|
| 1355 |
+
"nct_id": "NCT06671483",
|
| 1356 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06671483"
|
| 1357 |
+
},
|
| 1358 |
+
{
|
| 1359 |
+
"event_date": "2027-05-19",
|
| 1360 |
+
"ticker": "MRK",
|
| 1361 |
+
"asset": "nemtabrutinib",
|
| 1362 |
+
"event_type": "READOUT",
|
| 1363 |
+
"event_window": "May 19, 2027",
|
| 1364 |
+
"date_precision": "day",
|
| 1365 |
+
"confidence": "medium",
|
| 1366 |
+
"source": "clinicaltrials",
|
| 1367 |
+
"nct_id": "NCT05624554",
|
| 1368 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05624554"
|
| 1369 |
+
},
|
| 1370 |
+
{
|
| 1371 |
+
"event_date": "2027-05-31",
|
| 1372 |
+
"ticker": "TEVA",
|
| 1373 |
+
"asset": "deuruxolitinib",
|
| 1374 |
+
"event_type": "READOUT",
|
| 1375 |
+
"event_window": "May 2027",
|
| 1376 |
+
"date_precision": "month",
|
| 1377 |
+
"confidence": "medium",
|
| 1378 |
+
"source": "clinicaltrials",
|
| 1379 |
+
"nct_id": "NCT03898479",
|
| 1380 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03898479"
|
| 1381 |
+
},
|
| 1382 |
+
{
|
| 1383 |
+
"event_date": "2027-05-31",
|
| 1384 |
+
"ticker": "LLY",
|
| 1385 |
+
"asset": "orforglipron",
|
| 1386 |
+
"event_type": "READOUT",
|
| 1387 |
+
"event_window": "May 2027",
|
| 1388 |
+
"date_precision": "month",
|
| 1389 |
+
"confidence": "medium",
|
| 1390 |
+
"source": "clinicaltrials",
|
| 1391 |
+
"nct_id": "NCT07613307",
|
| 1392 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07613307"
|
| 1393 |
+
},
|
| 1394 |
+
{
|
| 1395 |
+
"event_date": "2027-05-31",
|
| 1396 |
+
"ticker": "VOR",
|
| 1397 |
+
"asset": "telitacicept",
|
| 1398 |
+
"event_type": "READOUT",
|
| 1399 |
+
"event_window": "May 2027",
|
| 1400 |
+
"date_precision": "month",
|
| 1401 |
+
"confidence": "medium",
|
| 1402 |
+
"source": "clinicaltrials",
|
| 1403 |
+
"nct_id": "NCT06456580",
|
| 1404 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06456580"
|
| 1405 |
+
},
|
| 1406 |
+
{
|
| 1407 |
+
"event_date": "2027-06-02",
|
| 1408 |
+
"ticker": "NVS",
|
| 1409 |
+
"asset": "pelabresib",
|
| 1410 |
+
"event_type": "READOUT",
|
| 1411 |
+
"event_window": "Jun 2, 2027",
|
| 1412 |
+
"date_precision": "day",
|
| 1413 |
+
"confidence": "medium",
|
| 1414 |
+
"source": "clinicaltrials",
|
| 1415 |
+
"nct_id": "NCT06401356",
|
| 1416 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06401356"
|
| 1417 |
+
},
|
| 1418 |
+
{
|
| 1419 |
+
"event_date": "2027-06-07",
|
| 1420 |
+
"ticker": "MRK",
|
| 1421 |
+
"asset": "belzutifan",
|
| 1422 |
+
"event_type": "READOUT",
|
| 1423 |
+
"event_window": "Jun 7, 2027",
|
| 1424 |
+
"date_precision": "day",
|
| 1425 |
+
"confidence": "medium",
|
| 1426 |
+
"source": "clinicaltrials",
|
| 1427 |
+
"nct_id": "NCT05899049",
|
| 1428 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05899049"
|
| 1429 |
+
},
|
| 1430 |
+
{
|
| 1431 |
+
"event_date": "2027-06-18",
|
| 1432 |
+
"ticker": "REGN",
|
| 1433 |
+
"asset": "mibavademab",
|
| 1434 |
+
"event_type": "READOUT",
|
| 1435 |
+
"event_window": "Jun 18, 2027",
|
| 1436 |
+
"date_precision": "day",
|
| 1437 |
+
"confidence": "medium",
|
| 1438 |
+
"source": "clinicaltrials",
|
| 1439 |
+
"nct_id": "NCT07220772",
|
| 1440 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07220772"
|
| 1441 |
+
},
|
| 1442 |
+
{
|
| 1443 |
+
"event_date": "2027-06-30",
|
| 1444 |
+
"ticker": "PFE",
|
| 1445 |
+
"asset": "binimetinib",
|
| 1446 |
+
"event_type": "READOUT",
|
| 1447 |
+
"event_window": "Jun 2027",
|
| 1448 |
+
"date_precision": "month",
|
| 1449 |
+
"confidence": "medium",
|
| 1450 |
+
"source": "clinicaltrials",
|
| 1451 |
+
"nct_id": "NCT05615818",
|
| 1452 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| 1453 |
+
},
|
| 1454 |
+
{
|
| 1455 |
+
"event_date": "2027-06-30",
|
| 1456 |
+
"ticker": "AZN",
|
| 1457 |
+
"asset": "datopotamab deruxtecan",
|
| 1458 |
+
"event_type": "READOUT",
|
| 1459 |
+
"event_window": "Jun 30, 2027",
|
| 1460 |
+
"date_precision": "day",
|
| 1461 |
+
"confidence": "medium",
|
| 1462 |
+
"source": "clinicaltrials",
|
| 1463 |
+
"nct_id": "NCT06564844",
|
| 1464 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06564844"
|
| 1465 |
+
},
|
| 1466 |
+
{
|
| 1467 |
+
"event_date": "2027-06-30",
|
| 1468 |
+
"ticker": "PHVS",
|
| 1469 |
+
"asset": "deucrictibant",
|
| 1470 |
+
"event_type": "READOUT",
|
| 1471 |
+
"event_window": "Jun 2027",
|
| 1472 |
+
"date_precision": "month",
|
| 1473 |
+
"confidence": "medium",
|
| 1474 |
+
"source": "clinicaltrials",
|
| 1475 |
+
"nct_id": "NCT05396105",
|
| 1476 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05396105"
|
| 1477 |
+
},
|
| 1478 |
+
{
|
| 1479 |
+
"event_date": "2027-06-30",
|
| 1480 |
+
"ticker": "IMMP",
|
| 1481 |
+
"asset": "eftilagimod alfa",
|
| 1482 |
+
"event_type": "READOUT",
|
| 1483 |
+
"event_window": "Jun 2027",
|
| 1484 |
+
"date_precision": "month",
|
| 1485 |
+
"confidence": "medium",
|
| 1486 |
+
"source": "clinicaltrials",
|
| 1487 |
+
"nct_id": "NCT06726265",
|
| 1488 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06726265"
|
| 1489 |
+
},
|
| 1490 |
+
{
|
| 1491 |
+
"event_date": "2027-06-30",
|
| 1492 |
+
"ticker": "PFE",
|
| 1493 |
+
"asset": "encorafenib",
|
| 1494 |
+
"event_type": "READOUT",
|
| 1495 |
+
"event_window": "Jun 2027",
|
| 1496 |
+
"date_precision": "month",
|
| 1497 |
+
"confidence": "medium",
|
| 1498 |
+
"source": "clinicaltrials",
|
| 1499 |
+
"nct_id": "NCT05615818",
|
| 1500 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| 1501 |
+
},
|
| 1502 |
+
{
|
| 1503 |
+
"event_date": "2027-06-30",
|
| 1504 |
+
"ticker": "GMAB",
|
| 1505 |
+
"asset": "epcoritamab",
|
| 1506 |
+
"event_type": "READOUT",
|
| 1507 |
+
"event_window": "Jun 2027",
|
| 1508 |
+
"date_precision": "month",
|
| 1509 |
+
"confidence": "medium",
|
| 1510 |
+
"source": "clinicaltrials",
|
| 1511 |
+
"nct_id": "NCT05578976",
|
| 1512 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05578976"
|
| 1513 |
+
},
|
| 1514 |
+
{
|
| 1515 |
+
"event_date": "2027-06-30",
|
| 1516 |
+
"ticker": "IMNN",
|
| 1517 |
+
"asset": "niraparib",
|
| 1518 |
+
"event_type": "READOUT",
|
| 1519 |
+
"event_window": "Jun 2027",
|
| 1520 |
+
"date_precision": "month",
|
| 1521 |
+
"confidence": "medium",
|
| 1522 |
+
"source": "clinicaltrials",
|
| 1523 |
+
"nct_id": "NCT03651206",
|
| 1524 |
+
"source_url": "https://clinicaltrials.gov/study/NCT03651206"
|
| 1525 |
+
},
|
| 1526 |
+
{
|
| 1527 |
+
"event_date": "2027-06-30",
|
| 1528 |
+
"ticker": "AZN",
|
| 1529 |
+
"asset": "rilvegostomig",
|
| 1530 |
+
"event_type": "READOUT",
|
| 1531 |
+
"event_window": "Jun 30, 2027",
|
| 1532 |
+
"date_precision": "day",
|
| 1533 |
+
"confidence": "medium",
|
| 1534 |
+
"source": "clinicaltrials",
|
| 1535 |
+
"nct_id": "NCT06564844",
|
| 1536 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06564844"
|
| 1537 |
+
},
|
| 1538 |
+
{
|
| 1539 |
+
"event_date": "2027-06-30",
|
| 1540 |
+
"ticker": "GILD",
|
| 1541 |
+
"asset": "sacituzumab govitecan hziy",
|
| 1542 |
+
"event_type": "READOUT",
|
| 1543 |
+
"event_window": "Jun 2027",
|
| 1544 |
+
"date_precision": "month",
|
| 1545 |
+
"confidence": "medium",
|
| 1546 |
+
"source": "clinicaltrials",
|
| 1547 |
+
"nct_id": "NCT05633654",
|
| 1548 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05633654"
|
| 1549 |
+
},
|
| 1550 |
+
{
|
| 1551 |
+
"event_date": "2027-06-30",
|
| 1552 |
+
"ticker": "AMGN",
|
| 1553 |
+
"asset": "sotorasib",
|
| 1554 |
+
"event_type": "READOUT",
|
| 1555 |
+
"event_window": "Jun 30, 2027",
|
| 1556 |
+
"date_precision": "day",
|
| 1557 |
+
"confidence": "medium",
|
| 1558 |
+
"source": "clinicaltrials",
|
| 1559 |
+
"nct_id": "NCT05920356",
|
| 1560 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05920356"
|
| 1561 |
+
},
|
| 1562 |
+
{
|
| 1563 |
+
"event_date": "2027-06-30",
|
| 1564 |
+
"ticker": "JAZZ",
|
| 1565 |
+
"asset": "zanidatamab",
|
| 1566 |
+
"event_type": "READOUT",
|
| 1567 |
+
"event_window": "Jun 2027",
|
| 1568 |
+
"date_precision": "month",
|
| 1569 |
+
"confidence": "medium",
|
| 1570 |
+
"source": "clinicaltrials",
|
| 1571 |
+
"nct_id": "NCT05615818",
|
| 1572 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05615818"
|
| 1573 |
+
},
|
| 1574 |
+
{
|
| 1575 |
+
"event_date": "2027-07-02",
|
| 1576 |
+
"ticker": "NVO",
|
| 1577 |
+
"asset": "ziltivekimab",
|
| 1578 |
+
"event_type": "READOUT",
|
| 1579 |
+
"event_window": "Jul 2, 2027",
|
| 1580 |
+
"date_precision": "day",
|
| 1581 |
+
"confidence": "medium",
|
| 1582 |
+
"source": "clinicaltrials",
|
| 1583 |
+
"nct_id": "NCT05636176",
|
| 1584 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05636176"
|
| 1585 |
+
},
|
| 1586 |
+
{
|
| 1587 |
+
"event_date": "2027-07-05",
|
| 1588 |
+
"ticker": "AMGN",
|
| 1589 |
+
"asset": "tarlatamab",
|
| 1590 |
+
"event_type": "READOUT",
|
| 1591 |
+
"event_window": "Jul 5, 2027",
|
| 1592 |
+
"date_precision": "day",
|
| 1593 |
+
"confidence": "medium",
|
| 1594 |
+
"source": "clinicaltrials",
|
| 1595 |
+
"nct_id": "NCT06211036",
|
| 1596 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06211036"
|
| 1597 |
+
},
|
| 1598 |
+
{
|
| 1599 |
+
"event_date": "2027-07-28",
|
| 1600 |
+
"ticker": "AZN",
|
| 1601 |
+
"asset": "datopotamab deruxtecan",
|
| 1602 |
+
"event_type": "READOUT",
|
| 1603 |
+
"event_window": "Jul 28, 2027",
|
| 1604 |
+
"date_precision": "day",
|
| 1605 |
+
"confidence": "medium",
|
| 1606 |
+
"source": "clinicaltrials",
|
| 1607 |
+
"nct_id": "NCT06103864",
|
| 1608 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06103864"
|
| 1609 |
+
},
|
| 1610 |
+
{
|
| 1611 |
+
"event_date": "2027-07-30",
|
| 1612 |
+
"ticker": "GMAB",
|
| 1613 |
+
"asset": "acasunlimab",
|
| 1614 |
+
"event_type": "READOUT",
|
| 1615 |
+
"event_window": "Jul 30, 2027",
|
| 1616 |
+
"date_precision": "day",
|
| 1617 |
+
"confidence": "medium",
|
| 1618 |
+
"source": "clinicaltrials",
|
| 1619 |
+
"nct_id": "NCT06635824",
|
| 1620 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06635824"
|
| 1621 |
+
},
|
| 1622 |
+
{
|
| 1623 |
+
"event_date": "2027-07-30",
|
| 1624 |
+
"ticker": "AZN",
|
| 1625 |
+
"asset": "darolutamide",
|
| 1626 |
+
"event_type": "READOUT",
|
| 1627 |
+
"event_window": "Jul 30, 2027",
|
| 1628 |
+
"date_precision": "day",
|
| 1629 |
+
"confidence": "medium",
|
| 1630 |
+
"source": "clinicaltrials",
|
| 1631 |
+
"nct_id": "NCT05794906",
|
| 1632 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05794906"
|
| 1633 |
+
},
|
| 1634 |
+
{
|
| 1635 |
+
"event_date": "2027-07-30",
|
| 1636 |
+
"ticker": "PFE",
|
| 1637 |
+
"asset": "ritlecitinib",
|
| 1638 |
+
"event_type": "READOUT",
|
| 1639 |
+
"event_window": "Jul 30, 2027",
|
| 1640 |
+
"date_precision": "day",
|
| 1641 |
+
"confidence": "medium",
|
| 1642 |
+
"source": "clinicaltrials",
|
| 1643 |
+
"nct_id": "NCT06072183",
|
| 1644 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06072183"
|
| 1645 |
+
},
|
| 1646 |
+
{
|
| 1647 |
+
"event_date": "2027-07-31",
|
| 1648 |
+
"ticker": "AZN",
|
| 1649 |
+
"asset": "dapagliflozin",
|
| 1650 |
+
"event_type": "READOUT",
|
| 1651 |
+
"event_window": "Jul 2027",
|
| 1652 |
+
"date_precision": "month",
|
| 1653 |
+
"confidence": "medium",
|
| 1654 |
+
"source": "clinicaltrials",
|
| 1655 |
+
"nct_id": "NCT05374291",
|
| 1656 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05374291"
|
| 1657 |
+
},
|
| 1658 |
+
{
|
| 1659 |
+
"event_date": "2027-07-31",
|
| 1660 |
+
"ticker": "LLY",
|
| 1661 |
+
"asset": "retatrutide",
|
| 1662 |
+
"event_type": "READOUT",
|
| 1663 |
+
"event_window": "Jul 2027",
|
| 1664 |
+
"date_precision": "month",
|
| 1665 |
+
"confidence": "medium",
|
| 1666 |
+
"source": "clinicaltrials",
|
| 1667 |
+
"nct_id": "NCT07232719",
|
| 1668 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07232719"
|
| 1669 |
+
},
|
| 1670 |
+
{
|
| 1671 |
+
"event_date": "2027-08-04",
|
| 1672 |
+
"ticker": "PFE",
|
| 1673 |
+
"asset": "elranatamab",
|
| 1674 |
+
"event_type": "READOUT",
|
| 1675 |
+
"event_window": "Aug 4, 2027",
|
| 1676 |
+
"date_precision": "day",
|
| 1677 |
+
"confidence": "medium",
|
| 1678 |
+
"source": "clinicaltrials",
|
| 1679 |
+
"nct_id": "NCT05317416",
|
| 1680 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05317416"
|
| 1681 |
+
},
|
| 1682 |
+
{
|
| 1683 |
+
"event_date": "2027-08-07",
|
| 1684 |
+
"ticker": "AZN",
|
| 1685 |
+
"asset": "tezepelumab",
|
| 1686 |
+
"event_type": "READOUT",
|
| 1687 |
+
"event_window": "Aug 7, 2027",
|
| 1688 |
+
"date_precision": "day",
|
| 1689 |
+
"confidence": "medium",
|
| 1690 |
+
"source": "clinicaltrials",
|
| 1691 |
+
"nct_id": "NCT07363642",
|
| 1692 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07363642"
|
| 1693 |
+
},
|
| 1694 |
+
{
|
| 1695 |
+
"event_date": "2027-08-09",
|
| 1696 |
+
"ticker": "BMY",
|
| 1697 |
+
"asset": "golcadomide",
|
| 1698 |
+
"event_type": "READOUT",
|
| 1699 |
+
"event_window": "Aug 9, 2027",
|
| 1700 |
+
"date_precision": "day",
|
| 1701 |
+
"confidence": "medium",
|
| 1702 |
+
"source": "clinicaltrials",
|
| 1703 |
+
"nct_id": "NCT06356129",
|
| 1704 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06356129"
|
| 1705 |
+
},
|
| 1706 |
+
{
|
| 1707 |
+
"event_date": "2027-08-20",
|
| 1708 |
+
"ticker": "ARWR",
|
| 1709 |
+
"asset": "zodasiran",
|
| 1710 |
+
"event_type": "READOUT",
|
| 1711 |
+
"event_window": "Aug 20, 2027",
|
| 1712 |
+
"date_precision": "day",
|
| 1713 |
+
"confidence": "medium",
|
| 1714 |
+
"source": "clinicaltrials",
|
| 1715 |
+
"nct_id": "NCT07037771",
|
| 1716 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07037771"
|
| 1717 |
+
},
|
| 1718 |
+
{
|
| 1719 |
+
"event_date": "2027-08-27",
|
| 1720 |
+
"ticker": "AZN",
|
| 1721 |
+
"asset": "ravulizumab",
|
| 1722 |
+
"event_type": "READOUT",
|
| 1723 |
+
"event_window": "Aug 27, 2027",
|
| 1724 |
+
"date_precision": "day",
|
| 1725 |
+
"confidence": "medium",
|
| 1726 |
+
"source": "clinicaltrials",
|
| 1727 |
+
"nct_id": "NCT07596784",
|
| 1728 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07596784"
|
| 1729 |
+
},
|
| 1730 |
+
{
|
| 1731 |
+
"event_date": "2027-08-31",
|
| 1732 |
+
"ticker": "AAPG",
|
| 1733 |
+
"asset": "lisaftoclax",
|
| 1734 |
+
"event_type": "READOUT",
|
| 1735 |
+
"event_window": "Aug 2027",
|
| 1736 |
+
"date_precision": "month",
|
| 1737 |
+
"confidence": "medium",
|
| 1738 |
+
"source": "clinicaltrials",
|
| 1739 |
+
"nct_id": "NCT06319456",
|
| 1740 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06319456"
|
| 1741 |
+
},
|
| 1742 |
+
{
|
| 1743 |
+
"event_date": "2027-08-31",
|
| 1744 |
+
"ticker": "LLY",
|
| 1745 |
+
"asset": "orforglipron",
|
| 1746 |
+
"event_type": "READOUT",
|
| 1747 |
+
"event_window": "Aug 2027",
|
| 1748 |
+
"date_precision": "month",
|
| 1749 |
+
"confidence": "medium",
|
| 1750 |
+
"source": "clinicaltrials",
|
| 1751 |
+
"nct_id": "NCT06972459",
|
| 1752 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06972459"
|
| 1753 |
+
},
|
| 1754 |
+
{
|
| 1755 |
+
"event_date": "2027-08-31",
|
| 1756 |
+
"ticker": "CRNX",
|
| 1757 |
+
"asset": "paltusotine",
|
| 1758 |
+
"event_type": "READOUT",
|
| 1759 |
+
"event_window": "Aug 2027",
|
| 1760 |
+
"date_precision": "month",
|
| 1761 |
+
"confidence": "medium",
|
| 1762 |
+
"source": "clinicaltrials",
|
| 1763 |
+
"nct_id": "NCT07087054",
|
| 1764 |
+
"source_url": "https://clinicaltrials.gov/study/NCT07087054"
|
| 1765 |
+
},
|
| 1766 |
+
{
|
| 1767 |
+
"event_date": "2027-08-31",
|
| 1768 |
+
"ticker": "ABBV",
|
| 1769 |
+
"asset": "telisotuzumab adizutecan",
|
| 1770 |
+
"event_type": "READOUT",
|
| 1771 |
+
"event_window": "Aug 2027",
|
| 1772 |
+
"date_precision": "month",
|
| 1773 |
+
"confidence": "medium",
|
| 1774 |
+
"source": "clinicaltrials",
|
| 1775 |
+
"nct_id": "NCT06614192",
|
| 1776 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06614192"
|
| 1777 |
+
},
|
| 1778 |
+
{
|
| 1779 |
+
"event_date": "2027-08-31",
|
| 1780 |
+
"ticker": "MRK",
|
| 1781 |
+
"asset": "tocilizumab",
|
| 1782 |
+
"event_type": "READOUT",
|
| 1783 |
+
"event_window": "Aug 31, 2027",
|
| 1784 |
+
"date_precision": "day",
|
| 1785 |
+
"confidence": "medium",
|
| 1786 |
+
"source": "clinicaltrials",
|
| 1787 |
+
"nct_id": "NCT06084936",
|
| 1788 |
+
"source_url": "https://clinicaltrials.gov/study/NCT06084936"
|
| 1789 |
+
},
|
| 1790 |
+
{
|
| 1791 |
+
"event_date": "2027-09-01",
|
| 1792 |
+
"ticker": "NVO",
|
| 1793 |
+
"asset": "cagrilintide",
|
| 1794 |
+
"event_type": "READOUT",
|
| 1795 |
+
"event_window": "Sep 1, 2027",
|
| 1796 |
+
"date_precision": "day",
|
| 1797 |
+
"confidence": "medium",
|
| 1798 |
+
"source": "clinicaltrials",
|
| 1799 |
+
"nct_id": "NCT05669755",
|
| 1800 |
+
"source_url": "https://clinicaltrials.gov/study/NCT05669755"
|
| 1801 |
+
}
|
| 1802 |
+
]
|
regulatory_events_sample.csv
ADDED
|
@@ -0,0 +1,14 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
asset,application_number,fda_sponsor,event_type,status,date
|
| 2 |
+
datopotamab deruxtecan,BLA761394,DAIICHI SANKYO INC,APPROVAL,Approved,2026-05-22
|
| 3 |
+
datopotamab deruxtecan,BLA761394,DAIICHI SANKYO INC,APPROVAL,Approved,2025-01-17
|
| 4 |
+
deucravacitinib,NDA214958,BRISTOL,APPROVAL,Approved,2026-06-30
|
| 5 |
+
deucravacitinib,NDA214958,BRISTOL,APPROVAL,Approved,2026-03-06
|
| 6 |
+
deucravacitinib,NDA214958,BRISTOL,APPROVAL,Approved,2025-10-27
|
| 7 |
+
deucravacitinib,NDA214958,BRISTOL,APPROVAL,Approved,2022-09-09
|
| 8 |
+
lebrikizumab,BLA761306,ELI LILLY AND CO,APPROVAL,Approved,2025-10-28
|
| 9 |
+
lebrikizumab,BLA761306,ELI LILLY AND CO,APPROVAL,Approved,2025-05-22
|
| 10 |
+
lebrikizumab,BLA761306,ELI LILLY AND CO,APPROVAL,Approved,2026-06-09
|
| 11 |
+
lebrikizumab,BLA761306,ELI LILLY AND CO,APPROVAL,Approved,2024-09-13
|
| 12 |
+
ritlecitinib,NDA215830,PFIZER,APPROVAL,Approved,2026-06-30
|
| 13 |
+
ritlecitinib,NDA215830,PFIZER,APPROVAL,Approved,2023-06-23
|
| 14 |
+
zanidatamab,BLA761416,JAZZ PHARMS,APPROVAL,Approved,2024-11-20
|